var title_f35_36_36416="Oriental cholangiohepatitis CT";
var content_f35_36_36416=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Recurrent pyogenic cholangitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT image of a patient with recurrent pyogenic cholangitis showing a massively dilated left hepatic system and numerous stones (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Hannah M Lee, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_36_36416=[""].join("\n");
var outline_f35_36_36416=null;
var title_f35_36_36417="Dermatofibroma dimple";
var content_f35_36_36417=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F80575&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F80575&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dermatofibroma \"dimple sign\"",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A \"dimple\" is elicited on compression of this dermatofibroma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_36_36417=[""].join("\n");
var outline_f35_36_36417=null;
var title_f35_36_36418="Sulfur and salicylic acid: Drug information";
var content_f35_36_36418=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sulfur and salicylic acid: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/11/23730?source=see_link\">",
"    see \"Sulfur and salicylic acid: Pediatric drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/27/41395?source=see_link\">",
"    see \"Sulfur and salicylic acid: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12959541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      ala seb [OTC];",
"     </li>",
"     <li>",
"      Pernox&reg; Lemon [OTC];",
"     </li>",
"     <li>",
"      Pernox&reg; Regular [OTC];",
"     </li>",
"     <li>",
"      Sebex [OTC];",
"     </li>",
"     <li>",
"      Sebulex&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13865172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiseborrheic Agent, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13865188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     General guidelines; consult specific product labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo: Topical: Initial: Use daily or every other day; 1-2 treatments/week will usually maintain control",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cleanser: Topical: Use daily or every other day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F13865187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/11/23730?source=see_link\">",
"      see \"Sulfur and salicylic acid: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F13865224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F247574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cleanser, topical [scrub]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pernox&reg; Lemon: Sulfur 2% and salicylic acid 1.5% (56 g, 113 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pernox&reg; Regular: Sulfur 2% and salicylic acid 1.5% (113 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ala seb: Sulfur 2% and salicylic acid 2% (118 mL, 355 mL) [contains soya lecithin]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sebex: Sulfur 2% and salicylic acid 2% (118 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sebulex&reg;: Sulfur 2% and salicylic acid 2% (200 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F13865223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F247576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For external use only",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F247575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic shampoo for dandruff and seborrheic dermatitis; acne skin cleanser",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13865174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Local: Topical preparations containing 2% to 5% sulfur generally are well tolerated, local irritation may occur, concentration &gt;15% is very irritating to the skin, higher concentration (eg, 10% or higher) may cause systemic toxicity (eg, headache, vomiting, muscle cramps, dizziness, collapse)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F247579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contraindicated in patients allergic to sulfur",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F247566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Infants are more sensitive to sulfur than adults; do not use in children &lt;2 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For external use only; avoid contact with eyes; discontinue use if skin irritation develops.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to salicylic acid monograph.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14287365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to salicylic acid monograph.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Pernox External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5-2% (113 g): $20.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Shampoo",
"     </b>",
"     (Ala Seb External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-2% (118 mL): $8.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Shampoo",
"     </b>",
"     (Sebulex External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-2% (200 g): $12.35",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F14721641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dermax (BR);",
"     </li>",
"     <li>",
"      Klenyl (VE);",
"     </li>",
"     <li>",
"      Meted (GB, IE);",
"     </li>",
"     <li>",
"      Salicylic Acid &amp; Sulphur Cream (HK);",
"     </li>",
"     <li>",
"      Same-Seb (IT);",
"     </li>",
"     <li>",
"      Sastid (BR, ID, MY, PH, SG, ZA);",
"     </li>",
"     <li>",
"      Sastid Jabon (CN, CO, PY, UY);",
"     </li>",
"     <li>",
"      Sastid Soap (HK, IN, NZ);",
"     </li>",
"     <li>",
"      Sevorex (SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F247564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Salicylic acid works synergistically with sulfur in its keratolytic action to break down keratin and promote skin peeling",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F247578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: 1% of topically applied sulfur is absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Sulfur is reduced to hydrogen sulfide",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83320 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-F1B7A60FFB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_36_36418=[""].join("\n");
var outline_f35_36_36418=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12959541\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13865172\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13865188\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13865187\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13865224\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F247574\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13865223\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F247576\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F247575\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13865174\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F247579\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F247566\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287364\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287365\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323531\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14721641\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F247564\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F247578\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/83320\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/83320|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/27/41395?source=related_link\">",
"      Sulfur and salicylic acid: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/11/23730?source=related_link\">",
"      Sulfur and salicylic acid: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_36_36419="Psoriatic arthritis";
var content_f35_36_36419=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Psoriatic arthritis (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?35/36/36419/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/36/36419/contributors\" id=\"au4359\">",
"       Dafna D Gladman, MD, FRCPC",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?35/36/36419/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/36/36419/contributors\" id=\"se174\">",
"       Joachim Sieper, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?35/36/36419/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/36/36419/contributors\" id=\"de4792\">",
"       Jerry M Greene, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/36/36419?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      PSORIATIC ARTHRITIS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Psoriatic arthritis is a type of arthritis that causes joint pain, swelling, and stiffness in people with psoriasis. Psoriasis is a chronic skin condition that causes patches of thick, inflamed red skin that are often covered with silvery scales.",
"    </p>",
"    <p>",
"     Psoriatic arthritis affects men and women equally. Most people who develop psoriatic arthritis have skin symptoms of psoriasis first, followed by arthritis symptoms. However, in about 15 percent of cases, symptoms of arthritis are noticed before psoriasis appears. In another 15 percent of cases, psoriatic arthritis is diagnosed at the same time as psoriasis.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      PSORIATIC ARTHRITIS RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     Researchers have not identified the exact cause of psoriatic arthritis. However, they believe that the disease develops due to a combination of genetic, immunologic, and environmental factors.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Genetic factors",
"     </span>",
"     &nbsp;&mdash;&nbsp;About 40 percent of people with psoriasis or psoriatic arthritis have family members with psoriasis or psoriatic arthritis. This means that a close relative of a patient with psoriatic arthritis is about 50 times more likely to develop the disease than an unrelated person. If an identical twin has psoriatic arthritis, the other twin is very likely to have or to develop the condition.",
"    </p>",
"    <p>",
"     Genetic researchers have identified areas on certain chromosomes that may increase the risk of developing psoriatic arthritis. Other genetic factors may contribute to the severity of disease.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Immunologic factors",
"     </span>",
"     &nbsp;&mdash;&nbsp;A variety of immune system abnormalities have been noted in people with psoriatic arthritis.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Environmental factors",
"     </span>",
"     &nbsp;&mdash;&nbsp;Exposure to certain infections, including those caused by bacteria and viruses, may also contribute to the development of psoriatic arthritis. Some experts believe there is a link between streptococcal infection and the development of psoriasis and psoriatic arthritis, although the link has not been proven. Psoriatic arthritis also occurs more commonly in people infected with the human immunodeficiency virus (HIV) than in the general population.",
"    </p>",
"    <p>",
"     Psoriasis frequently appears at sites where there is skin trauma. This is called the Koebner phenomenon. Some patients develop arthritis in an injured joint.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      PSORIATIC ARTHRITIS SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Symptoms of psoriatic arthritis include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Pain and tenderness in the joints (",
"       <a class=\"graphic graphic_picture graphicRef69282 \" href=\"mobipreview.htm?14/39/14975\">",
"        picture 1",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Difficulty moving or stiffness in the joints",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       in the back. About half of all patients have morning stiffness lasting more than 30 minutes.",
"      </li>",
"      <li>",
"       Skin patches (also called plaques) that are dry or red, usually covered with silvery-white scales, which may have raised edges (",
"       <a class=\"graphic graphic_picture graphicRef74211 \" href=\"mobipreview.htm?38/13/39135\">",
"        picture 2",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Nail abnormalities, such as pitted, discolored, or crumbly nails (",
"       <a class=\"graphic graphic_picture graphicRef71998 \" href=\"mobipreview.htm?13/35/13886\">",
"        picture 3",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Some people with psoriatic arthritis have more difficulty with stiffness and immobility than with joint pain. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/49/30488?source=see_link\">",
"      \"Clinical manifestations and diagnosis of psoriatic arthritis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Patterns of psoriatic arthritis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Psoriatic arthritis tends to affect certain groups of joints. The following terms are used to describe patterns of psoriatic arthritis:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Distal arthritis &mdash; This type of psoriatic arthritis affects the end joints of the fingers and toes.",
"      </li>",
"      <li>",
"       Asymmetric oligoarthritis &mdash; This type of psoriatic arthritis affects fewer than five small or large joints in the body but does not necessarily occur on both sides of the body (for example, a person might experience joint pain in one elbow but not the other).",
"      </li>",
"      <li>",
"       Symmetric polyarthritis &mdash; This type of psoriatic arthritis affects five or more joints on both sides of the body (ie, the right and left knee). It produces symptoms similar to those of rheumatoid arthritis.",
"      </li>",
"      <li>",
"       Arthritis mutilans &mdash; This type of psoriatic arthritis deforms and destroys the joints, and it is often accompanied by a shortening of the affected fingers or toes.",
"      </li>",
"      <li>",
"       Spondyloarthropathy &mdash; This arthritis affects the joints of the spine.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Polyarthritis is the most common type of psoriatic arthritis, followed by oligoarthritis. Less than 20 percent of patients experience distal arthritis, but those who do may also have spondyloarthritis. Arthritis mutilans, the deforming type of arthritis, can occur along with any other pattern of arthritis.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Associated problems",
"     </span>",
"     &nbsp;&mdash;&nbsp;In addition to the joint pain and stiffness that psoriatic arthritis causes, there may also be swelling in the areas where tendons attach to bones, a condition called enthesitis. Sites that are commonly involved include the Achilles tendon attachment to the back of the heel, the attachment of plantar fascia (the tendon in the sole of the foot) to the heel, and the area that tendons attach to the pelvic bones. Another condition, tenosynovitis, can occur when the sheaths surrounding certain tendons, especially those in the hands and arms, become swollen and inflamed.",
"    </p>",
"    <p>",
"     Almost half of people with psoriatic arthritis also experience dactylitis, which causes an entire finger or toe to swell (sometimes called sausage finger or toe). Dactylitis may be associated with progressive joint damage (",
"     <a class=\"graphic graphic_picture graphicRef64253 \" href=\"mobipreview.htm?18/8/18560\">",
"      picture 4",
"     </a>",
"     ). People with psoriatic arthritis sometimes develop swelling of the hands and feet that is not limited to the joints. This swelling may occur before any joint symptoms of psoriatic arthritis are noted.",
"    </p>",
"    <p>",
"     Eighty to 90 percent of people with psoriatic arthritis have nail problems. They may develop pitted nails, which look as if someone has taken a pin and pricked the nail several times, or there may be early separation of the nail from the nail bed. The severity of a person's nail problems is often similar to the severity of the skin and joint problems (",
"     <a class=\"graphic graphic_picture graphicRef71998 \" href=\"mobipreview.htm?13/35/13886\">",
"      picture 3",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     In some cases, people with psoriatic arthritis also experience eye problems. Inflammation of the structures of the eye can cause eye pain and redness and is referred to as uveitis or iritis.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      PSORIATIC ARTHRITIS DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Healthcare providers diagnose psoriatic arthritis by obtaining the medical history, performing a physical examination, and taking x-rays of the joints to check for inflammation. Blood tests or joint fluid tests may be done to rule out other diseases, such as rheumatoid arthritis and gout.",
"    </p>",
"    <p>",
"     In some cases, a magnetic resonance imaging test (MRI) may be used to detect joint and soft-tissue inflammation that cannot be seen on x-rays. Because psoriatic arthritis may be associated with a loss in bone mineral density, tests may also be used to determine if you are at risk for osteoporosis or have an increased risk of bone fractures. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/29/1491?source=see_link\">",
"      \"Patient information: Bone density testing (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Psoriatic arthritis may be confused with other forms of arthritis, such as rheumatoid arthritis. However, the skin lesions, nail problems, and specific patterns of inflammation mean that it is usually possible to definitively distinguish psoriatic arthritis from other forms of inflammatory arthritis.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      PSORIASIS TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Psoriatic skin disease may be treated with topical applications (creams or lotions) or phototherapy. Skin problems that are resistant to topical therapy may require the use of oral treatments (pills). (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/11/3252?source=see_link\">",
"      \"Patient information: Psoriasis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Although effective in controlling the skin symptoms in most patients, none of these treatments work in all patients. Moreover, none can cure psoriasis; most patients have a flare of symptoms if treatment is discontinued. Thus, prolonged therapy is generally required.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      PSORIATIC ARTHRITIS TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Psoriatic arthritis treatment can help to relieve joint pain and stiffness as well as the other symptoms of psoriasis. More detailed information is available separately. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40234?source=see_link\">",
"      \"Treatment of psoriatic arthritis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Exercise and physical therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Treatments such as heat, exercise, and physical therapy may also help to relieve the pain and stiffness associated with psoriatic arthritis. A separate article discusses exercise and arthritis. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/62/28645?source=see_link\">",
"      \"Patient information: Arthritis and exercise (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Nonsteroidal antiinflammatory drugs (NSAIDs)",
"     </span>",
"     &nbsp;&mdash;&nbsp;NSAIDs can help to control inflammation and to relieve the pain of psoriatic arthritis. NSAIDs must be taken continuously and at a sufficient dose to have an antiinflammatory effect.",
"    </p>",
"    <p>",
"     NSAIDs must usually be taken for several weeks before their full degree of effectiveness as an antiinflammatory is known. If the initial dose of an NSAID does not improve symptoms, a clinician may recommend increasing the dose gradually or switching to another NSAID.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Nonselective NSAIDs include over-the-counter drugs, such as aspirin, ibuprofen, and naproxen, and a number of prescription-strength NSAIDs.",
"      </li>",
"      <li>",
"       Selective NSAIDs (also called COX-2 inhibitors) are as effective as nonselective NSAIDs and are less likely to cause gastrointestinal injury and side effects. Celecoxib (Celebrex&reg;) is the only COX-2 inhibitor currently available in the United States.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Detailed information about NSAIDs is available in a separate article. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/13/2262?source=see_link\">",
"      \"Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Glucocorticoid injections",
"     </span>",
"     &nbsp;&mdash;&nbsp;Glucocorticoids, also called steroids, can suppress inflammation and can relieve pain when injected into affected joints. Oral glucocorticoids are not usually recommended for people with psoriatic arthritis because they may cause a severe form of skin psoriasis.",
"    </p>",
"    <p>",
"     Joint injections have few side effects, but some people experience a brief flare of pain after an injection. There is also a very small risk of joint infection.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Methotrexate",
"     </span>",
"     &nbsp;&mdash;&nbsp;Methotrexate is a disease-modifying antirheumatic drug (DMARD) that reduces excessive production of skin cells and that may also suppress the immune system. It is often recommended for people with multiple swollen joints caused by psoriatic arthritis.",
"    </p>",
"    <p>",
"     It is usually taken once per week as a pill or by injection. Treatment with higher doses may require that it be injected under the skin, which may be done by a patient or family member.",
"    </p>",
"    <p>",
"     Taking folic acid or folinic acid can reduce the risk of certain methotrexate side effects, including risk of liver problems related to methotrexate. Patients who use methotrexate should not drink alcohol. The most serious potential side effects of methotrexate include liver toxicity, lung disease, and bone marrow suppression. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/40/27266?source=see_link\">",
"      \"Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Sulfasalazine",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sulfasalazine (sulphasalazine, salazopyrin) is a disease modifying antirheumatic drug (DMARD) that may be effective for the joint pain and skin lesions associated with psoriatic arthritis.",
"    </p>",
"    <p>",
"     However, not all patients benefit from sulfasalazine, and many patients cannot tolerate it due to gastrointestinal side effects. Patients who are allergic to sulfa drugs should not use sulfasalazine. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/11/17586?source=see_link\">",
"      \"Patient information: Sulfasalazine and the 5-aminosalicylates (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Leflunomide",
"     </span>",
"     &nbsp;&mdash;&nbsp;Leflunomide is a disease-modifying antirheumatic drug (DMARD) that can improve both skin and joint disease symptoms. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/40/27266?source=see_link\">",
"      \"Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Possible side effects include diarrhea and elevated liver enzymes, and only about 40 percent of people with psoriatic arthritis benefit from this treatment. Experts may recommend leflunomide if you have not adequately responded to or have had side effects with methotrexate.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      TNF inhibitors",
"     </span>",
"     &nbsp;&mdash;&nbsp;Tumor necrosis factor (TNF)-alpha inhibitors are among the group of drugs called biologic DMARDs or biologic response modifiers. These drugs interfere with inflammation and the immune response. Drugs in this class include proteins that interfere with the actions of TNF, such as etanercept (Enbrel&reg;), adalimumab (Humira&reg;), infliximab (Remicade&reg;), and golimumab (Simponi). If a traditional DMARD, such as methotrexate, has been ineffective, a medication from this class of agents will often be effective. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3384?source=see_link\">",
"      \"Overview of biologic agents in the rheumatic diseases\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Biologic agents, such as the TNF inhibitors, usually work rapidly, often within two weeks. They may be used alone or in combination with other DMARDs, NSAIDs,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     glucocorticoid injections. Because of their very high cost, they are often reserved for people who have not responded fully to DMARDs or who cannot tolerate DMARDs in doses large enough to control psoriatic arthritis symptoms.",
"    </p>",
"    <p>",
"     All biologic agents must be either injected or given intravenously, depending on the medication. Humira&reg; and Enbrel&reg; are injected under the skin by the patient, a family member, or a nurse. Intravenous infusion is necessary for Remicade&reg;; this is typically done in a doctor's office or an outpatient infusion center and takes one to three hours to complete.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H35335284\">",
"     <span class=\"h2\">",
"      Cyclosporine",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cyclosporine is a drug that suppresses the immune system and is also used to treat severe psoriasis and psoriatic arthritis. It was used more in the past, before the availability of the TNF inhibitors, but still may be helpful for some people with psoriatic arthritis. It may take three to four months before a response is seen. Adding cyclosporine to methotrexate may be more effective than either treatment alone. Side effects of cyclosporine can include impaired kidney function and high blood pressure.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      SUMMARY",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Psoriatic arthritis is a type of arthritis that affects some people with psoriasis, a disorder that causes inflammation and thickening of the skin.",
"      </li>",
"      <li>",
"       Researchers have not identified the exact cause of psoriatic arthritis. However, they believe that the disease develops due to a combination of genetic, immune, and environmental factors. (See",
"       <a class=\"local\" href=\"#H2\">",
"        'Psoriatic arthritis risk factors'",
"       </a>",
"       above.)",
"      </li>",
"      <li>",
"       Psoriatic arthritis can cause joint pain, immobility, and stiffness; dry, red patches (plaques) also form on the skin. Some people also experience problems with their fingernails or eyes. (See",
"       <a class=\"local\" href=\"#H6\">",
"        'Psoriatic arthritis symptoms'",
"       </a>",
"       above and",
"       <a class=\"local\" href=\"#H8\">",
"        'Associated problems'",
"       </a>",
"       above.)",
"      </li>",
"      <li>",
"       Psoriatic arthritis tends to affect certain groups of joints. The most common type of psoriatic arthritis affects five or more joints on both sides of the body. (See",
"       <a class=\"local\" href=\"#H7\">",
"        'Patterns of psoriatic arthritis'",
"       </a>",
"       above.)",
"      </li>",
"      <li>",
"       Physical examination, x-rays, and, sometimes, magnetic resonance imaging (MRI) are used to diagnose psoriatic arthritis. Skin and nail symptoms, as well as the pattern of joint pain and stiffness, help to determine if arthritis is psoriatic or not. (See",
"       <a class=\"local\" href=\"#H9\">",
"        'Psoriatic arthritis diagnosis'",
"       </a>",
"       above.)",
"      </li>",
"      <li>",
"       Symptoms of skin psoriasis are usually treated with creams or lotions and, in some cases, with light therapy. (See",
"       <a class=\"local\" href=\"#H10\">",
"        'Psoriasis treatment'",
"       </a>",
"       above.)",
"      </li>",
"      <li>",
"       Heat and physical therapy may help to relieve joint pain and stiffness. Joint inflammation is often treated with medications given as pills or injections. (See",
"       <a class=\"local\" href=\"#H11\">",
"        'Psoriatic arthritis treatment'",
"       </a>",
"       above.)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H863733804\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H292594620\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/9/3218?source=see_link\">",
"      Patient information: Psoriasis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/52/835?source=see_link\">",
"      Patient information: Psoriatic arthritis in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/21/26962?source=see_link\">",
"      Patient information: Disease modifying antirheumatic drugs (DMARDs) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/6/7267?source=see_link\">",
"      Patient information: Psoriatic arthritis in children (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H292594637\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/29/1491?source=see_link\">",
"      Patient information: Bone density testing (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/11/3252?source=see_link\">",
"      Patient information: Psoriasis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/62/28645?source=see_link\">",
"      Patient information: Arthritis and exercise (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/13/2262?source=see_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/21/18769?source=see_link\">",
"      Patient information: Joint infection (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/40/27266?source=see_link\">",
"      Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/11/17586?source=see_link\">",
"      Patient information: Sulfasalazine and the 5-aminosalicylates (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H863733797\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/49/30488?source=see_link\">",
"      Clinical manifestations and diagnosis of psoriatic arthritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23608?source=see_link\">",
"      Pathogenesis of psoriatic arthritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40234?source=see_link\">",
"      Treatment of psoriatic arthritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3384?source=see_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"     <br/>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Arthritis Society of Canada",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.arthritis.ca/\">",
"        www.arthritis.ca",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Arthritis Foundation",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.arthritis.org/\">",
"        www.arthritis.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/000413.htm\">",
"        www.nlm.nih.gov/medlineplus/ency/article/000413.htm",
"       </a>",
"       , available in Spanish)",
"      </li>",
"      <li>",
"       National Psoriasis Foundation",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.psoriasis.org/\">",
"        www.psoriasis.org",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Patient support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Arthritis Forum",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://arthritis.about.com/forum\">",
"        file://arthritis.about.com/forum",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?35/36/36419/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 8, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/36/36419?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36419/abstract/1\">",
"      Turkiewicz AM, Moreland LW. Psoriatic arthritis: current concepts on pathogenesis-oriented therapeutic options. Arthritis Rheum 2007; 56:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36419/abstract/2\">",
"      Helliwell PS, Taylor WJ. Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis 2005; 64 Suppl 2:ii3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36419/abstract/3\">",
"      Jones G, Crotty M, Brooks P. Interventions for psoriatic arthritis. Cochrane Database Syst Rev 2000; :CD000212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36419/abstract/4\">",
"      Heiberg MS, Kaufmann C, R&oslash;devand E, et al. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study. Ann Rheum Dis 2007; 66:1038.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f35_36_36419=[""].join("\n");
var outline_f35_36_36419=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           PSORIATIC ARTHRITIS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           PSORIATIC ARTHRITIS RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           PSORIATIC ARTHRITIS SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           PSORIATIC ARTHRITIS DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           PSORIASIS TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           PSORIATIC ARTHRITIS TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           SUMMARY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/39/14975\" title=\"picture 1\">",
"           Joints psoriatic arthr PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/13/39135\" title=\"picture 2\">",
"           Plaque type psoriasis PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/35/13886\" title=\"picture 3\">",
"           Nail psoriasis PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/8/18560\" title=\"picture 4\">",
"           Arthritis mutilans PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f35_36_36420="Solifenacin: Patient drug information";
var content_f35_36_36420=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Solifenacin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/33/39445?source=see_link\">",
"     see \"Solifenacin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F221517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      VESIcare&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat an overactive bladder.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702949",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to solifenacin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703505",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Trouble passing urine, glaucoma, or slow clearing of the stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a heart problem called congenital QT syndrome, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid grapefruit and grapefruit juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697889",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain or heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Allergic side effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11529 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-EE7AE732F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_36_36420=[""].join("\n");
var outline_f35_36_36420=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221517\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013306\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013305\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013310\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013311\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013313\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013308\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013309\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013314\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013315\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?38/33/39445?source=related_link\">",
"      Solifenacin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_36_36421="Single leg calf raise PI";
var content_f35_36_36421=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F82503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F82503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    Single-leg calf raises",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 370px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Stand behind a chair, holding onto the chair. Lift the \"good\" foot off the floor so that you are standing on the injured leg. Slowly rise up and stand on the ball of the foot and toes. Hold for 5 seconds then slowly roll down onto the entire foot. Rest as needed. Repeat 10 to 15 times (one set). Increase the difficulty of this exercise by rising higher, holding longer, or moving up and down more quickly. Perform a total of 3 sets.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_36_36421=[""].join("\n");
var outline_f35_36_36421=null;
var title_f35_36_36422="Orphenadrine, aspirin, and caffeine: Drug information";
var content_f35_36_36422=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Orphenadrine, aspirin, and caffeine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/31/34292?source=see_link\">",
"    see \"Orphenadrine, aspirin, and caffeine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F204068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Skeletal Muscle Relaxant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F204060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Muscular pain/spasms:",
"     </b>",
"     Oral: 1-2 tablets 3-4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F204061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended for use in the elderly; see individual agents",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F204049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: Orphenadrine citrate 25 mg, aspirin 385 mg, and caffeine 30 mg; orphenadrine citrate 50 mg, aspirin 770 mg, and caffeine 60 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F204040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F204051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of discomfort associated with skeletal muscular conditions",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14085447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F204054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the formulation; glaucoma; pyloric obstruction; duodenal obstruction; achalasia; prostatic hyperplasia; bladder obstruction; myasthenia gravis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F14085448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Muscle relaxants are poorly tolerated by the elderly due to potent anticholinergic effects, sedation, and risk of fracture. Efficacy is questionable at dosages tolerated by elderly patients; avoid use (Beers Criteria).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F204066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F204045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Salicylates may diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adenosine: Caffeine may diminish the therapeutic effect of Adenosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alendronate: Aspirin may enhance the adverse/toxic effect of Alendronate. Specifically gastrointestinal adverse events.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Salicylates may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the anticoagulant effect of Salicylates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: Salicylates may enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Salicylates may enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Salicylates may increase the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Salicylates may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: Weigh potential benefits of drotrecogin against increased bleeding risk in patients who have received  platelet inhibitors including aspirin (over 650 mg daily within 1 week). Monitor for bleeding and stop infusion if clinically important bleeding occurs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Floctafenine may diminish the cardioprotective effect of Aspirin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Formoterol: Caffeine may enhance the adverse/toxic effect of Formoterol. Caffeine may enhance the hypokalemic effect of Formoterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ginkgo Biloba: May enhance the anticoagulant effect of Salicylates. Management: Consider alternatives to this combination of agents. Monitor for signs and symptoms of bleeding (especially intracranial bleeding) if salicylates are used in combination with ginkgo biloba.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Heparin: Aspirin may enhance the anticoagulant effect of Heparin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Salicylates. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Salicylates may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving salicylates (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: Salicylates may enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indacaterol: Caffeine may enhance the adverse/toxic effect of Indacaterol. Caffeine may enhance the hypokalemic effect of Indacaterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Influenza Virus Vaccine (Live/Attenuated): May enhance the adverse/toxic effect of Salicylates. Specifically, Reye's syndrome may develop.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Nasal) may diminish the cardioprotective effect of Aspirin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Systemic) may diminish the cardioprotective effect of Aspirin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Salicylates may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Salicylates may increase the serum concentration of Methotrexate. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Aspirin. Aspirin may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, aspirin may decrease absorption of ascorbic acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Aspirin may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).  Management: Concurrent use of aspirin at doses beyond cardioprotective levels is not recommended.  While concurrent use of low-dose aspirin with a COX-2 inhibitor is permissable, patients should be monitored closely for signs/symptoms of GI ulceration/bleeding.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): May enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Aspirin may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of aspirin with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Acid Phosphate: May increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Salicylates may increase the serum concentration of PRALAtrexate. Salicylate doses used for prophylaxis of cardiovascular events are unlikely to be of concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: Salicylates may diminish the therapeutic effect of Probenecid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May decrease the metabolism of Caffeine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Gemifloxacin; Levofloxacin (Systemic); Lomefloxacin; Moxifloxacin (Systemic); Nalidixic Acid; Ofloxacin (Systemic); Sparfloxacin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regadenoson: Caffeine may diminish the vasodilatory effect of Regadenoson.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the anticoagulant effect of other Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teriflunomide: May decrease the serum concentration of Caffeine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: Aspirin may enhance the antiplatelet effect of Ticagrelor. Aspirin may diminish the therapeutic effect of Ticagrelor. More specifically, the benefits of ticagrelor relative to clopidogrel may be diminished in patients receiving daily aspirin doses greater than 100-150 mg daily.  Management: Avoid daily aspirin doses greater than 100 mg in patients receiving ticagrelor.  Canadian recommendations are to avoid daily aspirin doses greater than 150 mg.  Daily low-dose aspirin (U.S.: 75-100 mg; Canada: 75-150 mg) is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiludronate: Aspirin may decrease the serum concentration of Tiludronate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Salicylates. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Salicylates may increase the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varicella Virus-Containing Vaccines: Salicylates may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. Reye's Syndrome may develop.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Salicylates may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13205938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13205939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Orphenadrine-Aspirin-Caffeine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25-385-30 mg (100): $88.75",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F204056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Norgesic Forte (DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Norgesic&reg; (CA);",
"     </li>",
"     <li>",
"      Norgesic&reg; Forte (CA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F204053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/36/36422/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Capone ML, Sciulli MG, Tacconelli S, et al,  &ldquo;Pharmacodynamic Interaction of Naproxen With Low-Dose Aspirin in Healthy Subjects,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2005, 45(8):1295-1301.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/36/36422/abstract-text/15837265/pubmed\" id=\"15837265\" target=\"_blank\">",
"        15837265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Catella-Lawson F, Reilly MP, Kapoor SC, et al, &ldquo;Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(25):1809-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/36/36422/abstract-text/11752357/pubmed\" id=\"11752357\" target=\"_blank\">",
"        11752357",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cryer B, Verlin RG, Cooper SA, et al, &ldquo;Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Ibuprofen Effects on Thromboxane B2 Concentrations in Aspirin-Treated Healthy Adult Volunteers,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2005, 27(2):185-191.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/36/36422/abstract-text/15811481/pubmed\" id=\"15811481\" target=\"_blank\">",
"        15811481",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9803 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-76F9A528C7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_36_36422=[""].join("\n");
var outline_f35_36_36422=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204068\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204060\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204061\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204049\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204040\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204051\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14085447\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204054\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14085448\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204066\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204045\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13205938\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13205939\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422270\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204056\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204053\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9803\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9803|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/31/34292?source=related_link\">",
"      Orphenadrine, aspirin, and caffeine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_36_36423="Carbidopa-levodopa: Drug information";
var content_f35_36_36423=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Carbidopa-levodopa: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/6/31844?source=see_link\">",
"    see \"Carbidopa-levodopa: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F187993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Parcopa&reg;;",
"     </li>",
"     <li>",
"      Sinemet&reg;;",
"     </li>",
"     <li>",
"      Sinemet&reg; CR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F187994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Levocarb&reg;;",
"     </li>",
"     <li>",
"      Apo-Levocarb&reg; CR;",
"     </li>",
"     <li>",
"      Dom-Levo-Carbidopa;",
"     </li>",
"     <li>",
"      Duodopa&trade;;",
"     </li>",
"     <li>",
"      Levocarb CR;",
"     </li>",
"     <li>",
"      Nu-Levocarb;",
"     </li>",
"     <li>",
"      PRO-Levocarb;",
"     </li>",
"     <li>",
"      Sinemet&reg;;",
"     </li>",
"     <li>",
"      Sinemet&reg; CR;",
"     </li>",
"     <li>",
"      Teva-Levocarbidopa",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F188007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anti-Parkinson's Agent, Decarboxylase Inhibitor;",
"     </li>",
"     <li>",
"      Anti-Parkinson's Agent, Dopamine Precursor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F187997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Parkinson's disease:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release tablet, orally-disintegrating tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial: Carbidopa 25 mg/levodopa 100 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Dosage adjustment: Alternate tablet strengths may be substituted according to individual carbidopa/levodopa requirements. Increase by 1 tablet every 1-2 days as necessary, except when using the carbidopa 25 mg/levodopa 250 mg tablets where increases should be made using",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     -1 tablet every 1-2 days. Use of more than 1 dosage strength or dosing 4 times/day may be required (maximum: 8 tablets of any strength/day or 200 mg of carbidopa and 2000 mg of levodopa)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Controlled release tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Patients not currently receiving levodopa: Initial: Carbidopa 50 mg/levodopa 200 mg 2 times/day, at intervals not &lt;6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Patients converting from immediate release formulation to controlled release: Initial: Dosage should be substituted at an amount that provides ~10% more of levodopa/day; total calculated dosage is administered in divided doses 2-3 times/day (or &ge;3 times/day for patients maintained on levodopa &ge;700 mg). Intervals between doses should be 4-8 hours while awake; when divided doses are not equal, smaller doses should be given toward the end of the day. Depending on clinical response, dosage may need to be increased to provide up to 30% more levodopa/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Dosage adjustment: May adjust every 3 days; intervals should be between 4-8 hours during the waking day (maximum dose: 8 tablets/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intestinal infusion via PEG tube: Intestinal gel (Canadian labeling; not available in U.S.):",
"     <b>",
"      Note:",
"     </b>",
"     Conversion to/from oral levodopa  tablet formulations and the intestinal gel formulation can be done on a 1:1 ratio. Total daily dose (expressed in terms of levodopa) consists of a morning bolus dose, a continuous maintenance dose, and additional bolus doses when necessary. Nighttime dosing may be necessary in certain rare situations (eg, nocturnal akinesia). Dosage adjustments should be carried out over a period of a few weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Morning bolus dose (based on previous morning levodopa intake and volume to fill intestinal tubing): Usual: Levodopa 100-200 mg (5-10 mL); Maximum: Levodopa 300 mg (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous maintenance dose: Adjustable in increments of 2 mg/hour (0.1 mL/hour) and based on previous daily intake of levodopa: Usual: Levodopa 40-120 mg/hour (2-6 mL/hour) infused up to 16 hours; Range: Levodopa 20-200 mg/hour (1-10 mL/hour)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Additional bolus doses: Usual: Levodopa: 10-40 mg (0.5-2 mL), if needed for daytime hypokinesia;  in patients requiring &gt;5 additional boluses/day, the maintenance dose should be increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Restless leg syndrome (RLS) (unlabeled use; Silber, 2004):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release tablet: Carbidopa 25 mg/levodopa 100 mg  (0.5-1 tablet) given in the evening, at bedtime, or upon waking during the night with RLS symptoms",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Controlled release tablet: Carbidopa 25 mg/levodopa 100 mg (1 tablet) before bedtime for RLS symptoms that awaken patient during the night",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F187998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F10909896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution; manufacturer labeling makes no specific dosing recommendations.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F10909895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution; manufacturer labeling makes no specific dosing recommendations.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F187974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet: 10/100: Carbidopa 10 mg and levodopa 100 mg; 25/100: Carbidopa 25 mg and levodopa 100 mg; 25/250: Carbidopa 25 mg and levodopa 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sinemet&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     10/100: Carbidopa 10 mg and levodopa 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     25/100: Carbidopa 25 mg and levodopa 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     25/250: Carbidopa 25 mg and levodopa 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release: 25/100: Carbidopa 25 mg and levodopa 100 mg; 50/200: Carbidopa 50 mg and levodopa 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating: 10/100: Carbidopa 10 mg and levodopa 100 mg; 25/100: Carbidopa 25 mg and levodopa 100 mg; 25/250: Carbidopa 25 mg and levodopa 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Parcopa&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     10/100: Carbidopa 10 mg and levodopa 100 mg [contains phenylalanine 3.4 mg/tablet; mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     25/100: Carbidopa 25 mg and levodopa 100 mg [contains phenylalanine 3.4 mg/tablet; mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     25/250: Carbidopa 25 mg and levodopa 250 mg [contains phenylalanine 8.4 mg/tablet; mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, sustained release: 25/100: Carbidopa 25 mg and levodopa 100 mg; 50/200: Carbidopa 50 mg and levodopa 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sinemet&reg; CR:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     25/100: Carbidopa 25 mg and levodopa 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     50/200: Carbidopa 50 mg and levodopa 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10909903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intestinal gel:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Duodopa&trade;: Carbidopa 5 mg and levodopa 20 mg/1 mL (100 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F187958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11236626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Duodopa&trade; intestinal gel (Canadian labeling; product not available in U.S.):",
"     </b>",
"     In Canada, the Duodopa&trade; Education Program is a risk mitigation program established to provide safe and effective use of Duodopa&trade; in advanced Parkinson&rsquo;s patients. The program involves:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     - Education of prescribing neurologists and other healthcare providers on suitable candidates for treatment, surgical procedures (PEG tube placement), and follow-up care including infusion device education.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     - Distribution of educational materials to patients and caregivers describing Duodopa&trade; intestinal gel and its proper use, PEG tube placement, and complications associated with the mode of administration and/or PEG tube placement.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F187978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral tablet formulations: Space doses evenly over the waking hours. Give with meals to decrease GI upset. Controlled release product should not be chewed or crushed. Orally-disintegrating tablets do not require water; the tablet should disintegrate on the tongue's surface before swallowing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intestinal gel (Canadian labeling; not available in U.S.): Gel is administered directly to the duodenum via a portable infusion pump (CADD-legacy Duodopa&trade; pump). Administer through a temporary nasoduodenal tube for at least 3 days to evaluate patient response and for dose optimization. Long-term administration requires placement of PEG tube for intestinal infusion. Continuous maintenance dose is infused throughout the day for up to 16 hours.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F187977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Idiopathic Parkinson's disease; postencephalitic parkinsonism; symptomatic parkinsonism",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Duodopa&trade; intestinal gel: Canadian labeling (not available in U.S.): Treatment of advanced levodopa-responsive Parkinson&rsquo;s disease in which severe motor symptoms are not controlled by other Parkinson&rsquo;s agents",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F188004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Restless leg syndrome",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6842204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Sinemet&reg; may be confused with Serevent&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zimox: Brand name for carbidopa and levodopa [Greece], but also the brand name for amoxicillin [Italy]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zimox [Greece] may be confused with Diamox which is a brand name for acetazolamide [Canada and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F188005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, chest pain, edema, flushing, hypotension, hypertension, MI, orthostatic hypotension, palpitation, phlebitis, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, ataxia, confusion, delusions, dementia, depression (with or without suicidal tendencies), disorientation, dizziness, dreams abnormal, EPS, euphoria, faintness, falling, fatigue, gait abnormalities, headache, hallucinations, impulse control symptoms, insomnia, malaise, memory impairment, mental acuity decreased, nervousness, neuroleptic malignant syndrome, nightmares, on-off phenomena, paranoid ideation, pathological gambling, psychosis, seizure (causal relationship not established), somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, malignant melanoma, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hot flashes, hyperglycemia, hypokalemia, libido increased (including hypersexuality), uric acid increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, abdominal distress, anorexia, bruxism, constipation, diarrhea, discoloration of saliva, duodenal ulcer, dyspepsia, dysphagia, flatulence, GI bleeding, heartburn, nausea, sialorrhea, taste alterations, tongue burning sensation, weight gain/loss, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Discoloration of urine, glycosuria, urinary frequency, priapism, proteinuria, urinary incontinence, urinary retention, urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, anemia, Coombs&rsquo; test abnormal, hematocrit decreased, hemoglobin decreased, hemolytic anemia, leukopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase abnormal, ALT abnormal, AST abnormal, bilirubin abnormal, LDH abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, dyskinesias (including choreiform, dystonic and other involuntary movements), leg pain, muscle cramps, muscle twitching, numbness, paresthesia, peripheral neuropathy,  shoulder pain, tremor increased, trismus, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blepharospasm, blurred vision, diplopia, Horner&rsquo;s syndrome reactivation, mydriasis, oculogyric crises (may be associated with acute dystonic reactions)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Difficult urination",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, hoarseness, pharyngeal pain, upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Discoloration of sweat, diaphoresis increased, hiccups, hypersensitivity reactions (angioedema, pruritus, urticaria, bullous lesions [including pemphigus-like reactions], Henoch-Sch&ouml;nlein purpura)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F187981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to levodopa, carbidopa, or any component of the formulation; narrow-angle glaucoma; use of MAO inhibitors within prior 14 days (however, may be administered concomitantly with the manufacturer's recommended dose of an MAO inhibitor with selectivity for MAO type B); history of melanoma or undiagnosed skin lesions",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications: Clinical or laboratory evidence of uncompensated cardiovascular, cerebrovascular, endocrine, renal, hepatic, hematologic or pulmonary disease; when administration of a sympathomimetic amine (eg, epinephrine, norepinephrine or isoproterenol) is contraindicated; intestinal gel therapy in patients with any condition preventing the required placement of a PEG tube for administration.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F187962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dyskinesias: May cause or exacerbate dyskinesias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Impulse control disorders: Dopamine agonists used for Parkinson&rsquo;s disease or restless legs syndrome have been associated with compulsive behaviors and/or loss of impulse control, which has manifested as pathological gambling, libido increases (hypersexuality), and/or binge eating. Causality has not been established, and controversy exists as to whether this phenomenon is related to the underlying disease, prior behaviors/addictions and/or drug therapy. Dose reduction or discontinuation of therapy has been reported to reverse these behaviors in some, but not all cases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Melanoma: Risk for melanoma development is increased in Parkinson&rsquo;s disease patients; drug causation or factors contributing to risk have not been established. Patients should be monitored closely and periodic skin examinations should be performed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension; Parkinson's disease patients appear to have an impaired capacity to respond to a postural challenge. Use with caution in patients at risk of hypotension (such as those receiving antihypertensive drugs) or where transient hypotensive episodes would be poorly tolerated (cardiovascular disease or cerebrovascular disease). Parkinson's patients being treated with dopaminergic agonists ordinarily require careful monitoring for signs and symptoms of postural hypotension, especially during dose escalation, and should be informed of this risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Somnolence: Patients have reported falling asleep while engaging in activities of daily living; this has been reported to occur without significant warning signs. Monitor for daytime somnolence or pre-existing sleep disorder; caution with concomitant sedating medication; discontinue if significant daytime sleepiness or episodes of falling asleep occur. Patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Use with caution in patients receiving other CNS depressants or psychoactive agents. Effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease, including a history of myocardial infarction and arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Endocrine disease: Use with caution when interpreting plasma/urine catecholamine levels; falsely-diagnosed pheochromocytoma has been rarely reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with glaucoma; monitor IOP carefully in patients with wide-angle glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peptic ulcer disease: Use with caution in patients with peptic ulcer disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychotic disorders: Use with extreme caution in patients with psychotic disorders; observe patients closely for development of depression with concomitant suicidal tendencies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Use with caution in patients at risk for or with a history of seizures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to CNS effects of levodopa.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage forms specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intestinal gel: Canadian labeling (not available in U.S.): Product should be prescribed only by neurologists experienced in the treatment of Parkinson&rsquo;s disease and who have completed the Duodopa&trade; Education Program. Response to levodopa/carbidopa intestinal gel therapy should be assessed with a test period (~3 days) of administration via a temporary nasoduodenal tube prior to placement of a percutaneous endoscopic gastrostomy (PEG) tube for permanent access and administration. Sudden deterioration in therapy response with recurring motor symptoms may indicate PEG tube complications (eg, displacement) or obstruction of the infusion device. Tube or infusion device complications may require initiation of oral levodopa/carbidopa therapy until complications are resolved. Discontinue therapy 2-3 hours prior to surgical procedures requiring general anesthesia, if possible. May resume therapy postoperatively when oral fluid intake is permitted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dietary protein: Distribute dietary protein throughout the day to avoid fluctuations in levodopa absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Dopaminergic agents have been associated with a syndrome resembling neuroleptic malignant syndrome on abrupt withdrawal or significant dosage reduction after long-term use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F187967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics (Atypical): May diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist). Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson's disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics (Typical): Anti-Parkinson's Agents (Dopamine Agonist) may diminish the therapeutic effect of Antipsychotics (Typical). Antipsychotics (Typical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).  Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson's agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May diminish the therapeutic effect of Levodopa.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glycopyrrolate: May decrease the serum concentration of Levodopa.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the serum concentration of Levodopa. Only applies to oral iron preparations. Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: Levodopa may enhance the adverse/toxic effect of MAO Inhibitors. Of particular concern is the development of hypertensive reactions when levodopa is used with nonselective MAOI.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methionine: May diminish the therapeutic effect of Levodopa. Probably only with large doses of methionine.  Data was generated using 4.5gm daily.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May enhance the adverse/toxic effect of Anti-Parkinson's Agents (Dopamine Agonist).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May diminish the therapeutic effect of Levodopa. Multivitamins/Minerals (with ADEK, Folate, Iron) may decrease the serum concentration of Levodopa. Only applies to oral iron-containing preparations. Management: Separate doses of these agents by 2 or more hours.  Monitor for decreased levodopa effects, particularly if doses cannot be separated.  Concurrent use of a multivitamin and levodopa (without carbidopa) should be avoided.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May diminish the therapeutic effect of Levodopa.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pyridoxine: May diminish the therapeutic effect of Levodopa. Management: The concomitant use of pyridoxine and levodopa (in the absence of a dopa decarboxylase inhibitor (DDI)) should be avoided. Use of a DDI (e.g., carbidopa) with levodopa will essentially eliminate the risk of this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sapropterin: May enhance the adverse/toxic effect of Levodopa.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F187990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (due to CNS depression).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Avoid high protein diets due to potential for impaired levodopa absorption; levodopa competes with certain amino acids for transport across the gut wall or across the blood-brain barrier.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid kava kava (may decrease effects). Pyridoxine (vitamin B",
"     <sub>",
"      6",
"     </sub>",
"     ) in doses &gt;10-25 mg (for levodopa alone) may decrease efficacy. Iron supplements or iron-containing multivitamins may reduce absorption of levodopa.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F187970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F187985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were observed with levodopa and carbidopa in animal studies. There are case reports of levodopa crossing the placenta in humans.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F188001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F187986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid high protein diets (&gt;2 g/kg) which may decrease the efficacy of levodopa via competition with amino acids in crossing the blood-brain barrier. Some products may contain phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F187984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Carbidopa-Levodopa ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25-100 mg (100): $93.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-200 mg (100): $180.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Sinemet CR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25-100 mg (100): $138.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-200 mg (100): $266.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, orally-disintegrating",
"     </b>",
"     (Carbidopa-Levodopa Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-100 mg (100): $121.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25-100 mg (100): $137.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25-250 mg (100): $174.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, orally-disintegrating",
"     </b>",
"     (Parcopa Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-100 mg (100): $325.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25-100 mg (100): $367.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25-250 mg (100): $468.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Carbidopa-Levodopa Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-100 mg (100): $77.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25-100 mg (100): $80.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25-250 mg (100): $101.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Sinemet Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-100 mg (100): $109.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25-100 mg (100): $123.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25-250 mg (100): $157.52",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F187972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic hepatic function tests, BUN, creatinine, and CBC; periodic skin examinations; blood pressure, standing and sitting/supine; symptoms of parkinsonism, dyskinesias, mental status",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F187987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Levotard (MY);",
"     </li>",
"     <li>",
"      Bidopar (TW);",
"     </li>",
"     <li>",
"      Carbilev (ZA);",
"     </li>",
"     <li>",
"      Cardopar (SG);",
"     </li>",
"     <li>",
"      Carlevod (AR);",
"     </li>",
"     <li>",
"      Cloisone (EC);",
"     </li>",
"     <li>",
"      Cronomet (BR);",
"     </li>",
"     <li>",
"      Dopadura (DE);",
"     </li>",
"     <li>",
"      Dopicar (IL);",
"     </li>",
"     <li>",
"      Duodopa (AU, IL);",
"     </li>",
"     <li>",
"      DuoDopa (BE, GB, IE);",
"     </li>",
"     <li>",
"      Enpalevo (TW);",
"     </li>",
"     <li>",
"      Grifoparkin (CN, PE);",
"     </li>",
"     <li>",
"      Kinson (AU);",
"     </li>",
"     <li>",
"      Lebocar (AR);",
"     </li>",
"     <li>",
"      Levoda PRT (KP);",
"     </li>",
"     <li>",
"      Levohexal (AU);",
"     </li>",
"     <li>",
"      Levomed (MY);",
"     </li>",
"     <li>",
"      Levomet (HK, SG, TH);",
"     </li>",
"     <li>",
"      Nakom (EE, RU);",
"     </li>",
"     <li>",
"      Parken (CO);",
"     </li>",
"     <li>",
"      Parkin (KP);",
"     </li>",
"     <li>",
"      Parkomet (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Racovel (MX);",
"     </li>",
"     <li>",
"      Saniter (CN);",
"     </li>",
"     <li>",
"      Sindopa (NZ);",
"     </li>",
"     <li>",
"      Sinedopa (HK, MY);",
"     </li>",
"     <li>",
"      Sinedopa Mite (MY);",
"     </li>",
"     <li>",
"      Sinemet (AT, AU, BE, BR, CH, CR, CZ, DE, DK, DO, EE, EG, ES, FI, FR, GB, GR, GT, HK, HN, IE, IT, KP, MT, MX, MY, NI, NL, NO, NZ, PA, PK, PL, PT, PY, RU, SE, SK, SV, TH, TR, TW, UY, VE);",
"     </li>",
"     <li>",
"      Sinemet 25 100 (HK, MY, PH);",
"     </li>",
"     <li>",
"      Sinemet CR (AU, BE, BG, CH, CL, CR, CZ, DO, GB, GR, GT, HK, HN, IL, IT, KP, MY, NI, NL, NZ, PA, PE, PH, PT, SV);",
"     </li>",
"     <li>",
"      Sinemet Retard (ES);",
"     </li>",
"     <li>",
"      Sulconar (PE);",
"     </li>",
"     <li>",
"      Syndopa (IN);",
"     </li>",
"     <li>",
"      Tidomet (PH, TH);",
"     </li>",
"     <li>",
"      Tidomet CR (PH);",
"     </li>",
"     <li>",
"      Tidomet Forte (IN);",
"     </li>",
"     <li>",
"      Tidomet L.S. (IN);",
"     </li>",
"     <li>",
"      Tidomet Plus (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F187961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parkinson's symptoms are due to a lack of striatal dopamine; levodopa circulates in the plasma to the blood-brain-barrier (BBB), where it crosses, to be converted by striatal enzymes to dopamine; carbidopa inhibits the peripheral plasma breakdown of levodopa by inhibiting its decarboxylation, and thereby increases available levodopa at the BBB",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F187980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Levodopa: 0.9-1.6 L/kg (in presence of carbidopa), crosses the blood-brain barrier;Carbidopa: Does not cross the blood-brain barrier",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Levodopa: Two major pathways (decarboxylation and O-methylation) and two minor pathways (transamination and oxidation) of metabolism; Carbidopa inhibits the decarboxylation of levodopa to dopamine in the peripheral tissue to allow greater levodopa distribution into the CNS",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Controlled release: Levodopa: Bioavailability is 70% to 75% relative to availability from immediate release formulation; Carbidopa: Bioavailability is ~58% relative to availability from immediate release formulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intestinal gel: Levodopa: Similar bioavailability relative to oral administration of tablet formulations (81% to 98%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Immediate release: Levodopa (in presence of carbidopa): 1.5 hours; Half-life may be prolonged with controlled release formulations due to continuous absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Immediate release: 0.5 hours; Controlled release: 2 hours; Intestinal gel: therapeutic plasma levels reached 10-30 minutes following morning bolus dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Levodopa: Urine (as metabolites); Carbidopa: Urine (~50% of an oral dose)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Devos D, &ldquo;Patient Profile, Indications, Efficacy and Safety of Duodenal Levodopa Infusion in Advanced Parkinson&rsquo;s Disease,&rdquo;",
"      <i>",
"       Mov Disord",
"      </i>",
"      , 2009, 24(7):993-1000.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/36/36423/abstract-text/19253412/pubmed\" id=\"19253412\" target=\"_blank\">",
"        19253412",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Factor SA, &ldquo;Current Status of Symptomatic Medical Therapy in Parkinson&rsquo;s Disease,&rdquo;",
"      <i>",
"       Neurotherapeutics",
"      </i>",
"      , 2008, 5(2):164-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/36/36423/abstract-text/18394561/pubmed\" id=\"18394561\" target=\"_blank\">",
"        18394561",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Molina JA, S&agrave;inz-Artiga MJ, Fraile A, et al, &ldquo;Pathologic Gambling in Parkinson's Disease: A Behavioral Manifestation of Pharmacologic Treatment,&rdquo;",
"      <i>",
"       Mov Disord",
"      </i>",
"      , 2000, 15(5):869-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/36/36423/abstract-text/11009192/pubmed\" id=\"11009192\" target=\"_blank\">",
"        11009192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Olanow CW, Watts RL, and Koller WC, &ldquo;An Algorithm (Decision Tree) for the Management of Parkinson's Disease (2001): Treatment Guidelines,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2001, 56(11 Suppl 5):1-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/36/36423/abstract-text/11402154/pubmed\" id=\"11402154\" target=\"_blank\">",
"        11402154",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silber MH, Ehrenberg BL, Allen RP, et al, &ldquo;An Algorithm for the Management of Restless Legs Syndrome,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 2004, 79(7):916-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/36/36423/abstract-text/15244390/pubmed\" id=\"15244390\" target=\"_blank\">",
"        15244390",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stern MB, &ldquo;Contemporary Approaches to the Pharmacotherapeutic Management of Parkinson's Disease: An Overview,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1997, 49(1 Suppl 1):2-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/36/36423/abstract-text/9222162/pubmed\" id=\"9222162\" target=\"_blank\">",
"        9222162",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walker SW, Fina A, and Kryger MH, &ldquo;L-Dopa/Carbidopa for Nocturnal Movement Disorders in Uremia,&rdquo;",
"      <i>",
"       Sleep",
"      </i>",
"      , 1996, 19(3):214-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/36/36423/abstract-text/8723378/pubmed\" id=\"8723378\" target=\"_blank\">",
"        8723378",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weintraub D, Siderowf AD, Potenza MN, et al, &ldquo;Association of Dopamine Agonist Use With Impulse Control Disorders in Parkinson Disease,&rdquo;",
"      <i>",
"       Arch Neurol",
"      </i>",
"      , 2006, 63(7):969-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/36/36423/abstract-text/16831966/pubmed\" id=\"16831966\" target=\"_blank\">",
"        16831966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vignatelli L, Billiard M, Clarenbach P, et al,  &ldquo;EFNS Guidelines on Management of Restless Leg Syndrome and Periodic Limb Movement Disorder in Sleep,&rdquo;",
"      <i>",
"       Eur J Neurol",
"      </i>",
"      , 2006, 13(10):1049-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/36/36423/abstract-text/16987157/pubmed\" id=\"16987157\" target=\"_blank\">",
"        16987157",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8994 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-199.231.185.123-3EAB60D91F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_36_36423=[""].join("\n");
var outline_f35_36_36423=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187993\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187994\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188007\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187997\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187998\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10909896\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10909895\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187974\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10909903\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187958\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11236626\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187978\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187977\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188004\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6842204\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188005\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187981\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187962\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298971\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187967\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187990\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187970\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187985\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188001\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187986\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187984\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187972\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187987\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187961\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187980\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8994\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8994|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/6/31844?source=related_link\">",
"      Carbidopa-levodopa: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_36_36424="Clinical significance and treatment of ventricular premature beats";
var content_f35_36_36424=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical significance and treatment of ventricular premature beats",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/36/36424/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/36/36424/contributors\">",
"     Philip J Podrid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/36/36424/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/36/36424/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/36/36424/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/36/36424/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/36/36424/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular premature beats (VPBs), also referred to as ventricular premature complexes, premature ventricular beats, premature ventricular complexes, or ventricular extrasystoles, are triggered from the ventricular myocardium in a variety of situations. VPBs are common and occur in a broad spectrum of the population. This includes patients without structural heart disease and those with any form of cardiac disease, independent of severity.",
"   </p>",
"   <p>",
"    The clinical significance and treatment of VPBs will be reviewed here. Issues related to classification, prevalence, etiology, and evaluation of VPBs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9320?source=see_link\">",
"     \"Prevalence and evaluation of ventricular premature beats\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/57/1942?source=see_link&amp;anchor=H1#H1\">",
"     \"ECG tutorial: Ventricular arrhythmias\", section on 'Premature ventricular contractions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL SIGNIFICANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular premature beats (VPBs) are frequently detected during auscultation or routine electrocardiographic recording. VPBs produce few or no symptoms in the vast majority of patients, and there is no evidence that suppression can extend life expectancy or reduce the risk of an untoward arrhythmic event even in patients with heart disease.",
"   </p>",
"   <p>",
"    On occasion, patients are incapacitated by palpitations or dizziness related to VPBs. VPBs rarely cause true hemodynamic compromise except in patients with frequent ectopy and severely depressed left ventricular function or when VPBs are concurrent with underlying bradycardia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. On rare occasions, frequent VPBs can result in left ventricular dysfunction, which improves following suppression of the VPBs or ablation of the VPBs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27097?source=see_link&amp;anchor=H14#H14\">",
"     \"Tachycardia-mediated cardiomyopathy\", section on 'Frequent ventricular ectopy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While VPBs are often thought to be of minimal clinical significance, particularly in patients without a history of cardiac disease, most studies have reported an increased mortality in patients with VPBs. However, prophylactic treatment of asymptomatic VPBs in patients without cardiomyopathy has not been shown to improve mortality. As such, the presence of VPBs should alert the clinician to potential coexistent cardiac disease, which may require additional clinical assessment or therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9320?source=see_link&amp;anchor=H15#H15\">",
"     \"Prevalence and evaluation of ventricular premature beats\", section on 'Clinical evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     No apparent heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of simple ventricular premature beats (VPBs) in patients with apparently normal hearts is associated with increased mortality, as illustrated by the following studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Atherosclerosis Risk in Communities (ARIC) study of subjects without known heart disease followed for more than 10 years, those with a single VPB on a single two-minute ECG had a greater than twofold increase in mortality from coronary heart disease (CHD) compared to those without any VPBs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/3\">",
"       3",
"      </a>",
"      ]. A subsequent study from the ARIC group reported a twofold increase in sudden cardiac death (SCD) in patients with VPBs compared to those without VPBs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 45,402 veterans, 3.8 percent had VPBs on a resting ECG. Compared to those without VPBs, patients with VPBs had a significantly higher all cause mortality (22 versus 39 percent) and cardiovascular mortality (8 versus 20 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a meta-analysis of eight prospective observational cohort studies (3629 persons total) without apparent heart disease, the presence of VPBs was associated with a significantly greater likelihood of the combined endpoint of all-cause mortality, cardiovascular mortality, SCD, or development of ischemic CHD (pooled odds ratio 1.72, 95% CI 1.28-2.31) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are also conflicting data on the prognostic significance of frequent and complex ventricular ectopy in patients with apparently normal hearts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/7-12\">",
"     7-12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one cohort of 73 asymptomatic healthy patients with frequent and complex ventricular ectopy identified on 24-hour Holter monitoring (including multiform VPBs, ventricular couplets, and ventricular tachycardia), outcomes after a 6.5-year follow-up were similar to those in the general population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/11\">",
"       11",
"      </a>",
"      ]. Earlier studies also noted a favorable long-term prognosis in similar patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, analyses of patients from the Multiple Risk Factor Intervention Trial (MRFIT), a study of apparently healthy persons aged 55 years or older and the Framingham Heart Study have all shown a higher risk of mortality in patients with frequent or complex VPBs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/7,12,13\">",
"       7,12,13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Pulmonary dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with ventricular premature beats (VPBs) and no apparent heart disease, reduced pulmonary function may identify a group at increased risk. This was suggested in a population-based study of 402 men who were 68 years of age, had no history of stroke or myocardial infarction, and were followed for 14 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/14\">",
"     14",
"    </a>",
"    ]. Among subjects with frequent or complex VPBs, those with a reduction in the forced expiratory volume in one second (FEV1), vital capacity (VC), or",
"    <span class=\"nowrap\">",
"     FEV1/VC",
"    </span>",
"    had a significantly higher mortality (72 versus 27 per 1000 person-years with a high FEV1, adjusted relative risk 2.91) and more coronary events (38 versus 18, adjusted relative risk 2.16).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Post-MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular premature beats (VPBs), particularly if frequent (more than 10 per hour) or complex (ie, repetitive forms, primarily nonsustained ventricular tachycardia), appear to be associated with a worse prognosis in patients with a prior MI. However, attempted suppression of this arrhythmia with class I antiarrhythmic drugs in such patients has been associated with increased mortality (",
"    <a class=\"graphic graphic_figure graphicRef59975 \" href=\"mobipreview.htm?19/4/19534\">",
"     figure 1",
"    </a>",
"    ), while",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    significantly reduces arrhythmic mortality, but not total mortality. Thus, amiodarone is the preferred antiarrhythmic drug in patients with symptomatic VPBs despite beta blocker therapy. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/38/31336?source=see_link\">",
"     \"Prophylaxis against ventricular arrhythmias following myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Heart failure or cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with dilated cardiomyopathy or heart failure have a reported 70 to 95 percent prevalence of ventricular premature beats (VPBs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/15\">",
"     15",
"    </a>",
"    ]. Although data are limited, there is no evidence that VPBs alone are associated with a worse prognosis in patients with heart failure. In contrast, VPBs do appear to have prognostic value in patients with heart failure when the VPBs are associated with abnormal heart rate variability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/16\">",
"     16",
"    </a>",
"    ]. In addition, the combination of frequent VPBs and nonsustained ventricular tachycardia independently predicts mortality in ambulatory patients with chronic heart failure and has been incorporated into a mortality risk score [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/47/21241?source=see_link\">",
"     \"Ventricular arrhythmias in heart failure and cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with hypertrophic cardiomyopathy, VPBs are common, but unlike nonsustained ventricular tachycardia, VPBs have not been associated with an increased risk of sudden cardiac death. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/3/22586?source=see_link\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to symptoms related to ectopy, frequent VPBs can result in deterioration of left ventricular function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/18\">",
"     18",
"    </a>",
"    ]. Very frequent ventricular ectopy in the form of VPBs has been associated with a reversible cardiomyopathy. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Radiofrequency ablation'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27097?source=see_link&amp;anchor=H14#H14\">",
"     \"Tachycardia-mediated cardiomyopathy\", section on 'Frequent ventricular ectopy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Left ventricular hypertrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with left ventricular hypertrophy (LVH) have an increased incidence of ventricular ectopy that is related to the severity of disease. In one report of 49 patients without coronary heart disease, there was a two to threefold increase in the occurrence and complexity of ventricular premature beats (VPBs) for every 1 mm increase in wall thickness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/19\">",
"     19",
"    </a>",
"    ]. On the other hand, regression of LVH with antihypertensive therapy is associated with a reduction in the frequency of VPBs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with LVH are also at increased risk of sudden cardiac death compared to individuals with hypertension and no hypertrophy. The increase in risk is proportional to the severity of hypertrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/21\">",
"     21",
"    </a>",
"    ]. However, as noted above with patients who have had an MI or have a cardiomyopathy or heart failure, there is no clear evidence in patients with LVH that VPBs are an independent predictor of mortality or that pharmacologic suppression of this arrhythmia is associated with improved outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/22\">",
"     22",
"    </a>",
"    ]. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/23/1401?source=see_link\">",
"     \"Left ventricular hypertrophy and arrhythmia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Exercise-induced",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise-induced ventricular ectopy occurs in 2 to 8 percent of asymptomatic men and women as well as in 7 to 20 percent of patients undergoing exercise ECG testing for known or suspected coronary disease. The variability in frequency relates in part to the definition of ventricular arrhythmia that is used and to the population studied. One report found that exercise-induced ventricular premature beats were more common with increasing age, male sex, and a history of hypertension, but were not related to the occurrence of ischemic ST segment changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/14/26858?source=see_link&amp;anchor=H9#H9\">",
"     \"Monomorphic ventricular tachycardia in the absence of apparent structural heart disease\", section on 'Repetitive monomorphic VT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     No known heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between exercise-induced ventricular premature beats (VPBs) and long-term prognosis has been demonstrated in asymptomatic men and women who were free of known cardiovascular disease and underwent standard exercise testing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an analysis of 6101 men aged 42 to 53 years, 2.3 percent had frequent VPBs during exercise, defined as &ge;2 sequential VPBs or VPBs constituting more than 10 percent of all ventricular depolarizations during any of the 30 second ECG recordings [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/24\">",
"       24",
"      </a>",
"      ]. At 23-year follow-up, compared to those without VPBs during exercise, patients with frequent exercise-induced VPBs during exercise had a significantly higher rate of all-cause mortality (41 versus 26 percent) and cardiovascular mortality (16 versus 6.4 percent, adjusted relative risk 2.5, 95% CI 1.7-3.9) (",
"      <a class=\"graphic graphic_figure graphicRef64609 \" href=\"mobipreview.htm?20/26/20910\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In a report of 2994 women aged 30 to 80 years, 7.6 percent had ventricular ectopy (multifocal VPBs, greater than 10 percent VPBs during the last stage of exercise or recovery, or test termination for ventricular tachycardia) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/25\">",
"       25",
"      </a>",
"      ]. At 20-year follow-up, patients with ventricular ectopy had a significantly higher cardiovascular mortality rate (hazard ratio 1.53, 95% CI 1.0-2.3).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Even lower frequencies of exercise-induced VPBs may increase mortality risk. This was demonstrated in an analysis from the Framingham study of 2885 men and women (mean age 43 years) who were free of overt cardiovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/23\">",
"     23",
"    </a>",
"    ]. The median frequency of exercise-induced VPBs was 0.22 per minute (approximately 1 VPB for every 4.5 minutes of exercise). Compared to study subjects with no exercise-induced VPBs, those with infrequent VPBs (below the median) and frequent VPBs (above the median) had significantly increased mortality risk at 15-year follow-up (hazard ratios 1.86 and 1.71, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Known or suspected CHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increase in risk with ventricular ectopy has also been noted in patients with known or suspected coronary disease referred for a symptom-limited exercise test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. The frequency of ventricular premature beats (VPBs) was evaluated in 1293 consecutive nonsurgically treated patients with suspected CHD who underwent an exercise test within six weeks of coronary angiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/27\">",
"     27",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At least one VPB (but without paired complexes or ventricular tachycardia) associated with exercise testing occurred in 18 percent of patients.",
"     </li>",
"     <li>",
"      The development of VPBs was more common in patients with significant three-vessel coronary artery disease, reduced left ventricular function, more segmental wall motion abnormalities, and a greater degree of ST segment depression during exercise.",
"     </li>",
"     <li>",
"      VPBs added independent prognostic value to noninvasive evaluation, but provided no independent information once the results of coronary angiography were known. There was no relationship between VPBs and survival in patients without significant CHD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the study of over 29,000 patients referred for symptom-limited exercise testing, frequent ventricular ectopy occurred in 7 percent&mdash;only during exercise in 3 percent, only during recovery in 2 percent, and during both periods in 2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/28\">",
"     28",
"    </a>",
"    ]. Following propensity matching for confounding variables, the development of frequent ventricular ectopy during recovery, but not during exercise was associated with increased cardiovascular mortality (adjusted hazard ratio 1.5 and 1.1, respectively, compared to those without ectopy). Similar results were reported in a subsequent study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29129?source=see_link&amp;anchor=H7#H7\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Ventricular arrhythmias'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Diagnostic utility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular premature beats (VPBs) can be helpful to the clinician in the evaluation of certain cardiac conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      VPBs can help differentiate among certain murmurs. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41876?source=see_link&amp;anchor=H7#H7\">",
"       \"Physiologic and pharmacologic maneuvers in the differential diagnosis of heart murmurs and sounds\", section on 'Postextrasystolic potentiation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      VPBs can aid in the evaluation of patients with hypertrophic cardiomyopathy and an outflow obstruction. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/41/3737?source=see_link&amp;anchor=H8#H8\">",
"       \"Hemodynamics of valvular disorders as measured by cardiac catheterization\", section on 'Hypertrophic cardiomyopathy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      VPBs may precipitate pulsus alternans, a marker of severe left ventricular dysfunction.",
"     </li>",
"     <li>",
"      A post-VPB pause may permit normal conduction of the subsequent supraventricular beat in patients with rate-dependent bundle branch block, possibly allowing diagnosis of otherwise covert infarctions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In persons found to have frequent ventricular premature beats (VPBs), further evaluation and management is based on the presence or absence of underlying structural heart disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptoms. The presence of frequent VPBs should precipitate a diagnostic evaluation for the possible presence of underlying structural heart disease, which has prognostic significance and may require specific therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9320?source=see_link&amp;anchor=H15#H15\">",
"     \"Prevalence and evaluation of ventricular premature beats\", section on 'Clinical evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients found to have underlying structural heart disease will typically receive medical therapy specific to their disease process. In many cases this therapy will also reduce the frequency of VPBs. Examples of therapy which can reduce the frequency of VPBs are beta blockers, which improve survival in patients with a prior myocardial infarction or heart failure, and antihypertensive therapy, which may induce regression of LVH in patients with hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/53/11098?source=see_link\">",
"     \"Beta blockers in the management of acute coronary syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The second issue relates to whether the patient has symptoms attributable to the VPBs. There is no clear evidence that VPB suppression with beta blockers or antiarrhythmic drugs improves overall survival in patients who have no symptoms and have not had a major arrhythmic event. Thus, the only indications for the use of beta blockers or antiarrhythmic drugs for VPB suppression are for symptomatic patients or for patients with cardiomyopathy felt possibly related to frequent VPBs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Beta blockers and antiarrhythmic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;While there is no clear mortality benefit from ventricular premature beat (VPB) suppression in asymptomatic patients, some patients with significant symptoms from their VPBs will require medical therapy or ablation in an effort to reduce or eliminate symptoms. We suggest using a beta blocker as the first-line drug for treatment of symptomatic VPBs. While beta blockers have no direct effects on the ventricular myocardium and therefore are not likely to suppress VPBs (unless they are due to excess sympathetic stimulation or increased catecholamines), they may reduce symptoms. This is due to the fact that beta blockers reduce the post-extrasystolic potentiation via the Starling mechanism (increased inotropy related to the increased stroke volume) associated with the VPB.",
"   </p>",
"   <p>",
"    If beta blockers are ineffective, antiarrhythmic drugs can be used, often with excellent results. However, some antiarrhythmic drugs (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    and other class Ic antiarrhythmic drugs) (",
"    <a class=\"graphic graphic_table graphicRef56600 \" href=\"mobipreview.htm?2/52/2892\">",
"     table 1",
"    </a>",
"    ) are associated with increased mortality due to proarrhythmia when given to patients with a prior myocardial infarction (",
"    <a class=\"graphic graphic_figure graphicRef59975 \" href=\"mobipreview.htm?19/4/19534\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef71934 \" href=\"mobipreview.htm?33/24/34189\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Proarrhythmia with these drugs is less of a concern in patients without organic heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/38/31336?source=see_link\">",
"     \"Prophylaxis against ventricular arrhythmias following myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/53/16217?source=see_link\">",
"     \"Role of antiarrhythmic drugs for ventricular arrhythmias in patients with a prior myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Beta blockers are generally safe and effective drugs for suppression of symptoms related to VPBs. The lowest dose of beta blockers that relieves symptoms should be used in order to minimize side effects with the exception of patients with a prior MI or heart failure in whom the dose is titrated to that recommended for treatment of the underlying disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30679?source=see_link\">",
"     \"Beta blockers in the management of stable angina pectoris\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3704?source=see_link\">",
"     \"Major side effects of beta blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with symptomatic VPBs in whom beta blockers have not resulted in symptomatic improvement, we suggest the use of an antiarrhythmic drug. The antiarrhythmic drug of choice is variable and depends on the presence or absence of underlying structural heart disease, particularly coronary heart disease (CHD).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     Flecainide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    , class Ic antiarrhythmic drugs (",
"    <a class=\"graphic graphic_table graphicRef56600 \" href=\"mobipreview.htm?2/52/2892\">",
"     table 1",
"    </a>",
"    ), are highly effective at suppressing VPBs. However, both are contraindicated in patients with pre-existing CHD due to the potential for proarrhythmia and increased mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients who cannot take class Ic drugs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    are effective, alternative agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/33\">",
"     33",
"    </a>",
"    ]. Trials of amiodarone use in patients with VPBs and a prior myocardial infarction or heart failure have demonstrated a significant reduction in VPBs and in arrhythmic mortality, but routine amiodarone therapy in asymptomatic patients is not recommended because of the absence of a significant improvement in overall mortality and potential for side effects (",
"    <a class=\"graphic graphic_figure graphicRef67684 \" href=\"mobipreview.htm?26/38/27246\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. In addition, most patients with a prior MI or heart failure will also be taking a beta blocker as part of standard therapy for their underlying disease, which may be associated with a reduction in VPBs (",
"    <a class=\"graphic graphic_figure graphicRef80761 \" href=\"mobipreview.htm?23/13/23774\">",
"     figure 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef78949 \" href=\"mobipreview.htm?38/42/39597\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/53/11098?source=see_link\">",
"     \"Beta blockers in the management of acute coronary syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Radiofrequency ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Very frequent VPBs may be associated with worsening of systolic heart failure in patients with a dilated cardiomyopathy. Small studies have suggested that in selected patients, radiofrequency ablation of ectopic ventricular foci is associated with an improvement in left ventricular function and clinical improvement in symptoms, particularly palpitations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/1,2,39-41\">",
"     1,2,39-41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27097?source=see_link&amp;anchor=H14#H14\">",
"     \"Tachycardia-mediated cardiomyopathy\", section on 'Frequent ventricular ectopy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society of Cardiology",
"    <span class=\"nowrap\">",
"     (ACC/AHA/ESC)",
"    </span>",
"    guidelines for the management of ventricular arrhythmias included suggestions regarding ablation therapy for VPBs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/42\">",
"     42",
"    </a>",
"    ]. They note that ablation of VPBs may be useful in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      VPBs that are frequent, symptomatic, and monomorphic, if they are refractory to medical therapy or if the patient chooses to avoid long-term medical therapy.",
"     </li>",
"     <li>",
"      Ventricular arrhythmia storm that is consistently provoked by VPBs of a similar morphology [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/36/36424/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with symptomatic VPBs that are refractory to medical therapy, or for patients with frequent VPBs associated with left ventricular dysfunction, we suggest radiofrequency ablation in an effort to eliminate the source of the VPBs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/23/39281?source=see_link\">",
"       \"Patient information: Ventricular premature beats (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8259402\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ventricular premature beats (VPBs), frequently detected during auscultation or routine electrocardiographic recording, are triggered from the ventricular myocardium in patients with a variety of underlying structural heart disease as well as persons without any apparent structural cardiac abnormality. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      VPBs produce few or no symptoms in the vast majority of patients. However, patients may experience palpitations, a sense of heart racing or skipped beats, lightheadedness, or dizziness related to VPBs. Only rarely do VPBs cause true hemodynamic compromise except in patients with very frequent ectopy and severely depressed left ventricular function or when VPBs are concurrent with underlying bradycardia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical significance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of simple VPBs in patients with apparently normal hearts is associated with increased mortality. While there are conflicting data on the prognostic significance of frequent and complex ventricular ectopy in patients with apparently normal hearts, the largest study did report an increase in mortality in such patients. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'No apparent heart disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While VPBs appear to be associated with a worse prognosis in patients with a prior myocardial infarction (MI), particularly when the MI is recent, there is no evidence that VPBs alone are associated with a worse prognosis in patients with dilated cardiomyopathy, hypertrophic cardiomyopathy, left ventricular hypertrophy from hypertension. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Post-MI'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Heart failure or cardiomyopathy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Left ventricular hypertrophy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In persons found to have frequent ventricular premature beats (VPBs) or more importantly repetitive forms of VPBs (couplets or nonsustained VT), further evaluation and management is based on the presence or absence of underlying structural heart disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      symptoms. The presence of frequent VPBs should lead to a clinical assessment for the possible presence of underlying structural heart disease, which has prognostic significance and may require specific therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9320?source=see_link&amp;anchor=H15#H15\">",
"       \"Prevalence and evaluation of ventricular premature beats\", section on 'Clinical evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      On rare occasions, very frequent VPBs can result in left ventricular dysfunction, which improves following suppression of the VPBs or ablation of the VPBs. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Heart failure or cardiomyopathy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27097?source=see_link&amp;anchor=H14#H14\">",
"       \"Tachycardia-mediated cardiomyopathy\", section on 'Frequent ventricular ectopy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Since there is no clear evidence that VPB suppression with antiarrhythmic drugs improves overall survival, we suggest not using antiarrhythmic drugs in patients who have no VPB-related symptoms and have not had a major arrhythmic event (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with symptomatic VPBs, we suggest using a beta blocker as the first-line drug for treatment of symptoms related to VPBs (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Beta blockers and antiarrhythmic drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with symptomatic VPBs in whom beta blockers have not resulted in symptomatic improvement, we suggest the use of an antiarrhythmic drug (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The antiarrhythmic drug of choice is variable and depends on the presence or absence of underlying structural heart disease, particularly coronary heart disease (CHD). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Beta blockers and antiarrhythmic drugs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"       Flecainide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"       propafenone",
"      </a>",
"      , class Ic antiarrhythmic drugs (",
"      <a class=\"graphic graphic_table graphicRef56600 \" href=\"mobipreview.htm?2/52/2892\">",
"       table 1",
"      </a>",
"      ), are highly effective at suppressing VPBs. However, both are contraindicated in patients with pre-existing CHD due to the potential for proarrhythmia and increased mortality.",
"     </li>",
"     <li>",
"      In patients who cannot take class Ic drugs,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      are effective alternative agents.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with symptomatic VPBs that are refractory to medical therapy, or for patients with frequent VPBs associated with left ventricular dysfunction, we suggest radiofrequency ablation in an effort to eliminate the source of the VPBs (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/1\">",
"      Satish OS, Yeh KH, Wen MS, Wang CC. Premature ventricular contraction-induced concealed mechanical bradycardia and dilated cardiomyopathy:. J Cardiovasc Electrophysiol 2005; 16:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/2\">",
"      Chugh SS, Shen WK, Luria DM, Smith HC. First evidence of premature ventricular complex-induced cardiomyopathy: a potentially reversible cause of heart failure. J Cardiovasc Electrophysiol 2000; 11:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/3\">",
"      Massing MW, Simpson RJ Jr, Rautaharju PM, et al. Usefulness of ventricular premature complexes to predict coronary heart disease events and mortality (from the Atherosclerosis Risk In Communities cohort). Am J Cardiol 2006; 98:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/4\">",
"      Engel G, Cho S, Ghayoumi A, et al. Prognostic significance of PVCs and resting heart rate. Ann Noninvasive Electrocardiol 2007; 12:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/5\">",
"      Cheriyath P, He F, Peters I, et al. Relation of atrial and/or ventricular premature complexes on a two-minute rhythm strip to the risk of sudden cardiac death (the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol 2011; 107:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/6\">",
"      Lee V, Hemingway H, Harb R, et al. The prognostic significance of premature ventricular complexes in adults without clinically apparent heart disease: a meta-analysis and systematic review. Heart 2012; 98:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/7\">",
"      Abdalla IS, Prineas RJ, Neaton JD, et al. Relation between ventricular premature complexes and sudden cardiac death in apparently healthy men. Am J Cardiol 1987; 60:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/8\">",
"      Barrett PA, Peter CT, Swan HJ, et al. The frequency and prognostic significance of electrocardiographic abnormalities in clinically normal individuals. Prog Cardiovasc Dis 1981; 23:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/9\">",
"      Elkon KB, Swerdlow TA, Myburgh DP. Persistent ventricular ectopic beats: a long-term study. S Afr Med J 1977; 52:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/10\">",
"      Rodstein M, Wolloch L, Gubner RS. Mortality study of the significance of extrasystoles in an insured population. Circulation 1971; 44:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/11\">",
"      Kennedy HL, Whitlock JA, Sprague MK, et al. Long-term follow-up of asymptomatic healthy subjects with frequent and complex ventricular ectopy. N Engl J Med 1985; 312:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/12\">",
"      Bikkina M, Larson MG, Levy D. Prognostic implications of asymptomatic ventricular arrhythmias: the Framingham Heart Study. Ann Intern Med 1992; 117:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/13\">",
"      Sajadieh A, Nielsen OW, Rasmussen V, et al. Ventricular arrhythmias and risk of death and acute myocardial infarction in apparently healthy subjects of age &gt;or=55 years. Am J Cardiol 2006; 97:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/14\">",
"      Engstr&ouml;m G, Wollmer P, Hedblad B, et al. Occurrence and prognostic significance of ventricular arrhythmia is related to pulmonary function: a study from \"men born in 1914,\" Malm&ouml;, Sweden. Circulation 2001; 103:3086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/15\">",
"      Podrid PJ, Fogel RI, Fuchs TT. Ventricular arrhythmia in congestive heart failure. Am J Cardiol 1992; 69:82G.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/16\">",
"      Smilde TD, van Veldhuisen DJ, van den Berg MP. Prognostic value of heart rate variability and ventricular arrhythmias during 13-year follow-up in patients with mild to moderate heart failure. Clin Res Cardiol 2009; 98:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/17\">",
"      Vazquez R, Bayes-Genis A, Cygankiewicz I, et al. The MUSIC Risk score: a simple method for predicting mortality in ambulatory patients with chronic heart failure. Eur Heart J 2009; 30:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/18\">",
"      Duffee DF, Shen WK, Smith HC. Suppression of frequent premature ventricular contractions and improvement of left ventricular function in patients with presumed idiopathic dilated cardiomyopathy. Mayo Clin Proc 1998; 73:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/19\">",
"      Ghali JK, Kadakia S, Cooper RS, Liao YL. Impact of left ventricular hypertrophy on ventricular arrhythmias in the absence of coronary artery disease. J Am Coll Cardiol 1991; 17:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/20\">",
"      Gonz&aacute;lez-Fern&aacute;ndez RA, Rivera M, Rodr&iacute;guez PJ, et al. Prevalence of ectopic ventricular activity after left ventricular mass regression. Am J Hypertens 1993; 6:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/21\">",
"      Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 1998; 32:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/22\">",
"      Bikkina M, Larson MG, Levy D. Asymptomatic ventricular arrhythmias and mortality risk in subjects with left ventricular hypertrophy. J Am Coll Cardiol 1993; 22:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/23\">",
"      Morshedi-Meibodi A, Evans JC, Levy D, et al. Clinical correlates and prognostic significance of exercise-induced ventricular premature beats in the community: the Framingham Heart Study. Circulation 2004; 109:2417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/24\">",
"      Jouven X, Zureik M, Desnos M, et al. Long-term outcome in asymptomatic men with exercise-induced premature ventricular depolarizations. N Engl J Med 2000; 343:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/25\">",
"      Mora S, Redberg RF, Cui Y, et al. Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the lipid research clinics prevalence study. JAMA 2003; 290:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/26\">",
"      Udall JA, Ellestad MH. Predictive implications of ventricular premature contractions associated with treadmill stress testing. Circulation 1977; 56:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/27\">",
"      Califf RM, McKinnis RA, McNeer JF, et al. Prognostic value of ventricular arrhythmias associated with treadmill exercise testing in patients studied with cardiac catheterization for suspected ischemic heart disease. J Am Coll Cardiol 1983; 2:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/28\">",
"      Frolkis JP, Pothier CE, Blackstone EH, Lauer MS. Frequent ventricular ectopy after exercise as a predictor of death. N Engl J Med 2003; 348:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/29\">",
"      Dewey FE, Kapoor JR, Williams RS, et al. Ventricular arrhythmias during clinical treadmill testing and prognosis. Arch Intern Med 2008; 168:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/30\">",
"      Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/31\">",
"      Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996; 348:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/32\">",
"      Podrid PJ, Lampert S, Graboys TB, et al. Aggravation of arrhythmia by antiarrhythmic drugs--incidence and predictors. Am J Cardiol 1987; 59:38E.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/33\">",
"      Anastasiou-Nana MI, Gilbert EM, Miller RH, et al. Usefulness of d, I sotalol for suppression of chronic ventricular arrhythmias. Am J Cardiol 1991; 67:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/34\">",
"      Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997; 349:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/35\">",
"      Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997; 349:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/36\">",
"      Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995; 333:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/37\">",
"      Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986; 73:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/38\">",
"      Lichstein E, Morganroth J, Harrist R, Hubble E. Effect of propranolol on ventricular arrhythmia. The beta-blocker heart attack trial experience. Circulation 1983; 67:I5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/39\">",
"      Baman TS, Lange DC, Ilg KJ, et al. Relationship between burden of premature ventricular complexes and left ventricular function. Heart Rhythm 2010; 7:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/40\">",
"      Takemoto M, Yoshimura H, Ohba Y, et al. Radiofrequency catheter ablation of premature ventricular complexes from right ventricular outflow tract improves left ventricular dilation and clinical status in patients without structural heart disease. J Am Coll Cardiol 2005; 45:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/41\">",
"      Efremidis M, Letsas KP, Sideris A, Kardaras F. Reversal of premature ventricular complex-induced cardiomyopathy following successful radiofrequency catheter ablation. Europace 2008; 10:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/42\">",
"      European Heart Rhythm Association, Heart Rhythm Society, Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48:e247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36424/abstract/43\">",
"      Ha&iuml;ssaguerre M, Shoda M, Ja&iuml;s P, et al. Mapping and ablation of idiopathic ventricular fibrillation. Circulation 2002; 106:962.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 992 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-76F9A528C7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_36_36424=[""].join("\n");
var outline_f35_36_36424=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8259402\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL SIGNIFICANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      No apparent heart disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Pulmonary dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Post-MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Heart failure or cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Exercise-induced",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - No known heart disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Known or suspected CHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Diagnostic utility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Beta blockers and antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Radiofrequency ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8259402\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/992\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/992|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/4/19534\" title=\"figure 1\">",
"      Proarrhythmia with class Ic antiarrhythmic drugs in CAST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/26/20910\" title=\"figure 2\">",
"      Mortality VPBs during exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/24/34189\" title=\"figure 3\">",
"      Sotalol after MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/38/27246\" title=\"figure 4\">",
"      Amiodarone in CAMIAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/13/23774\" title=\"figure 5\">",
"      Propranolol after acute MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/42/39597\" title=\"figure 6\">",
"      Mortality metoprolol HF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/992|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/52/2892\" title=\"table 1\">",
"      Vaughan Williams classification of antiarrhythmic drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/53/11098?source=related_link\">",
"      Beta blockers in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30679?source=related_link\">",
"      Beta blockers in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/57/1942?source=related_link\">",
"      ECG tutorial: Ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29129?source=related_link\">",
"      Exercise ECG testing to determine prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/41/3737?source=related_link\">",
"      Hemodynamics of valvular disorders as measured by cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/23/1401?source=related_link\">",
"      Left ventricular hypertrophy and arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3704?source=related_link\">",
"      Major side effects of beta blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/14/26858?source=related_link\">",
"      Monomorphic ventricular tachycardia in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/23/39281?source=related_link\">",
"      Patient information: Ventricular premature beats (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41876?source=related_link\">",
"      Physiologic and pharmacologic maneuvers in the differential diagnosis of heart murmurs and sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9320?source=related_link\">",
"      Prevalence and evaluation of ventricular premature beats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/38/31336?source=related_link\">",
"      Prophylaxis against ventricular arrhythmias following myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/53/16217?source=related_link\">",
"      Role of antiarrhythmic drugs for ventricular arrhythmias in patients with a prior myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27097?source=related_link\">",
"      Tachycardia-mediated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/3/22586?source=related_link\">",
"      Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/47/21241?source=related_link\">",
"      Ventricular arrhythmias in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_36_36425="Radiologic evaluation of the painful shoulder";
var content_f35_36_36425=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Radiologic evaluation of the painful shoulder",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/36/36425/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/36/36425/contributors\">",
"     Shahla Modarresi, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/36/36425/contributors\">",
"     Cecilia M Jude, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/36/36425/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/36/36425/contributors\">",
"     Robert H Shmerling, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/36/36425/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/36/36425/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/36/36425/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/36/36425/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complex anatomy and physiology of the shoulder, the most mobile and unstable joint, requires choosing proper imaging studies for different clinical scenarios. The imaging modalities and recommendations for selecting appropriate studies in different clinical situations are discussed in this review. The history and physical examination, which are necessary to develop a differential diagnosis prior to the selection of imaging tests, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35961?source=see_link\">",
"     \"Evaluation of the patient with shoulder complaints\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A general review of imaging tests that are used in the evaluation of bone and joint pain, including the physical principles underlying their usefulness, is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/7/3193?source=see_link\">",
"     \"Diagnostic imaging of joint pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IMAGING STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of imaging studies are available that are appropriate in different circumstances. These are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef77001 \" href=\"mobipreview.htm?39/55/40828\">",
"     table 1",
"    </a>",
"    ) and are discussed in more detail below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Plain film radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain film radiography is the first imaging modality for virtually all shoulder pathology. Radiographs are often the only imaging study necessary for the evaluation of acute shoulder trauma, calcific tendonitis, arthritis, and osteolysis of distal clavicle (in athletes) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Computerized tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computerized tomography (CT) is usually reserved for evaluation of",
"    <span class=\"nowrap\">",
"     fracture/fracture-dislocation",
"    </span>",
"    or for a prosthetic shoulder. CT can demonstrate fracture complexity, displacement, and angulation. The ability to visualize images in the axial, sagittal, and coronal planes and in three-dimensional format can help in interpretation and preoperative planning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) is the main modality used for evaluation of the soft tissues of the shoulder, such as the rotator cuff, biceps muscles, and tendons, and of the",
"    <span class=\"nowrap\">",
"     subacromial/subdeltoid",
"    </span>",
"    bursa. MRI is also a sensitive modality for detecting subtle fractures, erosive changes of the distal clavicle, acromioclavicular joint changes, morphology of the acromion, bone marrow edema, and muscle atrophy. MRI is a second procedure of choice for evaluation of labral tear or shoulder instability when magnetic resonance arthrography is not performed.",
"   </p>",
"   <p>",
"    Interpretation of MR imaging of the shoulder can vary between experts; collaboration between the clinician and radiologist in assessing imaging findings is often of benefit. Abnormalities detected by MRI of the shoulder should be carefully interpreted in the context of the patient&rsquo;s clinical presentation, as abnormal findings do not always explain the patient&rsquo;s symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Radionuclide bone scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone scan is limited to evaluation of infection after arthroplasty and for suspected metastases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Arthrography",
"    </span>",
"    &nbsp;&mdash;&nbsp;A percutaneous puncture of the shoulder and instillation of a contrast agent into the joint are the initial step in any form of arthrography. This part of the procedure is frequently performed with fluoroscopic guidance to facilitate needle placement. Once the contrast agent is instilled in the joint, its presence makes the identification of normal or damaged structures within the joint easier. Extravasation of contrast into the subacromial or subdeltoid space, for example, is consistent with a full thickness rotator cuff tear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Conventional arthrography",
"    </span>",
"    &nbsp;&mdash;&nbsp;In conventional arthrography, plain film radiographs are obtained after instillation of radiopaque contrast. Conventional arthrography is the procedure of choice for the diagnosis of frozen shoulder (adhesive capsulitis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/3\">",
"     3",
"    </a>",
"    ]. Distention of the shoulder capsule during arthrography may be useful therapeutically. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/7/33912?source=see_link&amp;anchor=H13#H13\">",
"     \"Frozen shoulder (adhesive capsulitis)\", section on 'Intra-articular dilation (distension)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Magnetic resonance arthrography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance arthrography (MR arthrography) involves the intraarticular injection of a gadolinium-based contrast agent followed by MRI. MR arthrography is the gold standard for evaluation of shoulder instability or labral tear (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78773 \" href=\"mobipreview.htm?22/21/22864\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/4\">",
"     4",
"    </a>",
"    ]. MR arthrography is also indicated when there is high suspicion of rotator cuff tear with a normal or inconclusive MRI (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62646 \" href=\"mobipreview.htm?36/35/37427\">",
"     image 2",
"    </a>",
"    ). Administration of gadolinium-containing MRI contrast agents in patients with moderately to severely impaired renal function (eg, estimated glomerular filtration rate &lt;15 to 30",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    may increase the risk of development of nephrogenic systemic fibrosis (NFS).",
"   </p>",
"   <p>",
"    If gadolinium-based imaging must be performed in a patient with moderate to severely impaired renal function, there may be a role for dialysis to reduce the risk of development of nephrogenic systemic fibrosis. Approaches to prevention of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=see_link&amp;anchor=H24#H24\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\", section on 'If gadolinium must be given'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Computerized tomography arthrography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computerized tomography arthrography (CT arthrography) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60990 \" href=\"mobipreview.htm?25/54/26467\">",
"     image 3",
"    </a>",
"    ) is used only when MR arthrography is contraindicated (ie, pacemaker, incompatible vascular clips, claustrophobia) or unavailable, or when a prosthetic joint is being evaluated, which would result in artifact on MR imaging. With the advent of multidetector CT technology, tears of the supraspinatus and infraspinatus tendons of the rotator cuff can be detected and characterized with similar accuracy as MR arthrography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/5\">",
"     5",
"    </a>",
"    ]. However, CT arthrography is significantly less sensitive for evaluation of labral lesions or shoulder instability compared with MR arthrography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a shoulder joint imaging modality, ultrasonography is not as widely used nor as conveniently offered in the United States as it is in some other parts of the world, mostly due to the availability of MRI. Ultrasonography is useful in the evaluation of the rotator cuff [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/7-10\">",
"     7-10",
"    </a>",
"    ], biceps tendon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/7-10\">",
"     7-10",
"    </a>",
"    ], and calcific deposits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/8,11\">",
"     8,11",
"    </a>",
"    ]; in the measurement of subacromial space [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/12\">",
"     12",
"    </a>",
"    ]; and in detection of muscle atrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/13\">",
"     13",
"    </a>",
"    ]. Ultrasound is valuable in the dynamic evaluation of shoulder impingement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/10\">",
"     10",
"    </a>",
"    ]. Ultrasound can also be used to guide therapeutic interventions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/14-16\">",
"     14-16",
"    </a>",
"    ] and to detect periarticular soft tissue pathology in the setting of shoulder arthroplasty [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/18/4392?source=see_link\">",
"     \"Musculoskeletal ultrasonography: Clinical applications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/60/1991?source=see_link\">",
"     \"Musculoskeletal ultrasonography: Nomenclature, technical considerations, validation, and standardization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Advantages of ultrasound, when readily available, include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low cost",
"     </li>",
"     <li>",
"      Portability",
"     </li>",
"     <li>",
"      Safety",
"     </li>",
"     <li>",
"      Lack of contraindications",
"     </li>",
"     <li>",
"      Real-time diagnosis",
"     </li>",
"     <li>",
"      Utility for needle guidance for aspiration",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      injection",
"     </li>",
"     <li>",
"      Excellent patient tolerance and preference",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Limitations of ultrasound include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/8,19-22\">",
"     8,19-22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Limited acoustic window due to presence of bone",
"     </li>",
"     <li>",
"      Requirement for extensive training, as it is highly operator dependent",
"     </li>",
"     <li>",
"      Limited usefulness in evaluation of osseous lesions",
"     </li>",
"     <li>",
"      Lack of sensitivity for evaluating shoulder instability or labral tear",
"     </li>",
"     <li>",
"      Decreased accuracy in very small or very large (&gt;3 cm) rotator cuff tears",
"     </li>",
"     <li>",
"      Less sensitivity for partial thickness rotator cuff tears than MRI",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS FOR SPECIFIC CLINICAL SETTINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of Radiology (ACR) established criteria for selecting the imaging modalities of choice according to the most common clinical scenarios [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/23\">",
"     23",
"    </a>",
"    ]. Criteria are based upon the duration of symptoms, age at presentation, and clinical suspicion for a specific condition. Along with the imaging modalities included in the ACR recommendations, an update on the usefulness of ultrasonography for selected indications is included.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Acute shoulder trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The work-up for acute shoulder trauma, based upon ACR recommendations for the initial imaging of acute shoulder pain of any etiology, is presented in variant 1 of the table (",
"    <a class=\"graphic graphic_table graphicRef77202 \" href=\"mobipreview.htm?23/26/23968\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef70717 graphicRef50652 \" href=\"mobipreview.htm?35/37/36442\">",
"     figure 1A-B",
"    </a>",
"    ) and is discussed below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Plain film",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain film radiography should be the initial imaging test. Further imaging should be guided by the individual clinical scenario and by the plain film findings. For example, most patients under 30 years of age that suffer an anterior dislocation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78276 \" href=\"mobipreview.htm?31/56/32640\">",
"     image 4",
"    </a>",
"    ) of the shoulder have an associated labral injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/24\">",
"     24",
"    </a>",
"    ]. MR arthrography is indicated in these cases. Anterior shoulder dislocation may also be associated with rotator cuff injury in approximately 50 percent of patients under the age of 40 and in 80 percent of patients over the age of 60 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. In such cases, ultrasound may be of value as the initial screening modality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Computerized tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computerized tomography (CT) can detect intraarticular extension of fracture and can demonstrate fracture complexity, displacement, and angulation, as well as small loose bony fragments. With spiral CT technology and advanced computer software, reformatted and three dimensional images can be generated, which can help the surgical planning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) is the procedure of choice for evaluation of soft tissue injury, such as rotator cuff tear. MRI can also detect occult fractures. However, MRI is not the initial imaging modality for evaluation of acute shoulder trauma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Magnetic resonance arthrography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance arthrography (MR arthrography) should be performed in all people with suspected labral tear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/4\">",
"     4",
"    </a>",
"    ]. When MR arthrography is contraindicated, computerized tomography arthrography (CT arthrography) can be used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography is widely used in Europe as the initial modality for evaluation of full thickness rotator cuff tear, for which it has high sensitivity and specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/8,10,27\">",
"     8,10,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Persistent shoulder pain after acute or recent trauma with negative radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging of persistent shoulder pain after acute or recent trauma with negative radiographs should follow ACR recommendations for the setting of persistent significant pain and normal initial plain film radiographs, as presented in variant 2 in the table (",
"    <a class=\"graphic graphic_table graphicRef77202 \" href=\"mobipreview.htm?23/26/23968\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef70717 graphicRef50652 \" href=\"mobipreview.htm?35/37/36442\">",
"     figure 1A-B",
"    </a>",
"    ) and as discussed below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) is the procedure of choice for evaluation of occult fractures and soft tissue pathology, including the tendons, ligaments, and muscles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5133640\">",
"    <span class=\"h3\">",
"     Computerized tomography arthrography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computerized tomography (CT) arthrography can detect occult fractures when MRI is contraindicated. CT arthrography can also detect tendon tears.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography is recommended when MRI is not available or is contraindicated (vascular clips, pacemaker, etc). Ultrasound is useful in the evaluation of rotator cuff and biceps tendons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. Ultrasound has limited usefulness in evaluation of very small [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/20\">",
"     20",
"    </a>",
"    ] or very large (&gt;3 cm) rotator cuff tears [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/21,22\">",
"     21,22",
"    </a>",
"    ] or in detection of partial thickness rotator cuff tears [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Magnetic resonance arthrography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance arthrography (MR arthrography) is recommended for distinguishing between partial and full thickness rotator cuff tears and for identifying a suspected labral tear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Subacute and chronic shoulder pain",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Subacute shoulder pain, suspected tendinosis or bursitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rotator cuff or biceps tendinosis and subacromial or subdeltoid bursitis are common causes of subacute or chronic shoulder pain in primary care practice. Isolated bursitis may be seen in trauma; inflammatory disorders, such as rheumatoid arthritis; and infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21289?source=see_link\">",
"     \"Rotator cuff tendinopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25991?source=see_link\">",
"     \"Biceps tendinopathy and tendon rupture\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/45/14041?source=see_link\">",
"     \"Bursitis: An overview of clinical manifestations, diagnosis, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h4\">",
"     Plain film radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain film radiography with internal and external rotation views is the first study recommended in suspected tendinosis. Additional radiographic views may be of value. In the presence of calcific tendinosis, radiographic findings include focal, dystrophic calcification within the rotator cuff (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67158 \" href=\"mobipreview.htm?21/39/22143\">",
"     image 5",
"    </a>",
"    ). If the plain film radiographs are noncontributory, further work-up based upon the American College of Radiology recommendations is presented in variant 4 of the table (",
"    <a class=\"graphic graphic_table graphicRef77202 \" href=\"mobipreview.htm?23/26/23968\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef70717 graphicRef50652 \" href=\"mobipreview.htm?35/37/36442\">",
"     figure 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5133830\">",
"    <span class=\"h4\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) is indicated if the radiographs are noncontributory. MRI without contrast detects tendon degeneration and tear and is also indicated in evaluation of bursitis. In the case of calcific tendinosis, calcifications are difficult to detect on MR images [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h4\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;If local expertise is available, ultrasonography is equivalent to MRI for evaluation of tendinosis or bursitis. Ultrasonography is highly sensitive and specific for detection of rotator cuff calcification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/8\">",
"     8",
"    </a>",
"    ]. The presence of an echogenic focus with definite acoustic shadowing is the most frequent ultrasonographic finding in calcific tendinosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/11\">",
"     11",
"    </a>",
"    ]. Correlation with plain film radiographs indicates that a hyperechoic focus with minimal or no acoustic shadowing may also be compatible with the presence of rotator cuff or bursal calcific deposits. New treatments for calcific tendonitis utilize ultrasound-guided fine needle technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultrasound is also highly sensitive for detection of subacromial bursitis with effusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/9\">",
"     9",
"    </a>",
"    ]. Study may include injection of anesthetic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    glucocorticoid if clinically indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Subacute shoulder pain, suspected rotator cuff tear or impingement, over age 35",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rotator cuff tear is the most frequent disorder in this category after tendonitis. The frequency of rotator cuff tears increases with age. One study reported rotator cuff tears in 34 percent of asymptomatic patients in all age groups and in 54 percent of the patients over 60 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/46/6887?source=see_link\">",
"     \"Presentation and diagnosis of rotator cuff tears\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/33/32280?source=see_link\">",
"     \"Shoulder impingement syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MRI and ultrasound are comparable in both sensitivity and specificity for the detection of rotator cuff tears [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/30\">",
"     30",
"    </a>",
"    ]. MR arthrography is more sensitive and specific than either MRI (without arthrography) or ultrasound for diagnosing both full and partial thickness rotator cuff tears.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5133849\">",
"    <span class=\"h4\">",
"     Plain film radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The plain radiographs are usually normal or may show degenerative or osseous changes of the coracoacromial arch, including osteophytes or syndesmophytes. In the late stages of rotator cuff tear with complete loss of subacromial space, the plain radiograph may be diagnostic, and no further imaging study is needed (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69109 \" href=\"mobipreview.htm?38/7/39038\">",
"     image 6",
"    </a>",
"    ). The ACR recommendations for imaging for patients over age 35 with suspected rotator cuff tear or impingement and with normal radiographs or radiographs that demonstrate coracoacromial arch abnormalities are presented in variant 5 in the table (",
"    <a class=\"graphic graphic_table graphicRef77202 \" href=\"mobipreview.htm?23/26/23968\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef70717 graphicRef50652 \" href=\"mobipreview.htm?35/37/36442\">",
"     figure 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h4\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) is the initial recommended imaging test when rotator cuff tear or impingement is suspected. If subacromial injection was performed, MRI should be delayed a minimum of 24 hours to avoid misinterpretation of presence of fluid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MRI demonstrates both osseous and soft tissue abnormalities associated with impingement syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Osseous abnormalities such as shape of the acromion process, humeral head abnormalities, and osteophyte formation of the acromioclavicular joint can be demonstrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/34\">",
"     34",
"    </a>",
"    ]. Soft tissue findings include tendinosis (tendon degeneration or inflammation without disruption; clinically referred to as &ldquo;tendinitis&rdquo;), partial thickness rotator cuff tear (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72352 \" href=\"mobipreview.htm?1/16/1287\">",
"     image 7",
"    </a>",
"    ), full thickness tear (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51905 \" href=\"mobipreview.htm?6/5/6225\">",
"     image 8",
"    </a>",
"    ), biceps tendon abnormalities, thickened coracoacromial ligament, and subacromial bursitis. With large full thickness chronic rotator cuff tear, muscle atrophy is usually seen. Some of the above osseous and soft tissue abnormalities can be seen in asymptomatic individuals, and clinical correlation is required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/29,35,36\">",
"     29,35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reported sensitivity and specificity of MRI for detecting full thickness rotator cuff tears are 84 to 100 percent and 86 to 98 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. Reported sensitivity and specificity of MRI for detecting partial thickness rotator cuff tears are 55 to 80 percent and 83 to 90 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. The wide range of reported sensitivity for partial thickness rotator cuff tears is due to different imaging technique and criteria used for detection of these tears.",
"   </p>",
"   <p>",
"    MRI is also helpful in the preoperative assessment of the feasibility of rotator cuff repair by measuring the size of the tear and the degree of muscle atrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h4\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography (US) is a useful tool in the evaluation of the rotator cuff when specific expertise in shoulder sonography is available. US has comparable accuracy to MR imaging for identifying and measuring the size of full thickness and partial thickness rotator cuff tears when performed by an experienced examiner using high quality equipment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sensitivity and specificity for complete rotator cuff tears are reported to be over 95 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/8,10\">",
"     8,10",
"    </a>",
"    ]. For partial thickness rotator cuff tears, a wide range of variation exists in reported sensitivity, from 46 to 92 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/8,10\">",
"     8,10",
"    </a>",
"    ]. Possible explanations for this wide variation are differences in operator expertise and the ultrasonographic criteria used in deciding whether or not a partial rotator cuff tear is present.",
"   </p>",
"   <p>",
"    Dynamic ultrasound can also help to confirm the clinical diagnosis of impingement, with sensitivity between 70 and 80 percent and specificity over 95 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/10,42\">",
"     10,42",
"    </a>",
"    ]. Ultrasound is also highly sensitive in detection of effusion in the subacromial bursa as an indirect sign of rotator cuff tear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition to evaluation of the rotator cuff tendon, ultrasonography can also detect the coexisting muscle atrophy, which influences the decision and outcome of surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limitations of ultrasonography in this setting include decreased accuracy in very small [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/20\">",
"     20",
"    </a>",
"    ] or very large (&gt;3 cm) rotator cuff tears [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/21,22\">",
"     21,22",
"    </a>",
"    ] and in partial thickness rotator cuff tears [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5134065\">",
"    <span class=\"h4\">",
"     Magnetic resonance arthrography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance arthrography (MR arthrography) is recommended if rotator cuff tear is suspected and MRI is normal, or if glenohumeral instability is suspected as a cause of impingement syndrome. MR arthrography has greater sensitivity and specificity for detection of full and partial thickness rotator cuff tears involving the articular surface compared with MRI and has greater sensitivity and specificity than ultrasound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/30\">",
"     30",
"    </a>",
"    ]. MR arthrography has sensitivity and specificity close to 100 percent for detection of full thickness tears [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. For partial thickness tears, reported sensitivity and specificity range between 84 and 100 percent and between 96 and 100 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. MR arthrography differentiates between small partial tears, small full thickness tears, and tendinitis or tendinosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62646 \" href=\"mobipreview.htm?36/35/37427\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h4\">",
"     Computed tomography arthrography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) arthrography is indicated if the patient cannot have MRI or if ultrasonography expertise is not available. Sensitivity and specificity of over 90 percent for CT arthrography for detection of supraspinatus and infraspinatus tear have been reported, with low sensitivity for subscapularis tear detection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/5\">",
"     5",
"    </a>",
"    ]. CT arthrography is also valuable in preoperative evaluation, by demonstrating the extent of tendon retraction and fatty degeneration of the corresponding muscle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Subacute shoulder pain, suspected instability and/or labral tear, under age 35",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subacute shoulder pain in patients under 35 years of age is often related to sports injuries. Injuries of the upper extremity account for more than 25 percent of all sports-related injuries. As much as 30 percent of adolescents and children participates in school athletics. In sports that involve repetitive overhead actions, such as baseball, football, basketball, tennis, and swimming, the most common injuries involve the posterosuperior labrum, supraspinatus tendon, infraspinatus tendon, humeral head, glenoid cavity, acromioclavicular joint, anteroinferior capsulolabral complex, biceps tendon, and subscapularis tendon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/46\">",
"     46",
"    </a>",
"    ]. The ACR recommendations for imaging of a patient with shoulder pain in whom glenohumeral joint instability or a tear of the glenoid labrum is suspected are presented in variant 3 of the table (",
"    <a class=\"graphic graphic_table graphicRef77202 \" href=\"mobipreview.htm?23/26/23968\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef70717 graphicRef50652 \" href=\"mobipreview.htm?35/37/36442\">",
"     figure 1A-B",
"    </a>",
"    ) and are discussed below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h4\">",
"     Magnetic resonance arthrography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance arthrography (MR arthrography) is the method of choice for imaging the labrocapsular structures. Magnetic resonance arthrography (MR arthrography) is the most accurate imaging modality for sports injuries of the shoulder and for evaluation of instability. MR arthrography evaluates the dynamic stabilizers (rotator cuff muscles and tendons), which are extraarticular; the static stabilizers (glenohumeral ligaments and glenoid labrum) and the long head of the biceps tendon, which are intraarticular; and capsular morphology (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78773 \" href=\"mobipreview.htm?22/21/22864\">",
"     image 1",
"    </a>",
"    ). Sensitivity and specificity of MR arthrography for detection of labral tears range from 88 to 100 percent and 88 to 96 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/6,47,48\">",
"     6,47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of abduction and external rotation (ABER) technique increases the sensitivity for labral tears to close to 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/49\">",
"     49",
"    </a>",
"    ]. This was illustrated in a study that compared radiography, arthrography, and CT arthrography with MR arthrography and the use of arthroscopic findings to confirm the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/46\">",
"     46",
"    </a>",
"    ]. MR arthrography with abduction and external rotation (ABER) yielded the highest sensitivity and specificity for all lesions with the exception of bone sclerosis and enthesophytes. Therefore, MR arthrography is indicated in all suspected lesions of the rotator cuff and glenoid labrum in athletes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h4\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;With high field or high resolution and appropriate expertise, magnetic resonance imaging (MRI) is a good alternative to MR arthrography. Magnetic resonance imaging demonstrates bony and soft tissue injuries, including muscle, tendon, and labral tears. MRI has reported sensitivity between 90 and 93 percent and specificity between 63 and 96 percent in the detection of labral tears [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. Evaluation of the capsular structures is limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h4\">",
"     Computed tomography arthrography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography arthrography (CT arthrography) is accurate in delineating the anatomic derangement including the glenoid labrum (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60990 \" href=\"mobipreview.htm?25/54/26467\">",
"     image 3",
"    </a>",
"    ); however, evaluation of soft tissues is limited. Thus, it is usually performed only when MR arthrography is contraindicated (as with shoulder prostheses, pacemakers, and MR incompatible vascular clips). Reported sensitivity and specificity of CT arthrography for labral tears is between 73 and 76 percent and 92 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/6,51\">",
"     6,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Adhesive capsulitis (frozen shoulder)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adhesive capsulitis is caused by thickening and contraction of the joint capsule and synovium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h3\">",
"     Conventional arthrography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional arthrography is the procedure of choice for the diagnosis and treatment of frozen shoulder (adhesive capsulitis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/14\">",
"     14",
"    </a>",
"    ]. Decreased capacity to contrast injection in the joint is diagnostic of frozen shoulder. Distention of the shoulder capsule during arthrography may be useful therapeutically. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/7/33912?source=see_link&amp;anchor=H13#H13\">",
"     \"Frozen shoulder (adhesive capsulitis)\", section on 'Intra-articular dilation (distension)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h3\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) with intravenous contrast administration can show signal and thickness abnormalities of the shoulder joint capsule and synovial membrane [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h3\">",
"     Plain film",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain film radiography has limited use and is nonspecific.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Chronic arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most shoulder arthritides can be accurately diagnosed with plain film radiography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h3\">",
"     Plain film",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings on plain film radiography of osteoarthritis include joint space narrowing, hypertrophic bone formation (osteophytes), subchondral sclerosis, and subarticular cysts formation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83433 \" href=\"mobipreview.htm?11/5/11359\">",
"     image 9",
"    </a>",
"    ). Rheumatoid arthritis in the shoulder is characterized by &ldquo;high-riding&rdquo; shoulder. However, &ldquo;high-riding&rdquo; shoulder can also be seen with pseudogout and chronic rotator cuff tear. The acromioclavicular joint in patients with rheumatoid arthritis may reveal erosive change of the distal clavicle (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef85835 \" href=\"mobipreview.htm?13/17/13585\">",
"     image 10",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h3\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging is indicated when there is clinical suspicion for soft tissue abnormalities, such as rotator cuff involvement, subacromial bursitis, and muscular atrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/55\">",
"     55",
"    </a>",
"    ]. In addition, MR will detect synovial hypertrophy and bone abnormalities such as bone erosions, small subchondral cysts, and bone edema. MRI can help in diagnosis of synovial osteochondromatosis, amyloid arthropathy, and pigmented villonodular synovitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h3\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequent sonographic finding in rheumatoid arthritis is the presence of an effusion in the subacromial or subdeltoid bursa",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the glenohumeral joint; however, this is a nonspecific finding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h2\">",
"     Septic arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nongonococcal infectious arthritis should be suspected as a cause of acute arthritis in an infant or an older patient. In other age groups, septic arthritis is often associated with medical conditions such as diabetes, liver diseases, alcoholism, malignancy, chronic arthritis, shoulder prosthesis, or surgery and associated infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/58\">",
"     58",
"    </a>",
"    ]. In sexually active individuals, gonococcal arthritis should be suspected. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/50/11049?source=see_link\">",
"     \"Septic arthritis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/56/3976?source=see_link\">",
"     \"Disseminated gonococcal infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h3\">",
"     Plain film",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain film radiographs may demonstrate moderate to large joint effusion in the initial phases and, subsequently, joint space narrowing and erosive changes. Shoulder effusions are difficult to detect unless they are large enough to cause inferior displacement of the humeral head. ACR recommendations for further evaluation of septic arthritis are presented in variant 8 of the table (",
"    <a class=\"graphic graphic_table graphicRef77202 \" href=\"mobipreview.htm?23/26/23968\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef70717 graphicRef50652 \" href=\"mobipreview.htm?35/37/36442\">",
"     figure 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H475660\">",
"    <span class=\"h3\">",
"     Ultrasound arthrocentesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shoulder joint aspiration is the procedure of choice. Echogenic material in synovial fluid in the glenohumeral joint has been noted in bacterial infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/59\">",
"     59",
"    </a>",
"    ]. Ultrasonography may be helpful for joint aspiration, especially in difficult cases, by providing real-time guidance or by allowing marking of the shoulder for joint aspiration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h3\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) is highly sensitive but is not specific for the diagnosis of septic joint [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/61\">",
"     61",
"    </a>",
"    ]. The combination of bone erosions and bone marrow edema on MR is highly suggestive of the diagnosis. Synovial and soft tissue findings are also well-demonstrated on MR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h2\">",
"     Avascular necrosis of bone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of risk factors such as sickle cell disease or chronic glucocorticoid use may suggest avascular necrosis (osteonecrosis) of the humeral head. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/43/28346?source=see_link\">",
"     \"Osteonecrosis (avascular necrosis of bone)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h3\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) is the most sensitive and specific study for detecting the earliest changes when plain radiographs and radionuclide bone scans are normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56\">",
"    <span class=\"h3\">",
"     Radionuclide bone scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radionuclide bone scan is not as sensitive as MRI; however, abnormal uptake appears earlier than radiographic changes on plain films.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57\">",
"    <span class=\"h3\">",
"     Plain film radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain film radiography is not sensitive in the early stages, when only a small joint effusion is present. Sclerosis, crescent sign, or humeral head collapse may be visible weeks to months after the onset of pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58\">",
"    <span class=\"h2\">",
"     Postoperative pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging of the postoperative shoulder is indicated most often due to persistence of pain or functional limitation. Rotator cuff repair, capsulorrhaphy, or acromioplasty can produce symptoms, which may be indistinguishable from rerupture or inadequate surgical results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59\">",
"    <span class=\"h3\">",
"     Plain film radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain film radiography is indicated after surgical procedures, such as fractures, tumors, and prosthesis. Plain radiography can detect loosening of prosthesis, recurrence of tumor, and complications of fracture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60\">",
"    <span class=\"h3\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) is indicated for symptoms of persistent impingement or suspected reinjury of the rotator cuff.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61\">",
"    <span class=\"h3\">",
"     Magnetic resonance arthrography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance arthrography is most useful for optimal delineation of the rotator cuff, capsulolabral structures, and tendon tears [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/36/36425/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2016470\">",
"    <span class=\"h3\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound is useful in evaluation of suspected re-tear of the rotator cuff, depending on the local expertise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62\">",
"    <span class=\"h3\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI cannot be performed in the presence of a shoulder prosthesis due to significant metallic artifact. Computed tomography can be valuable for evaluation of soft tissue or bony abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H474838\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The choice of imaging modality depends upon the differential diagnosis generated based upon the history and physical examination. Each imaging technique has particular advantages and disadvantages for addressing different clinical questions (",
"      <a class=\"graphic graphic_table graphicRef77001 \" href=\"mobipreview.htm?39/55/40828\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Imaging studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plain film radiography is the first imaging modality for virtually all shoulder pathology. Radiographs are often the only imaging study necessary for the evaluation of acute shoulder trauma, calcific tendonitis, arthritis, and osteolysis of distal clavicle. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Plain film radiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Computerized tomography (CT) is usually reserved for evaluation of fracture or fracture-dislocation or for a prosthetic shoulder. CT can demonstrate fracture complexity, displacement, and angulation. The ability to visualize images in the axial, sagittal, and coronal planes and in three-dimensional format can help in interpretation and preoperative planning. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Computerized tomography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Magnetic resonance imaging (MRI) is the main modality used for evaluation of the soft tissues of the shoulder, such as the labrum, rotator cuff, biceps muscles, and tendons, and for the subacromial or subdeltoid bursa. MRI is also a sensitive modality for detecting subtle fractures, erosive changes of the distal clavicle, acromioclavicular joint changes, bone marrow edema, and muscle atrophy. Abnormalities detected by MRI of the shoulder should be carefully interpreted in the context of the patient&rsquo;s clinical presentation, as abnormal findings do not always explain the patient&rsquo;s symptoms. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Magnetic resonance imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of radionuclide bone scan is generally limited to evaluation of infection after arthroplasty and for suspected metastases. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Radionuclide bone scan'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Arthrography involves the instillation of a contrast agent into the joint, often using fluoroscopic guidance to facilitate needle placement. Once the contrast agent is instilled in the joint, its presence makes the identification of normal or damaged structures within the joint easier, usually with plain radiographic imaging or MRI. CT arthrography is used only when MR arthrography is contraindicated or unavailable and when shoulder prostheses, which cause MR artifact, are being evaluated. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Arthrography'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Conventional arthrography'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Magnetic resonance arthrography'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Computerized tomography arthrography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The availability of ultrasonography for musculoskeletal imaging varies. It is useful in the evaluation of the rotator cuff, biceps tendon, and calcific deposits; in the measurement of subacromial space; in the detection of muscle atrophy; and in the dynamic evaluation of shoulder impingement. It can also be used to guide therapeutic interventions and to detect periarticular soft tissue pathology in the setting of shoulder arthroplasty. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Ultrasonography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The American College of Radiology (ACR) has established criteria for selecting the imaging modalities of choice according to the most common clinical scenarios (",
"      <a class=\"graphic graphic_table graphicRef77202 \" href=\"mobipreview.htm?23/26/23968\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef70717 graphicRef50652 \" href=\"mobipreview.htm?35/37/36442\">",
"       figure 1A-B",
"      </a>",
"      ). Criteria are based upon duration of symptoms, age at presentation, and clinical suspicion for a specific condition. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Recommendations for specific clinical settings'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/1\">",
"      Willick SE, Sanders RK. Radiologic evaluation of the shoulder girdle. Phys Med Rehabil Clin N Am 2004; 15:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/2\">",
"      Haapamaki VV, Kiuru MJ, Koskinen SK. Multidetector CT in shoulder fractures. Emerg Radiol 2004; 11:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/3\">",
"      Khan AA, Mowla A, Shakoor MA, Rahman MR. Arthrographic distension of the shoulder joint in the management of frozen shoulder. Mymensingh Med J 2005; 14:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/4\">",
"      Steinbach LS, Palmer WE, Schweitzer ME. Special focus session. MR arthrography. Radiographics 2002; 22:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/5\">",
"      Charousset C, Bella&iuml;che L, Duranthon LD, Grimberg J. Accuracy of CT arthrography in the assessment of tears of the rotator cuff. J Bone Joint Surg Br 2005; 87:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/6\">",
"      Bitzer M, Nasko M, Krackhardt T, et al. [Direct CT-arthrography versus direct MR-arthrography in chronic shoulder instability: comparison of modalities after the introduction of multidetector-CT technology]. Rofo 2004; 176:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/7\">",
"      Backhaus M, Burmester GR, Gerber T, et al. Guidelines for musculoskeletal ultrasound in rheumatology. Ann Rheum Dis 2001; 60:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/8\">",
"      Kayser R, Hampf S, Pankow M, et al. [Validity of ultrasound examinations of disorders of the shoulder joint]. Ultraschall Med 2005; 26:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/9\">",
"      Alasaarela E, Leppilahti J, Hakala M. Ultrasound and operative evaluation of arthritic shoulder joints. Ann Rheum Dis 1998; 57:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/10\">",
"      Read JW, Perko M. Shoulder ultrasound: diagnostic accuracy for impingement syndrome, rotator cuff tear, and biceps tendon pathology. J Shoulder Elbow Surg 1998; 7:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/11\">",
"      Farin PU, Jaroma H. Sonographic findings of rotator cuff calcifications. J Ultrasound Med 1995; 14:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/12\">",
"      Azzoni R, Cabitza P, Parrini M. Sonographic evaluation of subacromial space. Ultrasonics 2004; 42:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/13\">",
"      Sofka CM, Haddad ZK, Adler RS. Detection of muscle atrophy on routine sonography of the shoulder. J Ultrasound Med 2004; 23:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/14\">",
"      Aina R, Cardinal E, Bureau NJ, et al. Calcific shoulder tendinitis: treatment with modified US-guided fine-needle technique. Radiology 2001; 221:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/15\">",
"      Galletti S, Magnani M, Rotini R, et al. The echo-guided treatment of calcific tendinitis of the shoulder. Chir Organi Mov 2004; 89:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/16\">",
"      Naredo E, Cabero F, Beneyto P, et al. A randomized comparative study of short term response to blind injection versus sonographic-guided injection of local corticosteroids in patients with painful shoulder. J Rheumatol 2004; 31:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/17\">",
"      Westhoff B, Wild A, Werner A, et al. The value of ultrasound after shoulder arthroplasty. Skeletal Radiol 2002; 31:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/18\">",
"      Middleton WD, Payne WT, Teefey SA, et al. Sonography and MRI of the shoulder: comparison of patient satisfaction. AJR Am J Roentgenol 2004; 183:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/19\">",
"      O'Connor PJ, Rankine J, Gibbon WW, et al. Interobserver variation in sonography of the painful shoulder. J Clin Ultrasound 2005; 33:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/20\">",
"      Zehetgruber H, Lang T, Wurnig C. Distinction between supraspinatus, infraspinatus and subscapularis tendon tears with ultrasound in 332 surgically confirmed cases. Ultrasound Med Biol 2002; 28:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/21\">",
"      Kluger R, Mayrhofer R, Kr&ouml;ner A, et al. Sonographic versus magnetic resonance arthrographic evaluation of full-thickness rotator cuff tears in millimeters. J Shoulder Elbow Surg 2003; 12:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/22\">",
"      Teefey SA, Middleton WD, Payne WT, Yamaguchi K. Detection and measurement of rotator cuff tears with sonography: analysis of diagnostic errors. AJR Am J Roentgenol 2005; 184:1768.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Radiology. ACR Appropriateness Criteria. Expert Panel on Musculoskeletal Imaging. Shoulder Trauma 2010; 1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/24\">",
"      Handoll HH, Almaiyah MA, Rangan A. Surgical versus non-surgical treatment for acute anterior shoulder dislocation. Cochrane Database Syst Rev 2004; :CD004325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/25\">",
"      Gumina S, Postacchini F. Anterior dislocation of the shoulder in elderly patients. J Bone Joint Surg Br 1997; 79:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/26\">",
"      Woodward TW, Best TM. The painful shoulder: part II. Acute and chronic disorders. Am Fam Physician 2000; 61:3291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/27\">",
"      Mancini GB, Malaspina C, Scalercio AM, Ferranti R. Anterior shoulder dislocation and injuries of the rotator cuff in patients aged over 40 years. Clinical and sonographic study. Chir Organi Mov 2001; 86:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/28\">",
"      Vahlensieck M. MRI of the shoulder. Eur Radiol 2000; 10:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/29\">",
"      Sher JS, Uribe JW, Posada A, et al. Abnormal findings on magnetic resonance images of asymptomatic shoulders. J Bone Joint Surg Am 1995; 77:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/30\">",
"      de Jesus JO, Parker L, Frangos AJ, Nazarian LN. Accuracy of MRI, MR arthrography, and ultrasound in the diagnosis of rotator cuff tears: a meta-analysis. AJR Am J Roentgenol 2009; 192:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/31\">",
"      Wright RW, Fritts HM, Tierney GS, Buss DD. MR imaging of the shoulder after an impingement test: how long to wait. AJR Am J Roentgenol 1998; 171:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/32\">",
"      Seeger LL, Gold RH, Bassett LW, Ellman H. Shoulder impingement syndrome: MR findings in 53 shoulders. AJR Am J Roentgenol 1988; 150:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/33\">",
"      Tasu JP, Miquel A, Rocher L, et al. MR evaluation of factors predicting the development of rotator cuff tears. J Comput Assist Tomogr 2001; 25:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/34\">",
"      Farley TE, Neumann CH, Steinbach LS, Petersen SA. The coracoacromial arch: MR evaluation and correlation with rotator cuff pathology. Skeletal Radiol 1994; 23:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/35\">",
"      Chandnani V, Ho C, Gerharter J, et al. MR findings in asymptomatic shoulders: a blind analysis using symptomatic shoulders as controls. Clin Imaging 1992; 16:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/36\">",
"      Liou JT, Wilson AJ, Totty WG, Brown JJ. The normal shoulder: common variations that simulate pathologic conditions at MR imaging. Radiology 1993; 186:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/37\">",
"      Tuite MJ, Yandow DR, DeSmet AA, et al. Diagnosis of partial and complete rotator cuff tears using combined gradient echo and spin echo imaging. Skeletal Radiol 1994; 23:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/38\">",
"      Quinn SF, Sheley RC, Demlow TA, Szumowski J. Rotator cuff tendon tears: evaluation with fat-suppressed MR imaging with arthroscopic correlation in 100 patients. Radiology 1995; 195:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/39\">",
"      Traughber PD, Goodwin TE. Shoulder MRI: arthroscopic correlation with emphasis on partial tears. J Comput Assist Tomogr 1992; 16:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/40\">",
"      Sugihara T, Nakagawa T, Tsuchiya M, Ishizuki M. Prediction of primary reparability of massive tears of the rotator cuff on preoperative magnetic resonance imaging. J Shoulder Elbow Surg 2003; 12:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/41\">",
"      Thomazeau H, Boukobza E, Morcet N, et al. Prediction of rotator cuff repair results by magnetic resonance imaging. Clin Orthop Relat Res 1997; :275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/42\">",
"      Farin PU, Jaroma H, Harju A, Soimakallio S. Shoulder impingement syndrome: sonographic evaluation. Radiology 1990; 176:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/43\">",
"      Toyoda H, Ito Y, Tomo H, et al. Evaluation of rotator cuff tears with magnetic resonance arthrography. Clin Orthop Relat Res 2005; 439:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/44\">",
"      Palmer WE, Brown JH, Rosenthal DI. Rotator cuff: evaluation with fat-suppressed MR arthrography. Radiology 1993; 188:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/45\">",
"      Meister K, Thesing J, Montgomery WJ, et al. MR arthrography of partial thickness tears of the undersurface of the rotator cuff: an arthroscopic correlation. Skeletal Radiol 2004; 33:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/46\">",
"      Roger B, Skaf A, Hooper AW, et al. Imaging findings in the dominant shoulder of throwing athletes: comparison of radiography, arthrography, CT arthrography, and MR arthrography with arthroscopic correlation. AJR Am J Roentgenol 1999; 172:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/47\">",
"      Waldt S, Burkart A, Imhoff AB, et al. Anterior shoulder instability: accuracy of MR arthrography in the classification of anteroinferior labroligamentous injuries. Radiology 2005; 237:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/48\">",
"      Applegate GR, Hewitt M, Snyder SJ, et al. Chronic labral tears: value of magnetic resonance arthrography in evaluating the glenoid labrum and labral-bicipital complex. Arthroscopy 2004; 20:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/49\">",
"      Cvitanic O, Tirman PF, Feller JF, et al. Using abduction and external rotation of the shoulder to increase the sensitivity of MR arthrography in revealing tears of the anterior glenoid labrum. AJR Am J Roentgenol 1997; 169:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/50\">",
"      Tung GA, Entzian D, Green A, Brody JM. High-field and low-field MR imaging of superior glenoid labral tears and associated tendon injuries. AJR Am J Roentgenol 2000; 174:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/51\">",
"      Chandnani VP, Yeager TD, DeBerardino T, et al. Glenoid labral tears: prospective evaluation with MRI imaging, MR arthrography, and CT arthrography. AJR Am J Roentgenol 1993; 161:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/52\">",
"      Gusmer PB, Potter HG, Schatz JA, et al. Labral injuries: accuracy of detection with unenhanced MR imaging of the shoulder. Radiology 1996; 200:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/53\">",
"      Emig EW, Schweitzer ME, Karasick D, Lubowitz J. Adhesive capsulitis of the shoulder: MR diagnosis. AJR Am J Roentgenol 1995; 164:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/54\">",
"      Carrillon Y, Noel E, Fantino O, et al. Magnetic resonance imaging findings in idiopathic adhesive capsulitis of the shoulder. Rev Rhum Engl Ed 1999; 66:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/55\">",
"      Kieft GJ, Dijkmans BA, Bloem JL, Kroon HM. Magnetic resonance imaging of the shoulder in patients with rheumatoid arthritis. Ann Rheum Dis 1990; 49:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/56\">",
"      Boutin RD, Weissman BN. MR imaging of arthritides affecting the shoulder. Magn Reson Imaging Clin N Am 1997; 5:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/57\">",
"      Alasaarela EM, Alasaarela EL. Ultrasound evaluation of painful rheumatoid shoulders. J Rheumatol 1994; 21:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/58\">",
"      Kaandorp CJ, Van Schaardenburg D, Krijnen P, et al. Risk factors for septic arthritis in patients with joint disease. A prospective study. Arthritis Rheum 1995; 38:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/59\">",
"      Mnif J, Khannous M, Keskes H, et al. [Ultrasonography in the diagnostic approach of septic arthritis]. Rev Chir Orthop Reparatrice Appar Mot 1997; 83:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/60\">",
"      Dubost JJ, Soubrier M, Sauvezie B. Pyogenic arthritis in adults. Joint Bone Spine 2000; 67:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/61\">",
"      Graif M, Schweitzer ME, Deely D, Matteucci T. The septic versus nonseptic inflamed joint: MRI characteristics. Skeletal Radiol 1999; 28:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/62\">",
"      Imhof H, Breitenseher M, Trattnig S, et al. Imaging of avascular necrosis of bone. Eur Radiol 1997; 7:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/63\">",
"      Rand T, Trattnig S, Breitenseher M, et al. The postoperative shoulder. Top Magn Reson Imaging 1999; 10:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/36/36425/abstract/64\">",
"      Mohana-Borges AV, Chung CB, Resnick D. MR imaging and MR arthrography of the postoperative shoulder: spectrum of normal and abnormal findings. Radiographics 2004; 24:69.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1829 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-B2700F0D78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_36_36425=[""].join("\n");
var outline_f35_36_36425=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H474838\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IMAGING STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Plain film radiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Computerized tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Radionuclide bone scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Arthrography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Conventional arthrography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Magnetic resonance arthrography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Computerized tomography arthrography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RECOMMENDATIONS FOR SPECIFIC CLINICAL SETTINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Acute shoulder trauma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Plain film",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Computerized tomography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Magnetic resonance arthrography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Persistent shoulder pain after acute or recent trauma with negative radiographs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5133640\">",
"      - Computerized tomography arthrography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Magnetic resonance arthrography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Subacute and chronic shoulder pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Subacute shoulder pain, suspected tendinosis or bursitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Plain film radiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5133830\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Subacute shoulder pain, suspected rotator cuff tear or impingement, over age 35",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5133849\">",
"      Plain film radiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5134065\">",
"      Magnetic resonance arthrography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Computed tomography arthrography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Subacute shoulder pain, suspected instability and/or labral tear, under age 35",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Magnetic resonance arthrography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Computed tomography arthrography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Adhesive capsulitis (frozen shoulder)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      - Conventional arthrography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      - Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      - Plain film",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Chronic arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      - Plain film",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      - Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      - Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      Septic arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      - Plain film",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H475660\">",
"      - Ultrasound arthrocentesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      - Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      Avascular necrosis of bone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      - Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H56\">",
"      - Radionuclide bone scan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H57\">",
"      - Plain film radiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58\">",
"      Postoperative pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H59\">",
"      - Plain film radiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H60\">",
"      - Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H61\">",
"      - Magnetic resonance arthrography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2016470\">",
"      - Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H62\">",
"      - Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H474838\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/1829\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1829|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?22/21/22864\" title=\"diagnostic image 1\">",
"      Labral tear MR arthrogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?36/35/37427\" title=\"diagnostic image 2\">",
"      Arthrogram full thickness cuff tear MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?25/54/26467\" title=\"diagnostic image 3\">",
"      Normal and torn labrum CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?31/56/32640\" title=\"diagnostic image 4\">",
"      Anterior shoulder dislocation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?21/39/22143\" title=\"diagnostic image 5\">",
"      Calcific tendonitis AP view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?38/7/39038\" title=\"diagnostic image 6\">",
"      Chronic rotator cuff tear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?1/16/1287\" title=\"diagnostic image 7\">",
"      Partial rotator cuff tear MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?6/5/6225\" title=\"diagnostic image 8\">",
"      Complete cuff tear MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?11/5/11359\" title=\"diagnostic image 9\">",
"      Shoulder OA radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?13/17/13585\" title=\"diagnostic image 10\">",
"      RA AC joint erosion x-ray",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1829|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/40/648\" title=\"figure 1A\">",
"      ACR relative radiation 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/36/31304\" title=\"figure 1B\">",
"      ACR relative radiation 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1829|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/55/40828\" title=\"table 1\">",
"      Imaging studies shoulder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/26/23968\" title=\"table 2\">",
"      ACR appropriateness criteria acute shoulder pain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25991?source=related_link\">",
"      Biceps tendinopathy and tendon rupture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/45/14041?source=related_link\">",
"      Bursitis: An overview of clinical manifestations, diagnosis, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/7/3193?source=related_link\">",
"      Diagnostic imaging of joint pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/56/3976?source=related_link\">",
"      Disseminated gonococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35961?source=related_link\">",
"      Evaluation of the patient with shoulder complaints",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/7/33912?source=related_link\">",
"      Frozen shoulder (adhesive capsulitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/18/4392?source=related_link\">",
"      Musculoskeletal ultrasonography: Clinical applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/60/1991?source=related_link\">",
"      Musculoskeletal ultrasonography: Nomenclature, technical considerations, validation, and standardization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/43/28346?source=related_link\">",
"      Osteonecrosis (avascular necrosis of bone)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/46/6887?source=related_link\">",
"      Presentation and diagnosis of rotator cuff tears",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21289?source=related_link\">",
"      Rotator cuff tendinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/50/11049?source=related_link\">",
"      Septic arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/33/32280?source=related_link\">",
"      Shoulder impingement syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_36_36426="Allergic contact dermatitis histopathology";
var content_f35_36_36426=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F82841%7EDERM%2F82840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F82841%7EDERM%2F82840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Allergic contact dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 332px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFMAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6n7UnsPzp2KO9YOAxuPfpRt7U6jtSVNdQuNxnjFLjtS0c1SggGgA9D04pcc0tFNQSAMcijHNLRVcqEJikUHncR14+lOop26gJijApaKLAFFFFOwBRRRQAUUUUwDHNFFFKwBRRRTAKKKKACiiiiwBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRSsAUYoop2ABRRRQAUUU122rnBP0HNJ6AOooByOKKYBRRRQAUd6KKVgCiignAyelABRio7eZLiJZIslD0JUjP51JRYBioFLEZJbrk04CloqVBLRAJS0UU7ANAFFOxRU2tsgEPXrQRS0U7AJRil60U7AJRRS96LAFFFFMAooooAKKKKYBRRRQAd6KKKACiiigAooooAKR2CKWY4ApaKACiikYhQSSABySaAFoqq+o2SIrtdwBG+6fMHP0rno/FTT3s9qlmGK3QiRoZvMDwkf63KjAOeNh54qlGUtkFzq6Ky9Llmm8wyA5WQqxL9OOhXsenFX/tEO7Hmx59NwocbOwEtFRiRWPyuM+mRSPKiAs0iqoFTZjsS0VCGEq4R3H+0BxSjcqqMtIRwScD8adgsS0VF5ixgB2IJ4AY8mhJFZ/lZjjgjHAoswsS0UgYN0OaY0uCAY5OTjgZ/GkKxJRSBskjB49RS0AFFQk3AH3Y256ZIoEzBcyxOv0+b+VOwE1FVvt9ruCmeNWPQMcH9aljuIZCRHLG5HUKwNFmBJRTXdUBLsqgDJJOKI3SRA8bK6HkMpyDSAdRSKyuMqQw9Qc0tABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUgCiiigAoo70UAFJzS0UWAKKDn0zRQAUUUUwCiiigAoprOq/eYCmmeNQCW4PTiiwWJKKhFzGy5Qs4/2VJqldaxFCQqwzPIwyF27f51Si3sgsadFcvd+JrmyCSXGl74GbG+C4Vyv1GBV+18SWFzLDFCZ2llJAXyW+XjPzHGBTdOSV2tA62NmisS31O4e9mstRtmsyZCLeYElJ4yOMH+F+xU/hnNW0gEX/HvGh5wWZiT+p60uUaVzQorDvlMoCXWoiz2n5WiJjJ/EnmqyymzgMFvrVxdOOQPJE8uPTj+tV7PTf8xanS0VjvdwTXTqZLyzeJRIzOhSMg9MkjaammuLwJD9hjhvAw+dzJsxkfKw4wRU8o7Fu8uo7SBpJNzYGQqDczfQVg61aw61Np63CmWAPvS2aUqjkc73C/eVfQ8ZP0rP8UXH9nQ3+qaxqcD6bDGGFsE5QcKwyOWy2AF9sc1u6Zf6dLcx6fb3Aa8S1ScxbSrrG3ALDHy5OeD+VXyqMeZjsY/9rw/aGtNI0iSaFTta5W2xCo77Noy34fnVoS3FvZCWKykBPLswjtFUep6kVx/j3X/Elh4wt7fSjcw2KEIsa24KzkocneQQFBx+PWue8RaprepQXFxf6z/Ytxa3Ajhu7eLzWlt9gaQ+QAdxypxkcHnNdUaTcVLp95KR1kviK3XUra01i4W2ubpd9nbxzMFlHqJGGG961YZ7R50jN1osEz5CxtN5zFuwPQGuI0g6FYeHLfT9IvJr5/KZ4r7UVw6NId+yNSM5yefQcc9sOzF7b3I0PVbuBrm7LSCfaBLycnYcfdHTFdEKLkuwpJRdlqe4aS9wiNFqM9mkoOQlsQox7g81dmvbOCOV7i9gREG5jJIoCD39vrXj+n21vBrUImUSajArpHtGXPszduPxArQs47ae5W2uImnjZHk8oqHB7kE4+b2zWcsEt7/gJTPUZ5GliAtQHDfxRyAED1oUXAjx5QbHTdMcn9K87vzeg27Rzm2j4WNMEMo7DaOoxWjaX84kIleaMB9kaq+Wm4yX2g5UZ45rN4RpaMpTR1Cv9oh89LixjiBKhwPM6HBG4kdxii1jul3+RfWrxEZASHofwauUvoRd27i4gguLN3KN5haQk9wcdD7VkXmpW2jTWiacttbiU7eVkVsD0AB/MmqWHdt/wByO9/tbyJWilutNll27gguAjn6g9q0bS5aaFZJUSPP92QOM/UV55Nql950dzZz2kcjKdyFA7MD0OTzj2q9F4kvHWNQYkmjBMqwRHJf0KnrmplhJPawudHb3TypGTEm5vQUsBmMQL43ehGK4zTNf1CPUTFeTRvI0Ima2kj2sqk4DKw4I7YrTl8STfaY/Jtg0BPzHdgqPWsnhprRJD5lY2bu9ltT81pLMp7w/Nj61CNUkMZc6fdIAcfOAPy5rN/4SuMuQkBdc43q2VA9T6VVvPE94VK2Nvb+a2PL84sA3v2pxw8+sfxC6LU3i7TY5BDdtFBOT8sU74Le44NTw6hp10FaS0VJCNwLxg/jkDp71gL4uvFkjhngt5rpsg+TExUY7DJ5pbjxLrEmBp76duz8yNksntgHk+1afVn2t8xcyN+/02wv7m2WXSopmT51kmhDIg74OevtWhYWMenxvDYRwwwly+0A9TyT1ril1jX7KVb64kF0hUh7KNFVR/tKeufrmtDTPE95eRiSazghIbGCT84/2TWbwtRaofMtjqnXehjHl7x0XkCiAy8I8PlqBwUfI/wAaxTqNhfZErXUMijlBnI+lMsI3luWOkaxNIqENJFcozgD0B4x+tZuk0tfyHfsdGFcZ/eZ+oFRn7SHOBEyY46g1Es00UeLpQ79/JQnj1xUP24s2Ld43YdUkBjP61Ci2DRZ864DbTasfdXGKe9wkahpz5QPHzHj86zbzUdQt0/d6PLcsTjEUyc+/JGKoRa7JPt+36NqlgxGCXVHVf++WP8qfs2+n3CR0cU8UpIiljcjqFYHFSVm2N3YyMFhK+Z0J8vac+/FSakrvblYbhreQjCuOQPrUuFpW2AvUVk2tpqFtGjfb/tbAciVcA/iKjutej054Rq0ZtopG2ef1jVj0BPb69Kfs39nUEbVFNMiCPzCy+Xjduzxj1zWLN4ltQjtawXV2qnAaGPIb6E4zUxhKWyC5uUViW3iBJ4wxtZbdicbLghG/Kr1lfrclht2EdPmyDVOlJatCumXaKheYg/KhcZx8pBqL7aApLwzJ82ACvJ96lRbGW6Kga7gVtrSAN1waIby3mbbHNGz/AN3dz+VLla6AT0UUUgCiuT1Tx5pNg2FjvbnBwTDAdo+pOBUN38QNGi+UXtrFJxxNKAefYVoqNR9BcyOyorjLW6l8RRfaLXWSbYEg/ZJFRR9T1/WqMlksDFG1TVb195GbZ/MYf7PoPzqvYO9myrHoJ6VQOoPvKpY3bKDjeVVR+pBri28M61cyw3Uut6jBbp8zQvc7TjHQkDFZep+INGguWitLqGSaE7JJpm84Kc/3ulXDD8zsmLbc77UUmvAi22qtYzHkoPLY/lzVSysL2yYve69NNF1+baD+grjrrxF4WtrEC98T2jTORlY4wGLegA7Vl3PjrT9OaJoNP1bUEIG+XKxREZ5wCck/hWkcO9v0H7vc9Fju/KnbDX96QOiqcEdu4q2upQRxorwPGxONjHJFeey/GDRzZvJZaTdsyH5klxFyPT+9XH6t8WtZ1S2ml0iF7FBwg2riU4zgP1FJUG94j5k3ZHvD33lxhhaTk9cLETUMl5ciMec1pakn70so/QZ/rXy/H8TfFuoyLb3LOyFWZ4NOuzGyADuzHkY61RlSbUrLEduLWSZzm8nBmdgSNsUe75UxyScZarjhk9UNux9I3OpWBnlgbxJYST7fMdG1FUIGeQFHIHvVKO60WK5iSHV0mmaTDfZ7oNKpI+8d7fdHqM5z0rwCx8IaNpwj+2me61OYhjJFADJsP8QK8CukuPhzpAsFfTkEd5PhpWuCZGCY9QcqfY1tHDSW7J5z03w94r8OX+ua3p0ltqX2rTphayPcYkWYnncpU4BGfaulvf7JtbK61FLi6thbRmSTyvmLKP4sc5/CvkU+EbjTNRiub1pL2ynaRY5VuCimQdgOufQnrXS6RpuoW73F5oWsanpVyieWqRzeYy57vGR9386UcNJrd39ROR9ReGp7HVLODUdM1ObU7WZT+980MhI7FexrnbPxppkXiybw/qGm6jpjX00sdndXABgvGjA3mNgSQcEdQK8p8O2+oaXo5hjv3nd2V2SANbxlsdcDv9azPEUXjARJLpmqiKUBsrKwyCeuw8gZ9KHgWle4ufU+oRbwTrHJKkU7AcOQCPqKz9b1SysNKnmXUbOxdlIjnlAZFbHBYAjIB9xXz5pl9q+m6dpFpqOoX0886MZGhTEUeBn769x0A71e1jRo9Y05rTULm+nt5AGkjebaWI9/SiOX33kDmdP4k1a41bQ49LtvGVneBbWWSS4it0W7uLjd+7MaHCKqjnuTgfWujsbfVrfTm1LVr2/1iOSzi06LTUMcSSliFad23csd2SwIwAcA8V4jeeCdMgkto4tLUxKcR+ZO4lX1x13VFq/hTU3vLJtH1mWK2hOVjZS44571o8DaNov+vwJ9pfc+jlTQtI0K2t9TSzhtbApsWVSVDJyCgbLHaTwTk55968nvvjLDqHiIQ6JcWllpt1OYjJFbNJezlBg8fdGeApOSKxzHq99CZvEKPfuw8prlckkehPb0/CpdC0zRNIvpSyW1tKoCu7LtjgLfwqe7t7c044GMfek7jcmnYfdePfF1vfFbGfZDG6yPF5ayyNuyDG5bJ445HGTU11rOsar4kt9VMr6Vb2ihF8kB2v3KkMZG9BnhcADNX49Og1O1lvNMSdYYZVicQkIrnGfmY+3Wus1vS7Pw/p4u9Fjhkt3KoqCTefObkgfUc+ta8tOEkraspT0ZzGjaPcaTayam1yj3rIxkkwGW3jbkgA8lv17Cr9ncxXYtry4sJbdpJNokdS7JGBku2M4yOdora8OCzhlu57KE3tybRLiezYZK7vvAH1BHU9s1H4d1W/s7Jklu90Golo7GIx/vN/TPso6ZPpmlKb1sv6/4BmtzPtNPlk8TRTxyx2sLo0qiT5ZnxyXYe6jkGq1w11NrKahZQi00C3YSx7D+9uXXkomedmOSeldR4VaB57iS6mN3c26jZsXKqpJyoP8AtMBn2FUPsDtBay3conmMjSLGhzhicbR6r2/CjnvJp9BW0ujp1hhuVtZY7ecmSJXGHATc3PLHmsqW2dkv9Nlu4re5aVBEyxlQqnlkDDk+tUbiTU3MGnvDNJPceasXlyDYr5AOcdAg5IP0qA6pHMf7X0m9S9soGEL3h/5ayBcALn+HOc1lGDva/wDVyxNYsoho0lumoiKDzd0ki7ow7nug9gMVj+IfE2l6NPpWnT3F5JLdMvl2sELSyye7+g9ielaOoajO+lRTXsNtPd+e/wBm3jYioqbiSB1ZicKO4qK3sdXuvHqQy3gbTJYYpG09rRVKIUy8hlHIfPy7e4q23Ff1/wAAmxLqpuI5123Ejhx5ilYdy+UemBjt3NWhcj7NExk8y4tSyyC3wo4AIznnOD0FP8UzSWGqGLWLVU0udhHp6Rkb1YDLOOeyg/L3pdQubOO5k1Cw06ycvtN1dtLiKW2xlZAuME8DpjHPNHPdKyHazY77QsMqSvdu1vOu8RMp6HsfTmoZrtLO2kL/AGcwyxAqQzMI5CcBWHUHPWqWryRhzDcXQMN3Mq2k0QEnlK2Mkj+Ic/dqGMzx6g0V/dRXkW0OmyLy03L8o+XJOeB+FaKNydjTsb6Z2228KR3yxgmEhWZXB5fA44HOO9F6khZPPuE8yZGX7UYdhMnU7RnO0DqeKowXkFvp95cTh7WaeRI2nVM+Yx5OB6Acmq+qh7W6lgk8+PSLS3ljL/Lvufl5IHUsWOfYcUcuo7aFzS5oYJ4YdzXH25XOVVgNyqSAAeeT19aZpdhcNa2V9HpyrLcyNCjhtmwZxgZ6Fjn8BUNrNcNrVhDZ3k0dpPp3nPPIgEgLwlmnJ/hZMKoA6VQjmnm1zVru5nitLRWSZLqeRhGgjCiF0B6krn3y1Tdy2/r+v0BR7nQWlw91e32kaVJcyX0DE5ljAKbPvLz0zngmkWaO2Zv7SeYuW+Zo2DGIH7qORwzfSq+qeJpNf0+9vNKhvdNubaUEyQRYnlhdSIXPBJVmU59AB0qxqN5BpWq3s8mmie4soLe43PIfLZ3GHYjpnOOamLb3X9f1YGrmnfvtAtZHIi2/KxByRjru70zT5pbdisd0yOfk85QQpwOPYn+dZrNDbXltFcXJja4VZyjfNsSQ4DN/d+bgU6+iuLaVzJFaTwLiMoGZXjbOCxYHBGOgwOe9OytYNdy3f2Nwz+Ybh/7Rk+7db/LkUegLnaD7d604dbv4tLY30rIEJCyABpMA4+bAxn1x+FczciKdBPPDmRwUTc7M8e3+JQvDcdQauwPMDaybpTbvGCWD7dg6jK9yfypSpJ/EJPU2Tq2oSSRsdRVI3U4jWJfnHrnr/SqOtapqtnbRTQ38Rj3lWjuY8rKMdCRyGHUHpSSSKGMtxLDzyquQuF98dayri48+a5jlkieB2WNQ8PlwxKBk/MAd+T37VKpRvsPmsauk63aHzxqlvCl0jYSexXIkTHUqe471rWeuaYYnEOtMoI5jlhO4D8q4SWZreW2iW3eKKWFmW4K/Kp342n3xyDxxU5S4jtomFxEJ5G3govzbOg6+/rVyw8ZdQVSSO6tfEum28cYN4rwOMrMyuMH0YYyv1NWLu/DxHzFS7t3+8oAlTHYgryPxFeeiFpN0W2K4m2/vI1b5s+grCvrVWlaMQzRRIm7h8Z46HBz/ADqPqcW7ple07nqAXREiQyiREJ+W38w+Wf8AgP8A9atWx8+eKR7aNbK27bU3SP75PA/WvIkl160ijmtriWFpEALLP5hjXsF3DA46nrRf399rl5EbzUrqeC3QFlguDFuGcZCjqfeiWEctmDqLsevvb3EsG2USvCw5G0Bj9e+adax2UQCmAxyAcRgsWx9K86sr+/muCsmoXSxBD5eJCVVenTvj0qOCbxBpPNjqjz+YRvygw49fmztOPSs5YaVrX/QnmW56c2rW8QKmKcH0MZH6077bbysBFdQ/MPuM4ri7nxhqGnRBr2KKePbl4mUiQD8OCatWXinSNQt2P9nbbgrv24BBHY7sdKweFa6fiUpo6ifTop1VgN5HUhh+IqrfaJZSxOuyWNyvWM5IFciurtprmefTGiiYliLQkkD+8ff6itvT9d0m4gWW21SLeW+7dHY4Hoabp1I9R+69yRbCWxs2WK6uYhjiQyHr7+lFWlWPUmY2UiSBUDefGoZCST8oGevFFJVI/a39CXDsed+JfG3g600Zbyy0y6vxckoiFTCXwcZLSchT6gVzcfibWGt7O20G38KaC0g3GNoTcycnp/tfWoL25ubu7AMX2+8kUF2Kg7U9ckYFU7Dw/Z3qzG9LhAxHzRlBkep6kfSuyOGVrSdxOR0svi2F/Ki1XVdLuHQ7ZIoIBGhb0+XJP0zV2Xx9dWqyBdRtdPs1/dwLDaGUg9zgcd65vSPCWmqJ7aWI2tnbRvInlDa87D5gqdhn39ataXp8P2ZZvs/+kToFlhZ/3ajuAp4yOhNUqUH7tguyve+L9Z1s3dudSl1CI/uyUjWGEDuNvVm/SsV9FEOl+ZftFaT7SSUl3GMfToT04xXUSzWVqTb2Dwhd5SEyocv6gYzzVvRYpL5r5vssOoi1UuNLtAGluTj5Vdz8kK55wTuI/KqahShsG7sjzjRPDdvfyKN5v9TZxFAl/GkEkgPaNeOnqa2L7wp9nujbx6xG7DBlWzcXKRnoUBYgqQfavZfDOjsXD33hnQtLidMNGj/abnd/dLbQBj1ya56X4Wafp8cQ8Mau1iqAqtpfwLdRKMkkc4ZeSecmuWOIjzWa0L5HY8t1K0sH1EW6Ost0I3Z2jlLGLbztde5x6VIdOt7Y20TJK0U4JzAGKuCvyAk/dBJBIArs/FvhnxlBFBfXDWty9pEQ0lhZxsHwflLrw5BHGR09K5PUtZikgitrszIAQ0j2w4tJONys3BJGRxgnFdEKkZK6C1jD8J2muXeplfESxhlTai/uo453B6KQMjOAATwDniu20p4nmvp9Rtn+0XiTosMobyvtAAKrt7bB2HXtU99GdPkurUTGYhYnil2AJduwO1xxlQD1Hc81uSRSTBbeG/EU01mwCMQds+wDdk8DDZwetaJJR6shvWxRn06SbQrSa+uVtoYwQkMQ2SyTHG2NfcjJwfXmrNr4a1TXtTsrT7PcadosdwHuJ4fllmKr8qZPVfU+orS+HGnS6isNjqVz5qWsaPLE3MjMDyS3U7m6n2xXWzX1vqItNC8WpFYaxqkdwsFnb3TN5ka/eZXAXkKQT6Z4zXLXxDg3AtRQ+20O0vdYuW1DRdPNhgGCWX55pJRkMSpGAuAuCDnrxXOeNtD1LRr+w1Xw7Y291pUYeK+t44gbhUc/6xGPLBf7o5x0zXbwWlv4a8OpDZiZrHT4CFjYmVvLUdMnLEgDjvUnhnW7TxHottqmnLcLbTg7FnhaJ+DjlWGR0ri9tOL5k9Cml0PJJNMaWe6iw9teROCkoHIiZcr5iHhgD39DVaS0W0Z0T988kYeNlPys4HOO4PUY967n4nxLYW0F/Dbt5rFoPtSgt5O4cKQP4WPGexIrjdOllm0+PUbRhtKqwJUAqT29wcEfnXrUKvtI8xg9HYzopLxZ5TFE4SdGCxMwU20gHyhlPVc96kAli0xry7gdpowHaJZQwz3AYehrc1C2t9atoDYzPHqcCi6iKqC4xkOnP3h7elZVpdtZSqt3FtuGYCVgmIpGwOVB9iOK1Umxl26txd2xbyNxKKY4Cdrqw5DA9jU2k6VcXGh3MoIheJw0luP3jlT1OR05/kamLLHuuOZJBJlYl+br2/D0pdC877PrsVtLJE0VshYow3bXJ2v64wD+tTKTUdPIOouu3bW2hGW7eSLTxEIXQDm3KnhXx94EHdmqLagjaZY+XphnvNRmWKKR4wYyygbcAjqR/FVrW7+8bSEbSjDNdQWoKrIoKyy9CJB/ED09qg1DW72wjt769y0oulQKIwYtoTOxR2PUDHapSdrWBvqM1TW4jJqmizfZozZOk01vZKoktnwBwB8o3A9/Wr8NnFZeK7Y6FDC2mmNL+f5cyI8cZxJNnvghRt5/Ksew8Qw6j4TaW6t4l1tZnsZDIoD+WGJiDsB0B2564Ga6DSLXVbXULue8ltD4nurfdFYW8uIJwAMsWIO2MkbR3HWspaR1039HtqUtGT+GJETWTrunTPFp+pTvHLazKMmQ/Mpz2XnP0NaXiLXo7ZUu/wCzjFqVrK1tC0q5QFl5OR1Ax0rnNVgt7SbUYNM06bT7+whN9Miy7gUaHYyofRdx6elT+EL2LX9P03TrqPzIA73ME38UxiAVCfXIzk98VDhGX71rT8bf8MHSxJ4i08W+mR2OgJAJltzc3aiYJIGbGwuT/Dkn6VkaDY2K67psOlafIl0ts11L9ocmSKXyjl+u0HccZHHORVrw3YnVrfxBaa8f7OOp2yWsm9RmSRiVBBPfoNorI0+/tbDw3rWqW1wbW/gg/sdRK21nSJtryoW6sRzj/Zq1dXhv/wAEaXUs2piVrS1vHns7O2jN7cyQyMktvM4+V+DkjnBB4PvUyXZttJ17TdNjZrXS4WkjuHXLzXLNt3svQBR0B9M03W7ddV0G4jspI/7cuEto5DMuB9mjK+ZIx74Bye/Snadb2PhjS01fRbue6sL+3neR7gjARQRyM92YHnsMU5au3X9f6uC016Gr4c028g8TxWn2iZI7OQXd7PNgteSvGTlz6KMAAdKf4f1i30h9RuDdXl4qOt1EoRR9sSc4jO84DMNpwM8Vy6eJX1PRNLjvpfI1GxCxX6qjK1zC6lI50/vDBz35OK6PXfCVlqvhDQ4NBvlbT9PuCoW5bbxgpjnGCjcgEdqzmtlProUn2IfEeJ/Geo6NrqXt9pBhbVHKRnFuqxkBd46NwcDPIqppV3pniXS9MbUnttPk0y9NlYQx5CljCDFk8g8EdePxroNWuvHsV9Z2dnZWVzaLbos90qjE8uBuOCcquBjv1rj/AB3aaZq+t/8ACPT6dDZQWMaz21soMR2SFTJKccHDDHHpU07zSWl/6/MV+Ufc2cmlx6LY39kbqS8neeeSN+IPLbDEH+I5wcegqzPO819pd5LbJ5bT7ZJg+BHuBG7b3z1rL8T6pF4c0aFdUFyYLa8lhtrmBTIrgAEKT6Fu/rVV9SjM00L3Nu90tzHK1sjfvFVh8x2nkgFhnFdiV92JXsmka0csF3NpVu8zR3n2iUJcTxM0Tjcvy7lyFPH8WO1LrNiZvDFnazXUltcWNxdzksMrHb+Z84J67vTFc3awxT7YLOadLSSV4Z4vM+US4wT7/MBxV7RNeXW4vFLXFrfQyrCrQvMhEJViA5X6Fcj1zSlGzTKXvJtBNffarm5geOeBTrAS3lgdlaS02eYc/wCwcKCO+K6SLRUn8FRRJG09zBI7iUjMSpnPzE/3eoHbNcjexfb7u+02zlWx1RobW5jjmPC4RRgnsGUk+3Fev+KPFeheGtGjTULuGI3NuY7cg5WVsYCgjuSayqTdPl5VdtgmtzzvSDq/hzS7GOdRZxXupPDHIzKXltWUkRjqf9YxI9M8dagnklPhrwba2twloJhK84dWxtV2zG/faCDx1zUHhe/Z/Dl3c6yd13o16GtYuW3HaSyDd0IYBt3qKqOl5rejQJqUTz3unpFGsiXJjZmbmYuR94sp+metXyPmvbZ/8N+ZN49BbC7/ALSvr+aJZFnuLZbzUo7jmRSp3RIn/TPao9gAR3retRqB1hNQs2juUjzNdBWBiCpyxC8bgd3TsTT72ysrHVYbq3iBSKO+aKMrlpFCKiIT1ZQxPB4rAt/CF+rpd380yK8Q1RreCTa8abgACM4CnHzYyevpTUla2w7XZ0P2zdcuryFJvLkk8uMBGjHcL6AhsHNWbm81WXVlOqaiYtOhRIoNPt0VY1cDhmf7zkgj5egqtq5WS51D7KGaWzSOZ5VxtlYIcAeqDgY61m/aDqvhrSopBFp91cuyXki8qgYfLsLfdyMjJ6U3FSs7EWtrc32vYDqZnk/1wbySWh8xCenAPSsrU83Vylp9pkVVBKWlvKVXCjI3kdcn8zVfQbbWmhsBvlminlMMU32cHCRnBOepJHVj6cVnahDHFdXFx5TyQxsTMikq0iKDtcYGSQeffirilfQOTqbhZ384pI0AkTPkTn7xXqxz0OegpLeGJ72DULm9ktg06JM4XLMSemK5+6u7K88NRTyu8t5d2IZFm/1kih+WwfUY4q/qdzdB4hHK8cs8ShUIyXZUypA/vcY47VSV1oDjY6qznsrrUryTEIsneaETQdSAp+7/ALZ9PWuNhutPYKCt2kVvaPOs5GXEan7rAY2tk8Z45q9pNxDZXFxMscbQ6fbrPNaxNk2jOowzD+8SSeKVL+60bT7y4tI7O/uvOitpY7wmSHLrnLHtkHOOxxWfw3sJojivLi8voRAqtaXI2P58eEMRGGDnsw7joaj+0wWstzeW0QTyi0L2kwCs5yFwXJ+Ud/yrR1DTb3w/Nq0RmW5dhGJBCnypA5xlU9BkAnsKm0q4i0yTUZtQSJ7TToGkhkubfabzjCEZ+8Fz+Bp86tdByGTaXPnoTZW8mU3LdRyOAsTdQBg4xjncK2tGe58sz6fiRpHaJ3d96hschU4LfUdKs2qfarbQ9Ol09rize3+03F0D5ZSTJDs0nbaMA5pln4b1WKC5vtL1q1M7RAafBaQedGi5PRsfKTxlvrniolVSVmHKNjiE95DZ3jyQXc0o8mS3JeUHgHAzwMHkHPrWncWNvZXM0OnTG8s7dv3wjZQ/mEZ6ng/TisvUjrenag8AbSLfU18ub5ImD3rDnCnAG8dyvUdRWHrl7ZaHdWt99lmk+2jmO2OFCM2HZvUoxJx+VSnze9fQXL2OkvHNxBF+8CTJw+2UZAxwT6VQjjCRs8FsTd43ByQFkI45x3qCWQWc7Rki/UloxJ5e1nXGQWHrjseaptsvJ7WK4iiEW8FBuZkbuNwPOD6jpWqjoS9Dpha6vFaQajPEsDH7kmcL7DGc/nRWcb/7ZpwsFnuZjbyZWJ22iQjIK+v4GisXFv4kh3Kmm2twivMzMqyPgImAI4+2AepNOuI/NBkW0kkWMgAtkhfQt25qzrty+n20wubO4e4jk3SW8JBdh0wvuev0qne6xLpWiahfXlpdzSNcRRx2lu2Nylvvv7J1I9atzsrjsSanMZbKNLuM3U28K4ik2mP6kdeKp64kCNBHYukk7R7p3V8pBHnAJP8AeboBWTcPM8F1YJPO8U07z3F0SFFvCBukI+mOB616H8PPCsGp2Vtq19b+Vpx2yWNmy7SyAYWWUd2I559airVVJXbLjHqzmfCPg7xFq2qNdpdJp2htH5auYVMhHcRg8/8AAyfoK9X0yztdItF0vQraOCEA4YHBZ+7E/wAR7k96s6gl3MZYLWWOKVB+6PO0ZHG4d8GuSS8C2OmeG/E+q3Y8QassqR3NjC0YJT5jtcAhDjHUivPnUdT3pPTsbRgo6nU22VMkKNGGhIUlTwpParJUqrl14Gfn28Vy9jqra9p+v6b4fL2ms6efshudQtWVVm28P/009cj+tWtMsNbmltk1G/mkNtboZJYiqw3c2PnO0glVyOBnHNQ7N7lububcioFDxs8TkYDDr+IrzX4n+DY9Ttn8Q6Zap/aCKFv12fLcRgYLY/vAZ5HOPoK9NG37GkqNiQkHgd89MVGuTaXNvE7B5lco+MhSQe1OM3HVdAmuaJ4RoF202lrbLvmksgiRTzBWZwGyDx2xx+FarONOuNf1VGja40+MMqH5kBHzYI9eQTXMfD643zQtkk3sU00YVABiKba2fTDc496uaPotzq/iqDSr2Jxpc0k00k6uSZQ7j5SPTA616jleN0c1u57F4OsILawuPEc8e6+1OFZ52jQj5QMhVUfUn3zWv4d1C11+wttT+xmC5QspiuAvn2xPVW67GIwSOvPNaogRYkji/dogAVV4AA6cVFb28Nt5xhiiieVjJIUULvc9WPqeleJOfO3I10sZN34gtbOzv57ieG2jtZvJMjSq65OMbsfcJLYwa0LlL66sU8qdbC6KEthRKFYrx1wCAfzxXMaLpXiSK4+0ape6OhnvHeeytbTKSxc7DvOG8zG0knI4rrW3eaYwyKzj7pBPHciqduhXLcyNAsNZuPDjWfjKaxur6QMsklkjJGVzxgNyD0P1rya3s7q0vL3SbdpJG0xpbW6E42+ZuAkikXHUc4/GvcoYWjdQGHlopGMd64DxsIbXxb5zyCJJrOPzSAclRLtY/XYxArowlRqfKtmZTinscU07ySaZe6fFOb2J4kVY4mcsJGwd2OmCDz0wea3dVvIbGWW8sEglumuRBOtwC0TOP9XIFPCEHI9O/anaRGya+82mTkR2bssaK2DNBt/d/wAs89c1lajc20s+o3UZNwwK3RgZflI3bsgjuMHivStzPUi/YdrkUWjreT3BnNtJId8Kjbtfuyt3APIIroItTh0PRo23iaG4dI5JdoLCKRevHXrn8Pes7xDYafrmq6bqt4ISgt3MKCXLxK4wxC9Ov5Uz+zl/sKewuppXaKKFvMj2/IEbq3Y/eA470vjilILW2K0uktomoaetnfSXEUsAf5TlFKSZO0erDAINTRaon9s3pmWKfSr2WOSIOeFyxXj+6yMcVns8NxJdx206SXsN1G1lsPyTo67WGe2CD+VZ9xDe3MpgghDRsrlJEO1WLcEj1/eJ+orRRT3/AK6ivfY6O5uEgf8As3WSU03T4lu7W4WPdsmjfa6tjr97BqxfWGuzHQdX0F1uobNbq3nkLBHjU5IkGeTjG3b7isrxTdsNP1KwtS0/nQyzWpDYIYkCRGHb5lGMdxXpPw8gu4fDtsLy6ScNEhVEUbY8jJGepOSc57iuTESdOCn5/wBf8EqOp5jYePra+09p4YJbnWLewkgmvflEZUkBDLnkfNxjqTmuv0Xw/cWN3pUx1A30Vi8rSSNCtv5FvLHlVVV4+U9T1rkfEz+EYvhx4u07QtQ0z7fc3DySm1lHmExzDBY+qgY/l1rprTUL2HV9LNxIYYUkNtdxO2F8uOEfvJCeMfN+oqdZpuKtv89P+HsO1jGY6ja3VnNfGK4i0GWZlYNmMo20pKfX+maq6zqkWl30UFhGjG80B7xo7gBlLHcfN2nrg9/Q471V8Mw3+sWOraZeQOmiX8jWkWqqwAtyjAqpHcHIUHpkVsaDHb6h4pktNXso96W9xokbkYeJFKny1X+JWTndnrW8mlddt/69Q7Fnwxpl5NbSeJ5EjZntHmgYL8o3QgOuOwLLn26Vxen21xJoS6NfW5TTL0yWcDry9qZMM8mO/OzHsa3fC+vave+F7vTTL/Z1/wD25LZxSrgKsbBsfKeoXjIHpV3WNNVLDTp9PmW8traaGa3mP7vzGAMchP1ZQR26Uot3al12/r5la9Dt/D+gwI0V1dXC3cdniK1+QYRVUKB36YPHTPNYHjHw1puqz2tpaa3Lah7mUy2sUm6Fpm+c7sfccdRn1NXNDae1i8O6e9tqjLeWzySXduyi2jdm3gSchtx6Aj6VH4tit7G31Ga++zRacAZZ7ezLJeXE5A2sjAj5jjAHU1yRk/aXvsbQpxcbyLnhaPU7vxXe3l8bm10+yt47S2Vrr/j6JGTJJAOIyOAM8nr0roPEPh+z1o2r3MStLbvuVuhZDwyE/wB0jt9K4jxjaaBfeGDr2pW1zaKPI1G485HErGLBjjkVPmZxxhTzmu41PUxB4Xu9SYiILatKhbK9VyuQeQckcdawmpKSmnqTU0szy28R/B0HiaC9kivC0AubA3LeZDCXlKou0/d2nbn121kW0VvpnjWKaaO0/tazu1aeeRRl45kJ2k9CPmOPQgVG72Nh4cin12K5vNc8RutxfPF86wCMMdo9BtU4HUsSahvLXb4fvJ9BW3vdVhvYUe2u5NpmgmA8o5PR1Zu38IIr04WSbn6Gad+pCYms57XXI45/s+m3MvnLEQyyzEqyDI4OAwJzW3DbPa2r2ulTnUmt7wQTxxxlBIXUSKpDHLAE54wOaS28PWGhaFeWEl5NeJ5VxcXvkyDdE0cighc8bgoKjNZ0ZgudM0m5jhMclnItxLJvZZBHOuN7MO4wBnoM1opc2qB2I9IsLeDXTaTJNNrNtGLGbziNxRnZt5Hfadqj2xXoeh+DU1C2s4PEdh5sel30pg83BV4yoYBgR8y7iCPdRXGvdQzaU0s8csmt3tstuLvOGU243K7dyzEKD7Cuj8VePotX8MXdrphe3ndhFcSsMmGEqC8gx6Ege1Y1o1WlCCt3/wA/zITvqzibnV9R0/VdYudb0aC3gjkmnt7m0JktLiRwyna56ttxlT0OauyzS6DrM51GO4g/s/TvtdwFjBhZpCqxAP2IOQ2cABax9HS6s/h/5PjVWikuVk1CwtnfzNxUDy5tqngfMMqcdau6Kmq6qguL+e416E2lrc30YAEVyecQfNySWTdjGMEVpG/KrPT+v+GKubdjqGnyXs94LRXsNPsYJDMDhpiZAJC+eqnIIx/d96m0S3ks9Y8V6hM8U2nJDNHChmBc+Yw+UgZHAAyPcVleE7Fzo+v2+sW32WbW4X1CziEvmrHbhgwjLDgHsF/2a5i08P3iHT7uw1ye1tb391utodjpmbEgIP3pcqBu7UtJXt/XX/MdrbnY6HfzyXmqPe2b2OiyxTi3a8AHmNuUeUAOdykEjpkc1n3l/b2mgTzXrS3NrkxXE0UG9UCLuIYH+LHI+lVrjTgdF/te7f7SUv8Azri3WYlp2MJyWx0f5QOOlTS+IZ9Kgk0Q6cZG1NPtUi7N0KbCoKbyfvkEA8dq1Sa23J21Lfhq7muNWtb8ajugS5FylyJDuuLc/c2r0XK5BPA7HmpfFYuPD8+j6ppV7bLcXGDaC9QyR/viQBIq8khTgc4BrN1Dw5bQ6hFYzzG01C5v57T92d/l25Ckbl4wgJHTuPrUN+Z7HUtUi1G3iC6YwtfNlf5ACRtbB4AwAR9eKVlN79Au0rmnpV6PIs9Sks4bqOK2aMtLFmEFW8t2Q8cD07VXMJu10mK4j+1XckY2b2P+jSuGWMgr0yMHHuK6G/htrrxHpFhandp0gns1UZVdj4LkKPQ88/3a5qDVMahHd6JHK8BJNrPLHgTmI7G5/vkgkD6U0+bR7iv2Ken3t2yoRaTwP4fuEtnhlISEu5BKOOrlsYBOR2regtrKPTfFuoSz3t/ov2oXLQ2agSCcSKwXHoOnpimaTbtPpd9bQWzC+gijufMYbw7ecQsj5+8yAtwfaqei6hc+XqmjRwrGdRvZrGcGMksyr8rDv0OaiS5rrr/TGlpodJq2oXtvqF74ntLlkguba3nt43AYqr7QTn+7kYK9jWPd6ndahfWlxIAjWt7LHGSu5ShO9sr6dKbq9jJrdv5NrKdH1HTrZ9Mj82TIdY8Mg2kHaSR259alvpEj1zTxJfFbGB2WNpEyQrxhWbK9TuDA59KdNWVmtV+RMo26m14YibxBqT6Qbid9GIW7u0wCsshYyMpYdiWGQOwxXqdzPBp9rwiqkaErEmAdq9cD0ArjfhlFbQRzJBEkLW1vFbuqHIYpuy4/3uDWVr7xR3umuXvrnUJ75ZUkjgcBgc4RQBlUxjcePujNcFaHtavLskb0KfOzs7bxDomsG6gWSOf7LgypImdhIyMjscdK5Hxp4Ms73SJdS8KwJLJJl5beGT5bhT94j0b6YzTtE0DSZ7vUbOFLW2udS/fXoiUiWTblQWz/AA88Hrmm6Fp+tfDuK7hisxqfh8TRRWVtYp++hQ8FnLNzjqTnpS5VRl+7evZ9S61KKbSZyKRm1kkvba4uJ9GliV5pWUhowwwY2B5BVhn8xVmyIjnzK6M8ETKsBG7OBuUp7HrW98UNP2wrcWzMbO/cSHacBZFG7J9iAT9c+tefajqDXOmwW9qJTqlgWvI3AOJLdD1AHUYbP0BrupTU4cxyta2Ox0iGe51O/jvbSO6torT+0INRWUIYz/DEyj72cHntiiorzVbS40DQtY0uOWJdTQC6i37Ydi8uig8hmPK+1FTBOV3qHMluQ+MIZ7CVHM06yvEr75OSxYYyfWo9fmCiOJhtedz5c5feu4IAA3oSw/lWbLq0F3YaGupXCtqBGPNuN37wB8KE7cdMHrUcOmXl3Y39uY2lk84TQlWAIZXBY/Xbnj2rRJpXY1ZnIzlbLW9M1jWLRr6zttObdaPMRHHMz7NxB6jJyRX1JA8UVnBbwyFUSNAmwYG3GBg+leCeIbextNUv9Ke6s3E8zx29xdyBLdFbayhn9d3QdCeK7288QavF8P8AStXhubWyubeHdftPatIu2M7ZEVF5yT0rjxMFJqxUHbc75hEEOwsCTklR0+pNYWnf2LpGu6laWN4LbVLv/iYXcMkh2sBhTKM/KB0yBVXSPET6vfaatnYXN7o99aG4GpwJtjjOeI3UnIb9K27rT1uI7qGWC21GGRNjJLj/AFZGGT6EdPeuVpLRs2clYWGK6yWkuFe3lPmJK0m4Z7bcdjVieNDsS3GL10Zh8+CB3b88fnXl8GrW2hadHq0el+JrTSGlj0q20KSBdlsUY4nVckhSPf8ApXW+GS1lqmvxz6VJp1u9wJ7O4edppbpWUGRgp5jUEAbenehqWjRN9DeS6b7PGFlEmFw7bMMD36d6YkE1zcFyceQmVUdyefwNc7pst/rEbz6TbXGgX/8AaJaZL6EN50K8FlXPRwODWld67ZWFjf3yTxSRLC86rbzBt+DgcrkcnirtbSO5XOkjx3wtDO2rOPkS2hmvbCeHZgFtxYS5/h4yD6kVasSdMvrOxllYSXF0I/lYqTGrDcoPXODz9Kr6VHf6Z4e1efAm1Br+Qsw6uVRXZSD1BDtnHpVvVxa6m9vqjS28IaRLqFWBwJWG1kUj7p4B54r0YXsc7PdbY3h1C8+0SQ/ZvlECIDuHHzFj9cdKnlbYrM/KgdcZxUelXH2vTLW4IIMsSuQevI7+9Q3F4sdvdykTO9srO0Mce5yBkgKO5OOK8S2vobLUsl0ZgQQuep9Kr3EQmgkgimaCRlaMSJyy57jPQ0mns99bl7m0ktkLBo1d+WUgEFh1U84KnoRVuGERFsMSD0B6j8aLpDurDbFDBaw27SSytEgTzJjl3wMbie5PU15F8StXgu9edba4lWaGRbRVWMkSFfndQR3yQOfQ13/iLxNHawX8Gmsst9alElOPlhL8jPqcc4/OvIY5Y9P0Cz10tc3lraSvd3SREGXD/LGffJByfeu3B0+V+1kYyd9jT0VbnSbCdb67ea+X9xI8kQD9PlD+hGf0qG304WF8sCuWYHytm7JI8rdn2zWTrMurS6rdTfYIpLHULY3TEM3no+4LskTorYbI7nFaN7qM1vLHcQuhD3NvCk0gHzBFy6g/3jwMDtXpxv0M32I4rOeC7sTPEqKI5ckdkUEkH256VZ0W7i866a7INpOBIC3IRWXB2g9s4P1Gais5DF4hvLy6BlivzEp3rgbQrg89AMHpRc24t7XSvNjDySxqESP5v3YOPMXHYHAI/Gqeukh27FHSI/tEmo3Yu4GEzwwRKg+bzIkIlwB04II9etSaRdXFvoGkwujiZRcWE0fJ3yjMkZTHquCR7Vc1W2ax1hYiqJeq6yGKRwPMLKQSD68c+lW723untbm/0mZbfVbNzcwRsMhU8nDyDPU4z+dTLRJ3C19TEjSSfRtS1WCS3NlHYSTb5ZAGMjskiKo/3gRu6c4rS1C51jw9eX0fhRSbK9jF4WkfcvlSJvbaByHU78Hpiuc8UR2lxpllPoqx2FtDZRJGpJaKJXbL555UnkZrvvCmo3s3w5sJtNsUvrgXUkMagfMVAYYz0H3mXngVnUurSl16f16ArPRHD3phsdOg1zR9N0mSbTdIis9SgulU7MzAKzqOXYrk7u/Wu98T6fb2dtpLT3ssS3l+qXYUjL28hbarDsOg/CuWub268T2mtaNP4ZsbK7urWKEXcAyUWByWgnfu6lRwDxu60eLtSl1j4g3sEVvcR2kE1pEJFTMczKeGz0Ubm2hepKmsYJ8yS0Wv9fj+BT2NvV9uq/Da70y202PTp7aWKXT4LSQSRMgk/dzIVx97DMVPI7+tc3fanqWr6gJbVIYNY/tDa6wuQkchjBIBPXIQnn6VZsYhpXgXUdStI3X/AIlk0kgDfMZfP2sxx0JxnA9K6G3vDeajHpt7HLbXVzLIYJbiEKbiSFMiVO5DDpnjg1cOWne2u4nruQ6zHeReOvM06NIUeeK6kIVCzkcMUJ+6JFbkda0rVrWbwxqoFw0MWh3rx3RfBHlK4lKj6KxxXN6RaG91rVHaOK1EmbvMLOwkkKKV8osc5BUAjgA5xUOpC8tvDepNaxSW1xq1rcXd80jK32nG0BlHVVUZHvk5pypu0Ut1b+vuGpWPVPDE2naxpFndWEpe0icxxMp7BsrnHTgipNY8NWmv6zpuoXMzPa2Mv2hIFOEkmXhXb129R6HmvPvBmq6fJpt9pPiIvBCoNyZoXMQZBhgflwTgFTx7Vq/2lrLWfhe8t9WTU9LfUZHWTTMk3NkFPl+ZnqV/ix1xXFWpSjU5Yv8Arc2VVtaHVTXenX2sTaMbi5s57Bo71yJAonBzwSc5GcZHHUVyl/e6boPhi60O01M3kekMLm6e4czEhpN6QFicksxUey8VLrmhDUrbVP8AVW9xLpsluwQmSQea4xIcc7uMYzXPW+h6ZfGS5lu7ewsYrnTYFt1IbzVifHznjls8+mDnNVGko67pfmS+baRH4fRrxtbivb6K2dVQMu0DkRb3Kg/eILrgds1ja5e3Gka9aYjnnsIYovOlMf7pZm2qoJxyV3E8dzWv4lubiXTdQ1UWlrb6qsV2l1HGRIUk81YYFXHAbYFJPpmq+uahcJ/wkxWAXNholpAyRSqf9LchHwQO+QBkdq64TbVzNWTGavb3FvFrENjG9vfQX8txBPCN5djMu5gBncO20irXiS5jm8QX2n2UCxXOqWVpK6sgWTcsoTYccBcqOmOSantby71DXNT08hNOj1S1SOGWHiQSTqSzr/usEA79axIRrNjts73zI49US5ku1MYabzQgQRh/4QNvmBfVqFdySsK1ixpWtRSeKHuHt2NtpV1LBLGw4ZwuTn3HI/Ws/wAK/ZtO8OeJ9X09WU2Uc6WkV2Bl1uH+8xP3mTGM9CCM02OO407U7G3WGPdHBBfXVyxyZZOQwLdMeW3Oe9L4j1e3kvrm+0jTk+zQ2kgawkbYdoAXcmQQTxnmtnFy1/H5jvG+hqeKrq98URaHFf2wLf2P9pvgAFLKFJcH/ZOOg4JIp/hW9kvvC63Ph65SR7pftkdheN9n/wBHi+QSLt5UZ4A/i61X8RTCfVpL+3jmlv8AU7dLO3tFlCpCUiU4dugBJwR15rP0yaBdPvE1S1+x+J9Pmgs9Q+cfZYoA2dykfdHVcZ96hK0YxWnyDqbeoXVj4V8O6VodtLcq3m2sjW884Xz3dnMhZuTjgEAelVdX0CHUdZt9L0fU9XnspomgyvzpFNIjShgwxt553Hufaqtg5vY7Mai1tJLrVldTxGdN0luiS5hKkf8AAu+cVPqupXHhe/todKngkj12y8uykurh4VuA4XnYoOxkGcE8c1GiXuvUa5tjEt9H1A+F7SMwvA092jXuxm2hkkCMofJyWAz+dd4+nqE0S8u1t4FDz2P2WFCwwzn5ic8EcE1y1zqGm6C9v4bziGCNHa7a4JiuLlgxMgJxwCCOnJNbnhDVhDeaNYahbG4sYtDjdNq5xOzld/8AvHGCauTdk0N6uzOfi0J76+h1fUopWvUuEiMby5WQKdwbjnjkAeldh4qMGrah4t066BuLqxlt9RSMRhTJDEVPl7h1545z1rmYdVFxqS6XqUl3A8UpvI5rJAQjBQvlyMeMlwPetrw+kP8Awkep6jLqcMrXRSO6bBMlorIXQ++XUUqqvr2/zT/QlJot6D58uuzXS/uRdzQyWx42wLOxEkf+9gGqOsS/2NazeHp7ZpEhuJGspUAQqS+7KnPUZBB9affR6tJpEes6jJm5W3S0mVOGFw0pxIR2IRhyKiuooxdv4mSVXeSCG2jt5ctIlxgoZCp7fKGz3NEdZXfp81sS7LqO+1z2viSTS7uV5NPlv0iuAwYN+8UP8uOck9TXQznQrDw3da5oBguNUtJ5LxHmfDAuwVy2eduwgfhWR4a8jxLd2c+oXKzxmdJJLhDsxPGSNp985GPeuQlkhtb3U/DnnPcRpI1pJKoPKmbcsXI7jBz0qZU+eSjezVvR9y43tbud5Noy6hpFx4jcyTfbQ0zx48sxOVCYX1UY69a87tZ9Q+z6LczR7XZZ3lt5h8wQSAKcHnG3d+ddze6bPqGpafoaagE0/wC0CczW0uY40XlVwTw24FTn1rm9T1a4vrltV1GIxrITpsLFQFQozeYpP+1gHitKT15b6fp0HU5UvNHd+D7aSxmsdQs5A1q15LaTBmCDynVWB9yrrj6Gt2w8Qam95q+5bO6the/ZrEREhhhfm8w9OvTHaud8N+IYdN8Da7PdCGRNPiN0tvOduE28knHTcG+bFMsrvW7zwi2qwS6O9vO0U9lKgb92x+80ijAbHbGMjmuKrBTnLn72/U0w8YtpWuX9GFiniDVLm/03WI76OJLue9KEQT8lfLTB6rj7vvmtaTWdEGn6npcWomeXYSUkk+ZRIPlweMD09wayNKsLDR9Ha0h+3hpHa4RPNbaWY9WySRk9vTFZWo6Ro91bzXWpzPcPJEUayHImZDuUKvQNwOSeafs1N+9f9DtlQShzy7/I6HQ0sZPCT+Ho3Iuba1aaASMZHMeTtkyevORXlM8i6VoEGuS/aLddPMKMO5tWDAMo789q9H8O6u8Gq6dCYr+dJgYJVWMGOz3c7ZSPun27VzkNxp8A8RJrcJk06wEjmFDkvEkmNgB54DDj3rSK9m5223OCqo8+mxyET3/9kSXV/dpMk0RRblQoeKRDlPl7ja2OKKy9Ym0+5iilubY2ktjM99ay7h5QjEgVoiByPl2sD60VvzJaN2EuV7q5r+XYyeKpNpM+l2k4tmBHzBehH1Bq3DdQzaVN4XspBBHezTBQoJkV0GVwx7gDkema5rw3qkv2qbRJYRdXEUix3UyZw8yfMZQR2wQCPatGB5LmZ5I3ilR3e5hni6rKvytj3IyKq3Mrsh+Rl2yv9ghsLiWG8g2G0ullOZFIPBH04INeveE76+vfh4zXMzTXOnbradbaATPcDeMNs9SuPxBryA6dp9j9qvLIRTvZMbhri3GHuUzhy3qV/wAa7Lw94hvPDF7cappUCXWmXipK0RYjjG519A2DuU/UVnUpuUfd3WwuazudlZeGLa5lm0Sa1a0u7C5XVLd4ZniSaY52mTb95fUDg4PFa+lWfjC9iit9fg0q0dRNE91ZOSCMAxuEPqeqk9veuM8TfFXTvEGhXemQaXfwvdfu0nMgQxjIIcFTuDZ+6PUA1Wv/ABtr+iRaMl/4ntLP7VmFYr22824crxu+ReSTjPAxXG6dWXvWSLlUUnc9S/sK/XT7RJb+Se7G3z2UiNGOPvKvO3nHFczr/h3x1e+IbC6h1q2js7bYEFtuRm+YGQSqflZWAA45Has6W/8AF6TCG68SW0tycAR2cMSp8xxncc5IHNUL2a60bwve6vqPiTW3mjlEVy9mVuCUztDLEflK5PJXB/Kl7KoleTQc1zV1S8ltVt2g1i91u6sZmtf7P09QVnMuQIppOQNgGSeCAB6jPnvjbULG6i1TS/DGlWlveWkFvYTXUP7sIsknEIQcYA3Oc88ZrSls/C3h7TYIYtQbSrNymrNDayOsl6AMDg9BkgYOMd81zFhDpmj3tzbabcC91BZj5l68A5knjaRyM9CsYC/jmt4U9dROWup1fiHTNN1HU7PUHKSrY2Udx9kWTaZFmbyjJ15dgq89vxqil1aJp0UcdxbTRSw7TcAMohlV8bGB7DAB+uaqRWSaf4kS1ikitobzSLf7G9wCv2koV3RRsOAwYd6tanAdO8RapDdWrxNaBmxCBJuBUHKr3I4yPTJropcq/r+tiHe1j2f4caxBqGgRWozHdWaqksTdVH8JB7gjoa6sFSzYxu714HpMsktlbX+n621nfW8cl2wI+SdAuflPoV/hbPIrU8Da/PqGlrqutWP/ABOLryrlLlZmRZ4D93IHAYLwRXDXwd5txf8AX+Q4y6HrmqapYaTbG41O8gtIBgF5nCjnp1ridU+IgbxTYaVoa6fdW0kS3VxePdDbHBk7jtXJBHAG7GSelcDb6PZnxvcStqcrSzsLkwzq80T2+7GxWOVLA/lWtpOg2M76pL4c0VLvTri6jsnurKVUF0uT5jt/dMbAgnuelSsLTp252Xq1cy4PE0ayXkcepwarFc3rSS3Sxn7xQrDblT905Izn61nQX1veW9/bG7ZhFcW8M6ICANqbmbOMMN3ZeOKseOtF1O+t59PtdP0+1NpcJ9mtg2x3iKkGWVu56fN2qD7HY6fPolibqQxQQG5d4wMXE8iZ2j0RAPvHqTXoQtp/X/AMtiXXtTkm1F4Bfz29415HeywA7JHJYeUMnngc49BU+mRzXU0sT2kkGn/ao2sluIgpBRiJpEz2Yk4aq/2a01aEayLbyr6eCSbE02+XdDnaAehwBnHtQZrgQrJdSk3Uk1vHHLtwIklClh/usVDY9a0URNk19E+qw6ZpyXsk1vMJI2mVShbdLtb3OAcY9BUP2d7K78JWFndXMYtbh4ZLleCIoXHOPdTwB170yGW4jm0uO5t0TZLOBIDjaVbAGB1GFzV7wdq17A13M9hFOJLHeRMQcSs38HqOcmnKNo6DW+pr6JpM99Y6zo7jz9RS7luIZLgjzFDE7kDHkggg/jXK3+prYXN7eW6XNzHAY/L3sSYUVTG4/wB0966y91GG08T32oWl4uESN4ixIMrsoDRqPUYOa5bUbW+kvNSsrKKC7urxpYfJkyhCbVkZfQHGTmlBW1ez/pibZl+ELabUtAitdYtWt2voTCI1UsPKkDCKQD+7kKR+Neh/D6Se2tD4c0uSS2kvbCSYXSbWW1uVARjtPJycNnp2ri/Dd5PZaEHEk1m9pp72y3KjmNEkVokbHXIZgT6Gt7XbLzp9Ym0a58jXdV0pHtIo38qa1gyvnsg/iz2I6cVjXTlFxkiovsc/q8mr+F/C3iXQtc043f2q+gh1HWpL/wAkSRyKN02OfLyRjsMnJrpPEMUfhqbxTp8Ido5prbUNOZpCUhKBcc8nG/PrWv4UtLCPV5NN1eK31CO4so4Zru5jErXUKjMYlfo8gOQeP1rF8aahPqnihrkW6aaLRDbQTXAYwyRs3yTHAHy7QeB0xisYQfPytaWv/X3bDeiuUry4FpZaRpGnA3rKs0d5byjChC+Rkgc8lm57Vb0tbm4k8P6tJcXd5e6KkuXdPuRAlSzDqPlPXvgVmQ3N9YEXwlsr/Ub6WG0glijYW8kYQvIUB53spAyegya0vhObc6vq9nqO22m0391LEJSxaGRSuc9SNxX9K6ZuKg3b+mTq2Le6/Fds+pzrsdtPtx/o+I2DiVgJFJ4U5IGaztWfTrvQ7C/u4tTubvQp49LvraSQxyhbh1Z97rwx2nBA4OccZpbfTmisNU8Pavau09tpcmly7+DMZpDLA6npwOPY1tXN9p+qQGxWGW2tPEGnec0BPzwSx42lz13ARtk+1ZtXsoqy/r9B3t1HWNjY67d63puurcWVzY+WLWTT2KSRqpKrsXnkKqAg5BxWtq1vql34Qe3eeOfUUkjXTXZQmHLAfMEwCQM8YFcN4WvptR8UsLiCddQeGeSS4kfck2yQBMEdH28HPbFex65Bb2t5PqF1cJZ2scIuTJMcRo6c7z+Bwaiq1CS/q1u3qbUrNO5wmta1d+Gb690yJ7ubUo7RL23uPs29p5xlXTywcYYdBkc/SotQidLfRNd1mG5061mvllmsrlFaWKTdt2FlODvJHX7o960b3Wx4me41nwzdxWspsVaC5c4Em1t/IPQEArz61rLfw6jDpZ1mw+ym9eG/W0lYSeVIcMykjggEBs0rzVm92tQl73xMxW0oDSNXS7jMJN3d3AaI5aQb1iypP44riPD11eXser6RqFmuoaxdQJYDUYpBltx+RSvQFUTlh1PFbPiTWn1bw293O4jt7u+NrBHkpI1uLgZcAc4GCW+oFJqV7BpWvz39zKttYRot7cXCph5UWQqjKB0JXAA7mtorT3jG/Y1NXtb24083fg63E13DZywW5JGWnjCnI3Yxz3PQiorO+uNP+2td2Fvda3bkRp5pPlzXBBMzyfQLnI4yPesfXtMt7rQdJv0S4nlvBNC8IuGjVYmYsJAFxlsYBznJ+lWYL+/m1G2+WCaxihjlkUKPNklkG3J9lA59c1Sg5Ly2/ETdtjnmt4vsWoosksReyjDM4JxvckSY9DnApYrkDU7qcWzy2Wq28tnZlXHlo0SfvD/tEsOh6VZ1K/t7zxJ5lpNJLplxaWEE6+TsEQG5Sjf8CVT7cVDZJePbW2myKBcQXM8zeU3mJ87kOFwOSVHOPetU3JJ7CXu6DdDuGutPuLa1v5E0aMRkyQ2+ZLSYD95LuYYdugz04rU8HalfmC90aF2u5N5kunksP395GCSD83ErkNknoMcVTE13pM8EDvcSabHpk012LXb5TylTtikXG49AeD2HrXQsTb6dY6/e4i1WKzFrZWhIAJMBLOey5z+lRUttb+v+HLj3OUK38kei2gv9PhuNTbb5bsiGGBGIIiHQfJ1A6V0tqZoHuprdtHlvLSyjkls9Ut2b7Pbox2SAqfvtngcDjrWVqNlqT+DrttJsxPqsTxLveFSYkeHLopbuST04JxmnLaeHU1SCzuJdQhi1G3MF/cyNuHn7AivIOgjVsKqg43cVFSV0+yBdGLZQ3QvLZL/TLi5tBKiw6tNFGXgjeQMYQvUgqSFY9M1W0qXU7vxTpt39mWTRY7mKwUtIY3i2Mzo2PvEYOD2yOKPDl7eWen3C2011d28UPlQx38gDTzxSY3lzwBtwQvYVf06a9uU0mGOGS4uNJnEQvXYnzlbGRjuqAkDPU4Iq+Vjuytq2oT3GtR6bFIQ812y3RVRGyyK5fexA+cHKgV0V/r2n6J4il0/U4ZkbUo2htSkJUCRIsLvx2bkjPfNYt7Zm31iVmJjv7bWPKl28+fEgDL9M1W1Se/h1KHUrp5b+6utQYIiuCZVELbVHsFJH1FDgpRVtv+GIv3J59Wj0/R3e/nYxwotvdmVGRBM7hy4Y/exgAHpUf2ZNRtHjvNUuWuUUSec8m7DKcoB7gDI9jitvxk0Gs6bDDqVys9tDoxnSNBtMT7lUmVeikA8Z/izWVc6e9lA2mPHH/Z2ntFFBMjAl4jGG2kjq+T1NFKfNo1YHoaFnZ299aTrZXOmx2VxbPe2ss0hSBJWJB3qMHIZeSKpqbQ6JrWqXzoF0++snkkD7FZFCl1QnsSCQT2os9LF7aWegoVN2pnhg3DaCJAHUt64wSa6XX9DuoPAltp0MWni5kkbzLW4cLDKqtuw5PBHB69M8VFR8rtff8v8AghdvU4+31iG0XVdU8MwLLZ30huYorlTtuw53jbnkMAv0xWz431SGTQBrdpLCmj3FssllpjQAlrkyZkaXuMDgAcd65/7Ul3e6NHotna21oN0y3ZLON8aNjbnjYwBAA9sVJr6aZJ4h02/0iLyUnma4vkc5QAxAqi578HP4VXs05J9hX0On8IrZ3XimCB2ljuvLBtpEQshBBaSGU9CpGeD39wK725kudHv7u1tdFtjYSxIbQxZJkl6MrrjCgDGPWvM/CN7aRiEaczW8t0W+wsARsBfdyD1zyK9T1iCJ73Qpo9QtrSG3mw8NwM+erqQoU7hht2MHnuK5MWuWonLbt6f8H9TWjJJ3Zx0k0hkHy4LMflHBUjqMUmqWdtqtgLW5s7d1cJubBBZ1bcrnngggc961NY8J3Ed4TZx+Yod5Y5Wfpkfcx69Rx1B5rmtfuWNmJ47LUNL0gKY57yUYmjmHACRMPnBI4IpxlGet/wCv66HvzxVJxV9b9P8AM6Xw5oCT+HINP0ho7K3W8N1eyx5DzSltzce+Rkn8K4/U4LZtV8VW5Ll/tDQKD1KbVLMT7EnmrPhXXPF3i/SJ107SrzRLW4YQ2GoBVQmLOHnmRud4AOAOpPoM1wvjl7rTNOlkYTQ3duZYpriUYeRA6qWb+9ng06L96TvpvY8Ks1KT5VoXbXSmn0LUZpra2f7NftZfZvLP7mHhmmZ84LOowV9xRTPHl7bj5dPuxBEJPMIljJS6m2IHOzjJ2kgD1ora6T97X1JSdtDNsUOj+Lp7/Ugv7i1iu5jCAEmO0BsYGAGPBOOprQu3s7eCGfTZJBYyQSsyDDPCr5dA3uMED6VJcW9tb+IjogmmB/s6SVCjfKsT5bg9ThlBGK5zRr6Kykm1S40+W+0q709XdM4Thipwf7wznHWtNDO5BYX1zZ20tj9jjCSgHzWyWjD4w4PQqTyc+9W7rWdb0ia3eC2ilMKJDNAhyJueoHbgkenNdTaaS66JGLqHElmpiw3W4t2wynHX5fzrNtrZdVjvAsqp5rBrKYrnqCrRt6kFQQKqKVhSvc6vTvAthPa6Vr1uYr3Sbi28mW2ztIODs5XowYbTTINT03xFo1rBrSHTtVubqXTdDu4I/wB4SvDqrgHapIxk9qXwbetp+iazplx5qXZ8q5symdshJwxVeg55xWmloNMkvLW28RyNrup2sqxXV1EES2BOVYIAEGGOCRzjnrXJPmV12/r+u5otjgNNvrO0h1/wzFbRaXZgJcXa6hOBK7ZADxyg9GIHQ5zn1rqLQaUn2WBblt0++0u9MMpO2Jh1b0Y+o7VDb6Xdafd3+saron+ihFtb+3ys8VzPEAxlQYJWN+w7HmtOx0m3l1KDXLOxWwe/RZbq1lAaSN2HQMOMYxx2q4ST26/1qXBOVkjW8WeGtO1HSHt4LdI7S1hW3YcjMWAyxE9du5QM1xMOpaRBqtqL3TbVNUwrXcUWRA7vCVwB/sovXvmu813Uf+JxDo0F/ZfLZG/mhO8XDkNgc/dEY4Bz+Fec6ebvxLd3uqaraW1read9qjUJx56xoFDHsdgO3ipparUznvoWtZRm8Q6fqtqiJaWdpBJp1tcOfNR5ztyi9GBPGO3Wt/4iCLTNYlMUy3E9msNzPMz4ZHzwjkcfMuSF7j1rF168023udIu9Gsr3UNRtlgthDIi7wylX2gv0QZB4p3jyxTSfFGrXWiy/bV8XLHssjEZAs8YyxYnO0kDAHGM4puTU49hW0LemPpmpacmnS6e62n2spJtHyKTz5SnqA2Tj0Bre1myg0WGx0TTptT03TYXikg+y+W/yKcmBGbnJAyQMniseCysbm6tp4dc+xx3620zWDABppyCNnPZTgnHPFdA2rxXl22pQ/Y7O10rUo0ul1C3DK8m0oywOSNkgJ6jk596VZ31S/rQIlPwFcSanruvWUoS5023uVuXKsVe1bBZECj7w2857mtfRfifoYglU29zBpVv5SfbXgMaO8pI2BcA5BHP1qlo13P4S0HxDpWj6Kg1vTrmX7BC+9hewsfMjJlI5yCwwD8pAFU9U0fVPHWqwfabINoptfNa4S8AEU+Q4QR9GO4bS57VzScarcpq0fmVrayL3jSw+2eI7xFMrXupImmQMv3IUdC5LjrkbQfxrzm3srmVdOi824vRaWb2l6u0K8Um3ILgdARnHrtrufHEuqtoFldaJcpaXGltCr3EcYlAlY7Sox94YO3PbNcneywpqUy3udzXFzdXsMYO7NvGMKx7kk4H1rso3jG19v6/yIe97CWawWl1odiTvimvbmGz8z+BYoScKT13HPPvWhaaza6pDoMYt33XdnHJJCv8AyzSON1VmOODvHAPPFX9ReVZrS3sxFBJeMqWbtGC1srQglkz0bHBP5VyllpV7PoFzrOmXZtLsXBvJ2xu8yOJ2jCY9HJOK0vfVsSJE19J4fDLzQG4XZL5NxEhG92jIYuPzIHrT9SumsPCeg3FjK4uL/wA6OERgrMrRlflz3JHb3rWm1KNPFV1YadbkCG0aW6VYyUO+JY1SP02HLE+lcZm+k0qWTUXNrLYXP2uwuYzmNoyAplUjPDHHPY1Sd9tCvU9En0qzkmiTUgu+1sjfzQSqQ1tNjy1YepG7P0zVFNQGl+Jo9P1rclzbTwLJPt++ZI2iJHt0P41d8QanIdGm8RTWyy3DaclvdDdhgztsz9OBxUd7p6a7rkJij82UbbmDLYDhFDFGP1IqVfXm+f8AX9aESZzF/BL/AMIjpFhFcy2txa3oW/U/OsqNuiOfQEBfyrZS7mttQeG7aOWbQ7FLMyqApRWJ6H7xBGPbpUlu8Go+JbTV7df3Dt9nvrE4G4MBIhAPfO4fhVPU9NjtfEEmpy3F15Gqwi28ltoVQGyJs9cD7v1NWkr2aCN90bOiMv8Abnh290WJBY2VuY5lMmGnJblgemQccdaXxvKItF16ePWjqFkJpUIuEwYrhW2mADAG0FiT0H1qj4BSC20/W7Dy7m407T5oCbRIy0zI7gyOeQdowDkc4BNbF5p1vqNtrPh/V2t7kT3Lamok+VJVWU5DfgQSa55O1T3ehpvuc7fajHeaXDBY/wCjwW1nb3Fiz8/6Qch3B6nKEjHYAGql5Ne3Granptvi2lkt1llMUhw0duAV5GDk81Et7eaxqOoM0ca2ccEMCxbApzyY3X/bIBA9uKvy3cdtZaXZXEqWq2R8i+uX+ZjHMxRWZzyfvYPpiuhJRVyNWRMNYi07XLi5umvJp9Otb+ASEmaRkm5Uj1wrYA7Yq3YW6W13qV5dXkEsME7TWRlycKxUCBu4B3P+dZVnqsWqW2hWjC21JIpxYXDOCmdq8hSOh4OGHrV68s4/DlzqOj4kGnajJdvFNMxedZE2mIDP8Izg59Aanr6/1+QtDV8D3Ug1hLu6gSyhvpJftNkOY4r1ZFwU74MfUV3niuyh1+NdEuoxc2U8my4TdktAq7yB9fl9zXCaGt5pthcaxY7lJhGoTQv/AMs5Qdkn15B59DW1421W5tvCw1zSoW80vE8YV9jBG/dyLvH3T83HviuapTXMnH+mdFOVoNMz9Lt21rTmaaxbTvM01oZ9kLweTbqrrH5aPyhHGd3p6VpaA1vB4Uae7dr+6bTohHLPMJTK7LgHeOOeOR2BrD8Gvca7pc8Vr4lvnljYwyXk6iWVPJG2RJM4y5UgZ7496vaLDYt4B+z+G7mO5aztFWGV7Q2yOXYoSYjyuDz+frTej5W+23+fqStdzltKktLfV9Gtr+0uW0rS7BZyhyWmZpSMDP3stgsM9MUmmbY3Ona0iXGngG71G4b5oVjDg7Qf7iryF61f1XUba4jv9l0rnRkisOOARGPnYD/aY8Go7DSoba5uwk0dsv2GPT5VkJaNzu3Dd6EgEZ9q6UrxuZp9DPtpVstLXTp5WW5sttxDMWBjlgVmkjKkdB5ci59xiteGeOGEXGn+UyNCLi6lmO1I0xlWU/xE56DpmsrULGK6lsIXSSAXdk0W5BgbCCGUH6YxUU/lQ+F9Ojkt7i90x3itGuIyVaCSNAS230J4Oe1VblSQX6kL28NrI8s9mtzYJFGWVmw3mFz0I7rjcKmgW8ZrU6ZCqXMt+JEM0m0xhxnLEdSACMerVJqt7bRGWa7QCYw2FwDHnaZmkITGOAD0/Gma9fmWW9i0aDbd6aieainlYWfDTAdCAC3vgVTl1ZO+xpXKOJbzyWEovh9idY5QzGRSC5woOwHHBPpWOiCXT0j1FzLZXDvKplOGlihTbjn+HLA8cHjFT6V4hs/DFw95f2N3axM32ayYRDMhbKpMQOgYbuv5VSs/M83RFljt7yGznFoFc5EaktIUwegIAP0FLW/kMm1S8abwnc3OqWqXltc27GztYJGTz3UhGZmH3Sufr0xVq5NnDDpSgSQy280xnkKl0KxopUdxxu6nqa0dE1GG3gtdGWG6vLC4jjsy9vDvSKaSUsZpFPROgGfSuYivJn1O6sjDLHbQalcQMhGUlxhUIPdRuBJ/wqU7yaejAmaWyF9YaGNQtpLEKz2VxEjf8fLAs5z3GcqwPAxW5peoz6hq9r4fhiiuJ7FolvJrWTcDI2SpQ8BgVUHPQYxUPhe00mw8T3MGqhRrRkfSjG8wbG7O2WFevB4P1rPl1W0sbjSmcTWunW0c/wBqFvARKxQbFdcDJO7Bx6Gpv26FJdUdFaWkur+J9UuLi6eJVjF95fQo4Qnr3JwD7YqhZW6adqsUthDE1zcQi+jScgJC27LEHsvXI9T71Wt7ZZo9PtpVmbUG8jDNL86+VwN46/MGP5Vq+KmMfiO/sr2MCSGaNYnj7xiDdtHsflH51W0uVk3vsQ3/ANv1298R6lZm1sfDmqhIHv7vYqWx+Q/vFY8hidnHQsCaj1S0e91jVrO30qeSU3b/AGi3DAiGIBQzE5HHGA30rr9MWXU/DXgPSrDULaxjuWNzdWtxarMt5FEQZIcHockHP+z+Fcv4vvoH1251XSkVpbxghitzu8wxysj5x/eAB/CuehNuo4paf5afoxy0WpXdE0K6ur+CX9zpMMEgOTJMyxPyR/wE4I6sMdqqeMdR8OTaZqV+mX1jVUF3p/8AakrG2SJjlhgcJnJ5POcc8VZzGL3VbbyC9isebgqC0jheWUkdcDJ+lZmi6Na6ra+K9Jm003MFlazz6NHdTYFzEJN6gY6p0HtWtVRjq/6/r/MUXc3rC2sz4dt9K3QtZ6dpov7iGRd8cSxru25HO0liR61zWgNa6hpthFdWjW2nvqvnG7dCq3avE2wbSeNvHtW54XaDSVuI9VihTUL2xt/NEswSHZOSVDseCBjaBWW9vbLpWmadDo98mjRrMZ3nkL/Z5WfahIJzjGdh+lNavTYG0iS3iuLaS0ZZZGaFREA6CMiQuCpI7e2O9dFr9jbeKvENtYOLk6pJi+hUthDEyZYKc9VdScdgTXPoqWmrpBeXV1cm0XyJ43AIZQofzF9SK1PBd3PqutjRNQjf7SgkutHlDbVBH3XZhyGAzkfhV1duddBJ9D1zwXraav4fhje+V79FMUki9Sw43DPU9DXHapC8ITSU1G81LUbqY2smsS2ZnFsdu4AKvyb/AHwAPrVRbhpPCulSaxbJbX75IhJKRGUSMmTjox5Oe/StWz8WPpuk6pfarbS2qLNHDFDbwnJCkBmBHbBznHAzXnexcG50+vT5mqbsZ3i3xbPoMPhzTdWk1G93Th52tbUrcTxoBtJQYAUnlueAKxvGl3/b2s6dJeaRFIbvey2dyxdSirw2V7EAEemK3viN8TLHQprmS20OTVbu3BtrKVWUx3EkijeinqQPlzj6VwFz4u1B7vTY1vxH9ntJZLieOMbivO6JRj5QqgqOavDxvq42/wCCJ7mVqGmF4YEXVZtcg0y5GoXFqIgsiyA/KFbndGoI3HOe9FWUax0210m+gUtJq5NtFCikLCGPys5zjoep78UV1ctn7orsm1LQBqlzDqccszrbKbaNIzyCw3quOuAwI+lQX9vPpenWFi0hGmahdKsifw2/nKGXI6ghgfriuh1drm1vkjspbU6V4gs5XsruzBjdZlxgSAnAIDbRj3rltOubyW5mS9jhOrGBFksSGYTC2bcGJbgOQSOKfNzK6IVky/rdleW8EN/JcXBu7CY3F7cPCZUGDtOQOgPA9Oao322PSbq2cxQxSXZZLoMVFtKQHVgO/OM+3Sr9xr73ml6lpVzJPuvNQjEnmtlktWTK8Dque57ineLbXS7SynuZtRnltLu0RPssIUt58eVEhzypxz+dK77DbTNrw0x8PQXVxqs06NcSeVIZH8zySy4PlA8YyQ2PQ5HStjWrNLtb3w74r08T6XBaCSBoJgbi8fgmPZkcAYPXHNczaahBHo72moAR6d+5ia/YE+WWUGKQ9cgnKmttheXmt6lqukWcWoWzafGLHUYcSl5QpDrHk9/lUk49KyqrWxcHpYwNNOqW94dOudSvrVLht9sz/OYpCOI1boTtHIIxiumvNT1mzi8R3F6dJKWsQnsHnm8qOaAKAxd+gIY8GseO41fTPEdhd63Mq6XNIJPLlQeZZAgAxk5+8CcE88VLZR6dfeMdRv2mm1mHT0kt7PSrqMuIX6syHO14nz0YZGBiiSbV4otyS0ibWh+IdL1eDBiSI3UtuXk24kYMocoWI+6MY9Oc1yWmi7PijxBdeILRLTRbu0m+ybstDEhZgfLI43gJk+pNa2i3Frq2j6hrN4lvLdNIRHJIR88rLtEny/KFQce2K5Hwtpr2sGq32s3F5usQtsA0ha2aFG8yR9ueSegpqH/BM3LqdsEsNS8L215pk6+Rql3GqzSYR4PkHyHuCcZ49ql1/UtSm8T6q2lEpJIkUkS27DL/AGb5ioY8FuTkdwMViaXok8N1pesS3MUml3dtPcTW32XeUUt+7I5AVwGHJ6Cq0Njb2OrwxQ38X22C7DaZcicmLUIpFy6FAfvHuw5BFO0fUi7NW50Gx1DWtIvFuopNOAGqTRL8ktsDknYDyRknIFdhqujT3+p6fcKkV94fWSSe4tnZVV2Cjy52BGWcEYAGPU1wviETXWn2A0HTFtL3TwzWjxsxdfmInhkB+8pByPSuh8M+IUK6UdWu4tPt4tS+zOjWpQ3e5CqFy3Ubhww4NRWjLlu+hUHZm74m1bUD8NZL21ivRdTN/oqKoW7RSxBwG43Ac/Sn+DodN07SzJJFcbL6RYHF2ThnAy25egJ5OMY+lcb4ptze64dJv7x7y1Ie4hvwNkdrZSfI6RTjgTbgDg9egroHguLXxDEhlv005bN4Gs2Ku7ThAFnd/UqMEDvyay5FyuK666FrV3LRsQkd01hGIdCJnRdPjX/XSbQQ+fUEE4ryuVZrrU/El1erFpVpf28kVsEbzJo2YKEXaPu5IHHfPNei6lZy+FNW0vXb3U7pobPTZLa00xpsRXdy5zjA/wCWjZxk9wK8716wS2+It3d2FuI1v7iC6Mjg7g+BmEjpldvIrSl70rdO5E+53GsSRWduRq63d19iuYbCw8lhG6Fo9rsSRztGT79KxdRkvF8K6dBpy3LSafqH2KZA+VNuzny5G+tVR4lv7/S501SVb6Ox+y3Om+aDve5d2BaUj7w2nAHar+rWJ0LXte1i81y2traExXE9iEJlESMmCAPl2nJJPUVorx+LR/h/Wv3k77F3WLiPQ9Yu9TF8lrpVyzrIzkBNrQbSS3bD1yHh9NRi/s/TJIEbSIYY4CQflkaRS2F/2cAHHrXYulrPo2pTS+VMILKaa0j2rKHkkQsEZTxkBh1+tNuo5tM8P6HdXEEcOozR2KYhbdGpTI/PJ5+lXGSTsK2lzDS+Op+HrXTpp/LtdUuZoJHYESW8sQDRZHozZOD2ra8MCMax5Oom5sZ7WGS9J3DcitbhWjGOpztkA9M1BGkW+8TUkAhS+nCyDCqk0bKfMz1ZTkgfWoNHuVsNQ83VzHHLqTRRQ3B5WeQboeD2zkKfpTmuZO3ULmj4Islk/t2wuMf2vFaQSyupB+ZNxWUegb27Gse+trPUrSTVY4GNrawT2VvDNcbXYucPuYdsgMPyq1YWp0DXNfW4fF2luyx+Y3yvkYRQw6Mp4696i1qwaw/sK1js5LqC/ufJlgiy2Gclxkegwc+nvRpzXb0ZUb2OgtZoNQTTLHRtThuHnsUN44G0MsWdyEjBHQgj6VHAH1m6sL2zgiiW6s5ba9iBy8CbxtDMfXBG0d6qpFDpVjYxXep2uqasIrhrdoYREscLMCsBUfebIb5jzxVaTWrC7m03UtMMltBdeZ9qtYwdgkKjc7g87kK7se9ZxTkrpf1/X5FraxmeI9QttOTS9Nu5Ua4h1kspto9rypboVVmHou7aT681T0aBP+Eh8WrqUiTWksge3tGUsJHTDtg+gxkdsmoLid9b8QreR2Ey6bp8bfZ7mRhsuV5bah6liwJatK2kvpJYZjbrcXT5+1EjasnnKBGIx1BT071soJIzu0Rado+nWGoaPGwjWxfUreWGYyECR5JVZct6nJX07Vc1a/SDxXrcNxJGqW+pyi38043h15Ueo5YfhTLrTrPXvB1jYwTeddW+txxxxNmJjsYLcJg9lB3fkRT72bQ7rV7zSjdadqn2Mslqzsdq3IQtEpbuQw68/exUKS5210B3tYf4d0ySXTpdFS/nEFvcx6lbShyrvbvlHh/2k8zGR711NtYef4OOj67BBfzhlEsNi26NU3lsOGIOUwN3frivO/Ay232jVLi5/tEXHkPcW1iuX+zw7svtb13AMAf7teo3SQalbWktrrE+n8rcy3FtEDJchgf3UqkcE85PcdKyqJpmsNvM4DVL69jMtjqML3SSXjw3UNkywyRB0BVVZep2D7x56V3Et2I5bxdQeGOHU76BLeZZ1LTW2AEQE/xEL068E1xViliNUa7tdMubbWJysRuppvMtmcnPmNH1G0Acg4IzW1r+mXdva6WlnaJLZKxMEquGaK45/dEHkA5ZlYdB3q5xV0np/X/AFA5XUdMOn2BurqV9U/tS88tntogjTzLLwp9UVQqj3qzqMxn0fXr+2uY5NWt7kW7wg8K6sSYyD1OGzkVStnmu5bW8ltvsWmIrrbRuxwVj+YsvqS3pnpUlvPcWdnfpEiIzTw3iyPhj8wyXwfvMVYjArdRsiHqtSH7RfReGXEqu7/Z1ikwCWR/Kxj6gkcitn+1JZhp9ldMst1aWrme4jIJupGUKjY6Dbt21WXTWWy1aymleB7e4iELjjdJL91t3oQp/lVuw0qO5vJtUhj8ktpM15Z+b8isuVbJ9FJD8n2NTKUFq+glroiHWPEs66RfWJ0OR9ItdKhsra+MR8hHOI5Vlb+LDYK9wRkdaybSyQyfZIJIreX7WtjeXxyfmGwLG3bG0gZq75U8fhq4igtrt7XxDPDMbnzMpFAvzx4HQbjkHHcc0txdy/wBpal4fimjljglW6dMfO04Uea2e/YfhSpR5W1H+v6uD8xdeFrJqUvhzS9PMhQTW+yZAoubrPMka5JxzwxPbI61e8M3yafrupXN1ZrdmwvI7eOEqQGGzY7bWA+deR3FVrrTjr0n2jRdRu49Xlu5LW2Frw64XzDICehXAHXpkVRSymuda8Pul7Ncpqcs0piuJFYSEqUeQfxLtYE9cZo391v1B2Wxat7EJo3h7+1rgpcXGqSXTLGuPKslDbVlX8MZ/KqluryakLexjXztShfUZt7AiCFZwE+jMOfyFa9xq0F/oiy3su5o9Uj05bRRtlNqPvO4JyxJUnPTHFc5qVxe6aihbeGLV7iSQeY4BWS3LZRPbkZ/GiHM/W4XRq6UmnaR440LxNewPJqEj3SXEzyEoCw2xh+Dhic4z19azNFa8m1CZIZZpVkgW0uVz8omNwHMgJ9uPwro9Ql0KHTdQbwhcSx67qMkNnqciFyzzAhmi2n7px8uRxziqthaW8elR/Y4bmwv5Enha0mcNLA8bYLMw6n95kduKmCi25NWv+gNvoyxplhbL4ultraG2FzG9ysN0FxLJGqE7JDnoCcqcU2LxR4Z0ue1m15LxrTT133c5gYr57xps2t/GTg8DjkVT0lba31O00y61C8a+isZ7mKaYARpH5XygydickkGof+JjL45ewtjbXnh3xHYg2b3mJtPE0aDEqY5UqynjvmpqtWsmNHc6ZcXixSeJNE0+bU7yC3llstKjYRofOmHCsegAyT6VwMa+Vqz3X2RNPkW+kiS1ALJjJ3Dd0++T+PSugng1vRvDNlpt4TPaRAQT3trdGGYS5z5ny/MFycn24rmfFwEzXyeG9QGo2DtbyQGGbGJY13OwJ77hyD1zVUlabktbr+vzFJWVmbPh3VodO1vUPskjG5t7aSaaJx/qVOBIeew6A96yRb2769pNzPef2ask1wEXcFMUSEMzZ7Ky59qmXQbjUdetbyC6uI4UhCOwTdvSVGaZioxvOOAO1TA2/h/XtNid4dRfXLZHedIwomhgJJBQ5EZIKjsCQfWtJStKwtzrNTtdP8Q3cmoapbRah4d1eCG2ggEYR4QMeSJTnoSSw9ARmuEsrWysvD9/rN48g1ESx20lkkzOHZmKnavfChfUDFa2hjQJ/EGiaPeXOsy3OqxfbIY1/dxQyygq6kY2sIwo29cZp+tX0jOvizw7p09zfTasdPaERbGtGVSivt6Df7/3hWEZKL5dv6/pFPUwrmSwS6jnlsbyePA8sBvKZWOVZQScMQcHB/CtPTFt1sDdm5ezt7GVAkkcuyXziuUGSPk3NkH9aoapa6jb6tfX8t9DG0FxGkKyMNlsWGZN3H3sgEd66jw1rGkW9tfapqNu2oaPFarPKgTd50zDLMqH7zKAQM88muipJqLaJ0uT+GE1Zry/0iZU1B5Ior65vxP5nkyq3zIobjG7H3eOprpdSh1NtdMep6pbzW91tWC0gUBoWYbXw3+16GuHi8V6Do2r2uqWUmpQQ6wgt5dPZP3NnE67txB+YvuAHHGG9qu634sSW2OsQ6HdJJbh5mAQbFkJ2R4IJJZfvdOlczi3K9jSLSWo3UdTubyLU/C1pbQz3/hx2urLUXiCRBo1DmBUH/LQDg88gk1zmoXKtN/bukWMdvc3Fh5l5p0gUfZgPlcL/dEm7g9uajjHiPR3h1X7ddNrMV8kWsW+VMTrJD8kpBGRJgjJ7CsxrF7LWRo99DBdwvaJG6XgOxoiSQ5IOcDtzTpQtf8ArUlsfbx6mi+HrWZ7O1W2YGKKK7VmePqFLD5TtPfnmishfN0q/htpZGmnYTRWzQWw2JHgHKryAFHTNFbJ205b/d/mEmdprGoW1vYXNhaQ2wswgn8x93nRvKdpO08KqnGGHeo9aSOS7KNKJdVe7gtLhoGykkqKGBQjglu4/OpbQ2k+ou5sZJ5p9PeJI9x2yFv4V+jLnPqapQJNq0Noqlo/PZ2hJwquijG5cfddCRn1qrWZBcv9OTUvsd9BEY50sZ7ZZEADLIku47gP4hyPaueuwHv9LvldBbzrL5rFD5kjIw3BT0JA7H8K6Sa5upPCUml2ltDba7DPFdRyuxUPIz7Xjf037cj61qNHDeal4fNiiwSyy+Tc2NxjDFwQwX0ZGA+tQpNXK3MW6ubzTYYtJe28+Az/AGeRS2GEakSrnHXGdyn2xW5o2o6ZZ38N9ZXGqx2v2mTT7mxs4yIHdm5l2KNyMWIJfpWGY0s31W58SrdyQxTiSOGN83MgiKqSnqFycr1wTUmj3Ou+HPFiXejt9p0C+je5FznmBOqBweFySAe/FRO0lYcd7D59FuvEEFnrWo3VwNOu5pbOe0ZX+cxOfLddwG1ydxOOGArRsdIfwfJrWqJaWtrZXNrJc2t3HN5htzgsA4fHLEEFegxVfxc9/wCHPHdh4kGtzDSdZjhtmtN26JF24Zl3cfKxGAADgmpL/wAUSP4kvtF8Q6YfsjziyibCzpd7l53YPDY+bbjpWUW5LUvbQ6HwXpllL8NZbZrO20zUmsxfS28W3pKpO7b0wevHHauJ8CWE9loes6Fpl9d3M/24QsJoxt2BCzK27opGOlegXv8AZ9g2pT2dix1HyLa0gmkYRR3sXIRUY8Lg/wAPr9a4CDVJ9Wvk0zVgdN1O0M9pKiSZ8+bAfe7DqSoApUtdyankTadcz2Xh/V/DkGqB7ppVtXuZovMMqAfvQinrx0PqK0tKih0rTWglmt77VLCWWbTrhYw7bTjE6qe2GII7c1zF4YHl1nxFHcx2E63UAL3KFJwpbBUZ6Atgitk391qPiNfEcMNsbO0VJ3iAwjRFSCAR6jcPSt+VEI37HxXa2+jS3t9E41u0lkZJIkPzy7SQWXvuyFz7iuYGyw+Juo2GoyXKLrOlB5Jxc5/s5yvLJnIUKe4xjJFTXGpR61pFnu0SVry6ujFF5ZGxI0+aLdzlhj5c1Y8WaJa6pph1+2u7i11Oa6DQ6bK4UyEKBJEn9/oTt6ZFTKCTvtccdUM02z06zttPvbbxTZ2OiXdgbazi1CNmgmuEkwXZW4XaSDz39q7bS7vUtO1ySHW2W9FrbxGe/G0fabgnayiIH5cqQQemB71y+gLpeteDbiDUp9Sj+23CXVpdXluqk3DZQw7T1I28r0wfWt9bSO3tNS1i/s7XTdTks2FxfWM3mxOI02xhVJ4AAGfQ5FZPV6/16GsdJFbxbFoWpaCZtOumgttKvJXhaJQwtriM7gHDHktkhR0yR6Vzuo3OoT+J7b7FpV5NbzTLLerdMB5Cyx4UE4wCoDNx1J5pup2txexaBojWYsE1xTcXiI+1jOAsi/UnGR7Vu/FSy1C30hZIJ7mZ9RlNmBbRO7RIjDaPLHLNwcn69qcbR0uRJM4zS5NS0hNRjuLWO8e5sVvLGCKL5rYRkgea3qF9O5rSsL5by4fUtIuUnv1EGmvJOPOR/MIfzDngkYK49KtNpurR2HiHTrU291qtta21rbNJK0n2mCV8TNK3HyhjyBjGDWbfwxafZDQdINm1xfySTPcQR7Y454EGPJ9U4I561upJ+6Z7anSzvp9v4ui1B41g0i51dYrgu2FaVo2iLegUlB9Ks6PYTan4dnv7i9WeKy1SQTxxDcoiBOB7YypzT72+tbTw3eR2unwX0N7eW6pHcp5kZQhS3HZssxB7Ej0rnkutQ8NXt14VsC4czS391cxgOl1AyGIK3cEcEn2FZe9e0dNvu6lXSRZaZv7O0HzL1ZXuNTSG4tlC+ZaRSbuvoCq7gx60vgNdH1a0EOqT217a3M9xDZzSuQIZ45R5W8HBRmIDAdyOOtZ9hbXdxrXyxwTy3ulxzJg8fLC+05742kfWrcsGmp4fub42iG11bTLee5DHY8DL8pY+hC4I78VpJN+7zbiWnQw7EtqGhXOg6jNNeRteA3yW2Zp7e53Yk4OCVIAOO2TXZeMdf1OPW44tL0uOSO1MNxLJKu1JE3EELj7j4weORWPol/bl9SutYs4p9SnlVZb2CPyHukRdyByOoYbSGx161F4ujkk0TT7LRPtcOn6hveW8gkzJAxfOE9RguDRyttNo0i9Btxf6XcT6Q0GkzWqv5uolnuFeOBBnbGzDI2sV3bgeBjvW5p0EeiR2ukw6RKkmp6ZdXt5OpM0Vm8gJYlz3bPHTPSlhvbDRfFPhfw+lrb3OjWulvF5pX5GVlJ2sp65wMA9DWJPqFzr/AIUs/Fthqraa9rJKGF037rZHlGBQfeThWAPQgisneVkyloVribTfEOn+GLPw3c3UdjpaCBWmGwuwbazSA9AcEn2HFa2hJeWfiCy02C6tpdRupWtLiYkSRxmMs2Y8dCQUGT05FcrpV0I3STX5Hjt3tVM0yKWLeZIDyo5JcZPooq14f07XNI8R614gt9HdI0k2rcSXGEjgeXh0j6uduOR0Bx1raSUIqP8AVzK7budP4uvY77QJ7HSbK8bxRaaw72iIVUtOcs2SOAAvUHtjrVI6FDr1pa/aoE0/VdS0+9N5KmP9GvbeRGXef9k5HHardwJtOvdfmu7FLEwXDajpzmTfcXzImwu7r1Rh8w4yo4p5ur231awGj2JFxqV1Ldosq7zDIyFZkPfYykNu6ZA71haTj7rsUtXZHPrNql74cSz1e7stGubwt5epwo29pX2gxrGvLdM+nzZ4FdJq+gh9Q8RaTYSyfbdd02OK2E5KBfJG35Qv8Oc9OefSq/h6y0bw5bW+mWsU13rWnI93brLudnjyQxjZvv4GRxS+HJPEFtpv9v2cd3qmtzQS3Nta6iRBtlllGUKZOyNE6c80VH18vxNEuiOOE2pW0Ui3lhGNPS3xeXSyfvRzs8lB1UsM8+lepXMdsNPQwpLaWs8cbQqyF5bfIUAYHLNwRjrg1yN8EW702ymlKfbLtN0ewss6puZk/PBJ46V1Gqa3pz2UM7TXNtaT3rWtjLtPn/aZIz1AycBuhPTitqjd7jVoXSOC0+RHOmolzFqWl6a13IIyxUQk7uDn7pyACoPGai1Bb/VbRNQvEguZUthqUFuhzHbYiJx67iF4B6VJb6TENGudGS4m1a/sJfPvmlDJ5KJ1L8DLE+/aq1peSQ6lJHIAlpOYVtkgGWkgkj2QuT7knI7jmtF0aZh5HS67LbvJoAZpzBq1lFc3KjJT5ApjUtj5TncMV091JpOjeBbW5vo/IvJIptFiErEr5rBwkTegYjr7ivPfsurzeHGs/FOphU1mWXTmWyA3WT20m6M88FsZB9iK3NYh12W8kgluy0F/cRSyxzRBxP5SEb0IzsYlVP1Fc0lKokk9mUojfDGnxweAr4Q63PqdpPbRvHBK37rTJN2GVSOxcHp6Vzdtbf2nqviPUNNWSC3SIy28kuFfarAsQe5J49xXYa1rttbarqug2mjz6XpqxpfWWqRJ/o8yoBLIGb+8XyvfgGuGs7q40600K8ht5rgXVxelIrPDrNHuCjr2Ocg9MA1dF3T6XJehs626eDNda2so5JpI4t1vPGdxR2DEsSP4SWIOOc4FVj4Rgt/DOkLp93c6fqOoQW19KLmTejO7kfZkBGUBwxbn+EE1nMsShvD181zNOZVumjiUB4HA3mBxnK7hg+g/GrXiLTdTuzOmmaldtgi+t7WJ1L4cZEDj+IqASMYAU85NaSV2mugEIZ9X8RWzX9iukXyWcdqYnkC9Cf3vuH7euSan0m+t0ubbVtfguntrOOWwSTyGnxcBCBwM7QSQee+Kq6ddTarFd3nibSLWdWeO1lLllZ5Yo2CbSfmGDgtjg4xW1pN5rNiNMt7a5ks7C5tPtd6YCpXy26FxglWPAGOeadm42EnqW/Dl/qFxr1mdQsbRDHPCFSJAjzxLHlpXHY5G3PWs6Aa3Lolvq9hpNulpeXMk/wBrmuP3Sq8pBQfxFlC5z0J4rp0a7F2ubVYxexG4W7kYKI1X5FTJ6k/zrL0XVr+88OReH54re2todQjtpCzHM8rA7VXsBnDH2FTK6d0W0kV9WKTa5r1mZ/Nnv7cTZXgCOMLkFf7xz09K1vAPhaGHw1oXjSKWNH063urdLFwHjEbTFUyc/KUGTx1zXKKNU0zT7fxJr+Wu7W+maWOMggjBUnI7HHFavhv+2/D9u/gO9AS31OVrvT5kw/7oIJSGI4Xcwxg96zrJyUUn/wAN1JjZGkswD6LaTyxaiYJDFHdyqRJKNxDHAHAx+grBvY203VdW+zPbSwyGQNswBEznO6PHU9s+hrT0nVU01ZPtEF9DqEvn3Lec4LW/VSOONvoPesKZ5xrF5p+oWYiEmmx3UXlrgEhslR/tZx+ZreNkVI1dTurnVoU8Ox3kUN1JHttk5DoAv3kZeWAIPvjNc3D9u1sTsZJvs2n2AsLe4KgRzSAjz/JbGTg44rYOrC01vw/feHtI87xDaNOWtpT8kkLHl0fIw23dwe9WIGjvYvEOvarqCwC3AbTdHjUolqXOXYqBgnAB4696TupXtoRpsUtIvZ9Pt0tlt3vrzTrdymnX1yW2TsuPkbHyDA3DHU0eH5bvT/Bt/ZS36ia9v4pbhhIHNvcu2RGW7sNgzjOMipLDW7xLESLqY1i1vwLmK5FsYpEAfaN6nkHDHHtSabZWFxoa2cksPmi8keEE/NHI42iRux+VeM85p8l0pJf1uJPoF1e6jN4b01lg0zbfXyzOGnzKjsSSGjP8OQSDnvUmn30qSWVto11JLYQTjTnlMZR7dnBy7E9VXdwe1V/FVnoOoahe2A+0XDDyEgAQQvC0fKE9tpzj3pfFFxqt/oNpbaLG0N206RbjEZV+ZQZDtUEkLtzk9KHeKbtoPc177wy9p/Y2i3cNvrV7Zakl1qup+aqbGIKqgDHMmQQxUdO9QW+jW9hqTavFoVqtrcubtS180MtvbuwGQgO1l+Rjg8jHFSW+oaZqE+ma1qPh22h19xKGvC7RiERkGNlXnltp69c+lYVlKI7bU5r66bS4LJlvoL+acTJLISSIY+AqqSfuHOORWMYyS94Gza8Y6dqep+MpNT0yyGvaRcRG5uo87BLbBtsZixy7gA5rF1yyktJLvyWmEkDrEI3+eR7cnKQvnsOnsK3JNfTT9Ku4HIiF/DZzsI24hlLcvCeyn0PTmsi9LmIW91IhuIr5N880u1pLdlO7nvt6j61cIuN09ug732MG4Ntax3l5pVvIl4l1DHFOJS/3xg788f7PFFTLJD9sihsZoLqzXbuNucK4DdQCOCMgmir32Yn6G5pt1HLf2C6KjJOIzcWkrN8iswz364P86o+Jtui+ZFBIsNxd5H2ZgXw/mZKoR91juPI6jFSaHe29m0Vnrdg8UUsuy28mTKJKGO0hv7rZGR1Ga0tLuHbX9O1FyliL/e9xb4/dGZCcspPIHFK4Mn8Swl7e4MlzbwamibogT5ZlSLDsuP4mUgkHuDXN6pLrGqy2+opO0z2s8lyslrEB9qDL5ieZ6HAIyKs6jNZRW95a3W+b7F5s2nysNxDhgWQnupU5Brc0TWLPR2t5kZHVbb7THEzYBCN8hB7ldxyD1GKmza8wKw1J7u20a60GddP1LzpHhnmAlWzndNzRvnswJHNXdK8Sahd6rHoOo6NDHb3iPN9piYJE4KYGB3UkEcdDisiWbWbWK1VrGIa9e3/+myxqrWs2B8k8iLwrKDgqMZBFJqt6bLyktdKu5UxC32S2k3raTJJtcrn7qNn7ual66tAbur2f23UtCsb83KrY3JIt5IzNswDtYt0UA+nWrei+HtU07xzqsWiyadNpO43CRNJ5kxnZQzShyMhgRt2+hp1qbtfFVt5DeZY3Ia9nke5+aJ16wtnlSOycVn6PrT6D4la5D2YOpNJJFHOhDiMZUzkgcEAc568VMtdjZtblvRPEV1q5v9B8Uae48R211Jewy3cYNuuPnjdQv8W0cA+ma57QvED3+s2Nnd6KDJcmWYX/AAsrq4KzTSg9FxjGOeK2dW1awjiliW5gtGvC0ZuxHvd3ePBbH3sAbTuHas/wR/ZksNnc6xqsM17pUIga5EZ2PZyuACQOQ+SVOemM1KjyGcmbHhP7DdS2bPexfb9EmkleJ3DFoUB2PKf4VfO0MfaspBcwLqFtpmnSQpbWzWt9YqufIklyyxkk/MgzuLdq1NN8NeHBpMFjLfwSLqYuNJeSPiWRnO5Szj7yKVAx2zVSz8MzeHvE2tar4g1W91K6sdNFytqwERuQVZXjk28SuEGFI6cZodTlkyd0Ymjas2meBLzT2eeSEZ1CyuLWAefFKCP3QHQDI4Pb6V0egSXttb6lLqeivq+p2l4t/ZJduN000qEoAOigNn8awoNG0a502DxJcox0+xs1WaKV3Xy5gn7uXC/e4JyDxmuk8DXEniLSrbxHr1ldWNzox3Wb+YUSRHO0MV/iXBUgHoeRxVVOXVJFQV0M1Oy1HU7DT9Vub+70KS1ikT7NKqzrazyjKllPGVPTvg1EHKeFNI8P6VYw3l7c2ztdz20JigFqMiSVS3HmM2PlPUnpW9JcXT6zmG1DXVuyY+0ZMDs3V9o+9npnsa4vxFo2raJ4V0rR5ry21aG31P8AtC9s4rrbJI7Fm8sp96NVxuAHy5HNTO6a7lt3eh6P/aGm6s8M48uRUQRQtu2+SFXBKDswBPSuf8dHWLT4bWEur3yXPlWz2i3kSs0jAjBcr13FFIz2PNVPDWsaW3iLUX1G2hitdMY3ASNDJJbEqB5iBeerAHj1q7OraDc6jqc+m289vJKVMLXZkMqvGu51RuBISpUKPX1pOCjJJLYcndHG+CdNntbEXc1xeRi+israEzu25oWZzhieSBs4rpvCVnJMltdyQJ9ltNHlupSsoDtIQ26FO+cbCT2BFOtLnVhqEFjfXEMKJpsq25lUMu52372U9GViEX8cVlpNDYat4XtNX1GKKS3tbgG5gU+U5nkCqvH0wQegFaPmtZOxhpc2vDraTrvw50S1uLMnT9UdZrhBIUaCKNt2UYcncwUfQmq3irU7yy8RWWpX6PFrWoaU6JZQR/uYolmDPEzf3yp5J7jFQWWlT2/iDU7ePUJvsGkxOfs77Vtxi4VoyG6jfjGB6VP48vNSgsy9/uv7/RbWe7KiLzPP8+UARBRyQiAsW64Gayfuy5t+/wDw33D8jJZrmfW/EsumzYRrRrWySVvnU7lPlR44O3OQozxurO13xF/ZutrYGMPBqOxy0vKvEE2MFHTHmDP5YrW0DxBb+JvFFv8AZbOOzns72S9PlRtHA0a2xET7v4W+YDHU1k3WqtpHiI6b9jt7yylUQJBcAMJZlYMyIw5TJbHHtXRF3uId4N1e3t/Dk/8Aa9tLfW1vMskV5GoK20mwlFbvxj9K9J0220+RCEuLOzha2bzJNoUK8vRj6cngnGBXCT6ouqa/DpFrYppc8iMVWEBbefA48xWHynn5vce9bcWhQajoB0rWZI7TVtR8m0uWVvld48kpkeuBt7c9aVT4d9TWDsSXmmXraZaatf6qkcukSS6fetbwAG/tQfl6/cbaMFunpWZpVozeAGOoQQBJ5XmsrNFDJMrljlu25VwxHTIqz4mv2juLG1mnjVbmGe0mU/KHUoEIHPLDB7VN4ae3k8Fi7vrm4eFZNiCKILJsJaNU2+owoJ75zUqLgh6XMDwvpUmt2Vsb3U1FxOWmMtyV8soF2qpK9OvB7V0vhPTL+10nWry3vr4bSos7mZ90SSKpVjj+JfkU/ka4jwygGg3EEqyvImoRuwmYKIolbmKNPQkHHrVmDWntI7WCz1C8g0+6u0stPS9l3FYGVhLJ5Y5Q7mUd84NaTcmrGSsXNW0VNQv9Zu7TX7KDRbC2MZuEJO15AhjbPUIGcjaPeun8J2uqpf6fdeKbyK51PT7MyJe2642tNwAVwMgKBwK8/wDD+ladFP430W9vZlng08rIs0OI4Z1P7lBnhh8pYZx15r07wTFJJ4dslvIna5mhiSFpn3OqJhevYZycdqyls769DSmrsfHqNtY3cH9o64j38hWwt7IQAmCZiduMc4bGT2A61neINQmufAeoXt5JBMwRIYZLc5XKSfIQR05Vi3pUD2lpd+KdYtTK1lcoC8eowMC0ThSA67uxxtz9ayNW02Wfw21nHZWVrpsF4zzI7ErcI3zs+FPysH5A6E0cuuhavqWfBk9zJo2nX+q3DzyfbZYmdMb9hT5v90gHAH41c0XTNF8KX11fxM5mu7R7PT45pmM0iY/d8HgyElvm6gA1g2FwllcaHpGk20sliHee+v3GIrqeVd4k3DrGANuR0PFa2r21/q9vpd5fWckL6X5erRWsJWRnkwxCIzdBt+YD8KJJS3EtjNstQg0bxJdWja1dpLbW72s1rKnmeZ5iMRI79GbjaFPZs9qsTaT4e0O+1XTbS9llV9GgC3k0hfybmDGCo9kcE46AYql5SXun6xealBaWkdxFDcQXUj/vLiRuDHIh+6yIvH1HWpdCuL218La9eWcS6hPNMH8x4gFa2kXy5Y4891ULycZIqpJP3uv9fMy1vYk+Hv2i8gutIvEttRt0vTqFveCXzGlYKQX9uQOnWl0aWSxMNva202m2t5dS/uY42lkMp/eAGQn5AQG4Prit/TfC2kpoR0oW+IpIlaKMSFHixjhCOcdzzk5rR0/VI7HUbyJdPuTEvlyFWIKRuc5woORuA6njijmteyNGrWOO1rTTq2sSFvtZs/D+mMLQeaBbzzuTsRk6lhuPXggVzLw3t54Yh0u6iMYvA001wAQ8DDG0hR/AvI47cV6HJpk0/hiS7uny0bXKC4QgnymclW464U4x2rmp7YLH9ks7dZDDp6QWMk0haK6hONkq85bDZBUdvpVU+VXuTJdUZumsXDtHdwx38KpZ2t3duqgyrgqVc5ZiwzkHtitO91qz0LUoL22W0+035gsby5njZzA0YDSEDOC2O4qneWiaBorS20Gl6zeRa2vlFfmR38kKNucbUTJUt64pljI+j39xbfZo7i3dS9613biZHhJ2mKNWIy7Z7EEAU2+ZNpCWiLBkg0/SvttzeQ6hpcU0tzo6LOTPLcSyELNMo5wfTPpWPa2N1pvhFNetNSGo6xa3nmpbRSYaVZCQYpM8DbgED3FWNPjsTpupSSWzQ3lhbGewIg8pZUjbJyqk7JAMgdq6vwzZub2ey1O1tbeyYqbaM8usMm1xK3q3Q+vFDVla+oR1ZS8dS29/YWdpaXdjLqWmrE08FxM4WzkdSUICjDlnOMHp1rM1HT/Emq6jDc3QSxtxJbNLFAR/r14mZAPunaMZ9ziu7uES60Ez6bHbm3ntzCdRYKl4eSI3VWHzNu9eVxXNtBa6JawWE+qzmVbUTX+GMsz3DHDO5HRNpJI9azg+bYqSvcoW8txcanqV7eyRmyuIlgijX7kaDBDbexyx5PatbQL67Fr41TSbKKRotQtba2J3ZcjOTnoAFGSRxiuMtboaR4T1u/jaRZJQIXtJU8w/ZyhErDB9CvPbFWPC32zwlp9ppWnaZJEu2C71C/lmJVoZBggAnIZlGFx0q6icmooz2R2vie8tr37TZ2YWVGdbfzbMrHIgVQzs+eOqsNx46Vzd7K97YwX1lBNbNPK8rGSTzWjtUALhD6EgY981p2kYHh3+09InuNbOtXctrZpdRBHjtxKFYNt67V3Ek1zj6nNb+GYbo36x2dpcSWgOCzJHEWzACR0cYPGeKdOStoN6kfiqG4u9Jt7FRYtqFqj3EK2rGRIoAd2HOR+8ALFhnr0q/qV9pU+oyR6Rp8sWqX8NtaN9quABAyDcJETk/OBjJ9Kk0SCKy1/S9V1KKAWwhjWe0wdqh1LMDj7xOR1rQnktZ3urpLO3sbjUb2znjM6jz2t9mW2Z6qMYx705LVaCRXF/HHLe/ZisyXcDvcCZQjRyOpCRx46hSud1Z0dsq6bYecv/AB6QyLgYHm7QHj8z+8AzHnqaluZPn0+O0ts2/wC/it/LGZlcyHLt2C4GB6ZqvzeQR3OtWv2GKyucyqobEy4/dHb3BIFapdSb9jOa8vZPE1pa3Fs9tbQi3WR924TMGydjYwMHkA967q1hv/EFjqr6G0j36TbWjMnkM0CyfNhuBuw3brnFZuia3Jd+G7DUvNtWlf7S0sUyfIJRny1HqwQkissXl9qNxcWtjAZ4ROI5NkpDIhQMNg/iyV654qHdx3KvqSaQ8d+mvWi3FztISKK5kTJYxtkMqfeyM7cdTU+g3DeGfDl5HqWmy3NlrEZNrYarGzIreYQjhGHyL1JU8jIxWX4bfTL24028ntb0WaT+fyzR/v1I2OJe2JABg9q17HU9S1nxPE/ia4ea3a8mR1lYtHayPGQigD+AFQdo9KzlFy6Xj/WwM5rTxOsc0tzOZ7u/vPszi4jITcgygQj7vOMcVe1Wzlso7KFoZjPLey71k+YxgDH3Tz83BB7VJps175XlDWLeW+1CKRoBdIBFb3ERHzKQNyrsBIYjPNUob1tTmsrq7l+0XjToVu0kLx7QSGdTgE54+8KqMk3ZFNaamZJeyWchVLdoYoD5qJJgb1Y/NHjueaKtTabfvYbrpLGSHUJJVh865BdFUksTnlWz09c4oqJPsCNy3e3tbvxBeRRBtN1KS3aZmB/cPnLmMH7jbuc+lMmnvmu2TU5oM6Wj+bAvQFmyHPpvBOccVU8PXcGqT3ejwRy/v7QT8jPnRA4cqO/ByD7Gk1WS5F1cmMiNpbVNPaR22mVlwR5nswXAqlb7JNu5Nd72/shLFrRbS4sDb5mOGMhJGMjgdhn0NRaZcC40/TrbULe0XyLh7KUgAZVk2kKT6cjPfAqtd3UUWhtZyQqoh8i5iKZLmMyEsoHfB7io7/UpLx722u7aK2jguI5baMosRaMf8tFCj7+Dzn71PbQeh1epabZw+Ef7D+33MMD3Ki7kiYLL5uP3MmfQ7VzV3RbPW7vw9Y65a6vaW9rcPJba7aTZLzyZCRoEA+VyTngjrnpWTdW0Y0gXkrfaTIV82M5UXFqGJU56hgePYiofC1oIb28Xy7w2iWwRd8g8xpEk3o0mOGO3G1uvGM1nOD2iJFi0v7Sz1fxLDA11F4kiG/UYXXcsrABBIv8AwEAkdc81A+uS6zo2tahawxWt3pUkFtJqMse9tsrEOqj+LeOOegxWhrkJXxZO6v5Gvaq5nEdhHypCZAZycsoHJ9zWh4ZuoFutZZot2kRywRywDgtMYzlvpnOAfSpV+U0lGyWpwmqSt401Frq3BsX0+Jk3sgH2lcqq8diEUAY9K7a1ZLaLWJTos0Mz6fDf3dlHIESZlcIF2jsAMkDuc1iaBpVvqHhy6upL/AhRWSWE5ztyqIo6k8/N371eju77VV0LV9Xjazad3s5BHLvS5BA8mUAcqSwKsp7jJp6KyM2mbUME0uneE5ryCyt5ra/DmzjUJL5bZbzQg53L+uKwfFOvXNpodrb3OqzXOowfazZX9piRorp5Pkz7FCeD60zw9plxLPp1x4hnvV1u4vrgoZXw6LGf3bCQcbSOo9qqX8jS3mpSalPb/br+5ii0cWkHPmx8ybwOOecHvilypq5J0fhtLOLwTALh7tJBKsdwjR+Wy4b51b6jkCpfBWo2CeHLe91O9LpLM0UiPvCkPIeobk8hcEjkcYrm/CWtFtV1RdXjvHvJLaON7lwHtndZMgk9nA/L6V0Frdy6HD4p1RrB5rG6mF81uZBOwOQCVxn5B94gc1TTZrB2NJLHU38XSaxBDp6a9cLBC8ErMV+wqxDsH+4hZcEY5BFcz4rvEsfiFb3vlCCa9miW3tooAH8rPlu7ykZdCpzz0I4q3eaHbeIzrB0/WbC/tFeC51HTrqd1gjt0UsjIyc5Y8bSecVz2peM7yYWHiOXQvJl0WeOKwglbImXzPuoeuMfXAArJWTbXQu3Q3/DdnNoVtq11qEhh8QWGqy2EtwhHmS2r4ww9eCOe2K6zVBZo01r4us4DZ2hW/aVsPHFIgwgbuSQd2R0qutp4ZWDxfPrCtZXUsXmRi75uYDJHudUJ5YbsHjqMVleGryW48JQalr2jiTWoUU27Bybe/CgrG5PPlyEdzx60k76NP+rCi7HGaslpaNYXgmhS8ur6DVZLZd/kyxJJvH73ooIwAOhNaGuRi2trm81HTQ3l3IcQRsGYI7eZyB99fm69a3re5/tEN5G0wvHJDfaTqKALEwX5QjjHyB/4hlWycVr6ZLptj4qtbBFlGoXunNePAzeZZxLGPK2wqR8pyctnr261rz8mqW4nC+5nRalZ3/jW+i1C1Q2VxD5kSxDO5AcjjuV4z6UmvXeqWep2+u6EPlLW0Yg2hvMLExsH3dAR6Vs6homm3ep2uo2xnj+zI7Q2ivshEuzB3beo6Er3rlbSyn/4R+7vtW0iay3TgzTictFmLBRsNyITg4wMnNNNP8hOm+hygg1OQ3uhaTJcQpaIXWabKI80cmAV7EYYoR2xWtq3lTRwaLfWVsqSSRSQ3SsVkhkV8OmfXjg57CrbQXNtfyXF4s9s1z5jR2U0w8py2G6HkE9cE80zVNJ1SO+1C/MEV3ZxWUDrPAwKTJkM4I/vAk8/4VqmtnsyZQcdxzWb+JNY1611Ca6MZK2k8TW/lDJbD7Jf+WjEKGI7c16E0Uipd3mkobw6fHunt34eRSmVX/eYDj04rnPDqPqmoSanFqFxPaiSV8SoivCWTHkgjggDqSM1uatf6xofgyW08O6Q+qapcmMi2nm8t1DLgEf3iMA4OMfhWFSTtoaRVonC6iBFc/b9ZtIby8LIYLYOBNbo2MoT3YAkH6VsePpbTTLAaRe6pfpeRQ/bUlCBplhTDLkDrjlR3IX2qDxFoFxpOu3Q1O1tLzT9aWS7aSX5zYsEVWRSOu9sjPY9OtbHhKOzWyjuLq5ivijpBp1xcAtOokz5ts+eqgjKn0HtVObcVJf1/X9bAtWcdNaXV3rNpdSGxt4b3TSpt1vA8ihVJR0HXOPmPcFsVFJp1zeP4NlnntJrgRCK68xNswSBiUlR+gc5Bx1Yit++8JaDKh17w5cec9pLKskqN5zbgMvECfu88Z6Y4qLQ1udb0Ca8AtU1W4nQwI0rrbxlByvIBEhHHGR1qubmV2TyIYlsl5P4eiSaW5uJDcQySbd7yiQjNxcAja0gOcgngV1ekrqWnaXpsCXAea0l8iaWWJTJcQgnBVVwFJyvPXArL8P6DfWdszTeZbRt5rXaxSl1AbhEUnkLkknvW1fpqR0+4sYdQt7GL7LiKYfvJIAq5M78cYHHJqJJbLY1irFcwa1N4nhhfZ/YKWTSMGQDEm7buDEfMMnp6Vi63a23hfw94oaGN7gNNALNNLZZLuJSdplZXyNob5QxyBmrWtpq83hO2k0xVu9YiEQjLzGMTc5ZyPRutRtbR+H9bi1qJpdW1OHGn3M2msiwm2OWaJgSf4iORzxmpnzNWi9RS8yoY76ygm8N2+mNG7aVBDE+4MInZt0jZQbScntjmuse2uysdqpV2tk3TksVbIG3GT3x0qO31WKC9k0q0uLOO5iCv5MT7pFZhkFueAev4Vk+KvE7eE7GOT7HPfahM4QxQguZU5OX9BnOD1qk2kVH3U2Y114em0vw+IvLE5+zYutTun3QwLG2UWQHndtP3h021b8E6PeXkX9qS6hI2m3UmEsSuFfC8SxjtG+M/gK6A6rp9zaQWsltdSi8l+xyRx25eNTt3bpT0Cclc9DirMs0ulzzR4tn0uJEWxFq+7bxhlIzgYPQj6Ucz+FE2V7jTf3TJNqF5pE0V3C7COAnZl+g+ikYJ9hXKacl9YPJeLFC2o3m5VvZ2dxLOzZEZI+5GDkDP4VvL4nXWUs5tJ03V7mznQK88x8sQtyGMiH5hyMADk59KuarqNzZ3OjC1htJLSSU/wBoSu2G2KucRJ/fB44zjFJNW0WpXu8t76mBqPleG9Xt7n7ZZaVbz7YbyKeGSeO4ZiA2FTJXBIw+OO9c/wCONJm0vW7i51OWGy0Gwu4ryG/tg0jOzfKXdV/hHB+XAr1G4vbd4Vu7JoZpXiY2UznJjdhgFs9cdx36VQs/DEunaRbWGq4uDK+64MoOyV3OXIUn5Uz/AAjgVKk+bXT/ADCMVJ6HnWmaPq0tpNb36x3NhEkkcc0IXH7w5SXHUDO08cmsvyrxPESaN4jmlt9ReJLi5hePzYUMa43g54Oece9ej6vqdvoOk6hJf2dwumQSQnz7aUeYzb9vlY7c4Ib0zWL4y8PXuosLlrO0k33WAJJmXzLVR90t/e38n1ArVT96wSj0M7SxZ3Xn299e2tnIkKA2agxtMpcOwlboEKjI55zirvhGTVNV8S6neaS8MemrcoYEuIjk2zZJWNvUHGPQVzegeDLnU7z7RqdlNpbrdFpImbdC0QGEVZOr7TnjGBkVv6pBO/2HS9NsNRNuX3Wt5aXAiRDGcfvf4thyScdcAU5S5lczUOVHUXdhaanrWy7uLhoLoQxRywttjgmtyXyzHu5OOOTivJ2ureabULZNKaPU7nVcTXEsjBbhQSvlo3oOpHYV6UI9dOkapbXuo6ZFZWAN0twVBkiwV2GMDgnaH5PcisbU/FOi3fkTLYSBRZTajc2sSjzkU7SrD+9IV5yOBzmoi+VktHNazaWkl1aWWtavF/amoMtpO9qm0QNt+aNhnksoUk/hV+z+z3Wt39hfusl1oUMN7YTyysEuSq7PJc/3MAcdRWTJZ2La60V+iTXM8sWp3cBQ7yhf5SfQgMoPIrpPCFsum3E1hrWqWsOuTX1yLWOS2Dzq6KWiJPdDg4B4OKqT5d2TfmLsN9faTJpb+ErW3uJf7PuGTTkG2P7ZKf4CfvZweeK5W/ggg8PwaZMJWikgMlzbzD54LoOWI2k4DsQwAGeBk1oLLLd6a0k0k11fxIqzXkP7pVmdid6BeF+orDtvtok083S2Ey3Nt/pM8cu8W8xcqshx1JAJ4qoxV7jkuU2jqUtz4XntLqC5UXV+jQLtDmdQnzoHHKHbxz3p73sesaVdX1xbTRx6bYwDRoJB50sAA2uhYdflHuTWVZW80qXMOh3iz3MMsdytxGSAzbSHwCPvHb+FS2Uuranqtultawx6tKz+VLHIFt0mMfCn8O/rVOKvzE+RegnkuEtV05C0su+8gd1PyO8qkRyeijGT35NJqdxqEFx9pvIrefUre4mSZYwSjnbz5YHYdvpWR4onhfSrW805Zbe9DNBNL5xTypCVMi5Gd2SG47VsX+t/2ni+0yGFLjS4RJNPpzZSVlZV+Yt918HB7Hk1fMIg0+1/tm6sbCBvIjvXS6RB8rM7jB+XsTgjHvRFcXHhv+1rdY/sgjjGFUfPtWQhl5+8B3/On21uZ2kaEg3CzGaO8XDsp3eZ8jdmzwSO1P1S1utSvdPvNUiZ455lhkZzuVSzEFfbcCap33YtNkMKH+yGltbwbbWL7PbLIoZWZmV0GO5A3ZPYVImkza15QN2VN9cyWl1cQDb5JGDvUdN2OmKiupEXQ1XWLiGw0LS2a3t5ooyPs285RnGcu2OOOoNVtStYANW1BhJfWmoWMDJFueMAkbQwUEFDkDJHIrNu90iiOfWNP0nxQ8ZN7qOo6bqIs4ElQpGyMoUTP3wFyNvrzUV4LjS7S6tdNRFWNpZB5i7clW3BVP8AStjXbkRabpn9lRWsckMEUd1cS5lkjDKQ0TMOvIyrfrWVfXCX1t5dtZtNrf2FLSdZp8RqmTtlx03HI+as1db7jV3scrdzfb9JS2hC3EqyefbtMTnBYBt30bOKK3IuWvlZJnktQlsyumAkR67SOpDjoOxzRUuN9W/0Hr0Ro291NY6Iup22n24ns4pLiHUI2KtbOGH7rZ3jwTxVjV7JrzTtP1W4gaDRr5Sks4fLWzklkZ17LnI557VVnh3QrPpk4ufPne4gBA5QrhkZTwGBwcelZuitNJojWV/fj7ZqSMkdtcAgoNxaJ2PcBlIH1pyVtiFruXdfe01C2judDhkS8s1SGS4aZWEoZiAdvHljdnA7g1HfXk114gt7XbALyNhbgR4LNGi5YsTnJBxjHas0fa7myneeW1isf3KTeVbjzeBlW9X561q3yQzQFrW9Cy+ZCsVwcgxjGCp7qp6Y9aEupVx9h4gvLO1t7+KOKe7V2ivbG5wD5bOG3qO4PzcD1rooVg0zSvs9jIVsbqdMkfNLHuP7oKep43L6Yri3uJtTm+x3Fvaie0T78ZKyXS+Z9wEdCAc56YFdfoelWM8FsHvbmWK3lkt4/JfbO5jbcd5HO3+EEDkA0uZfMcUWW0qHWtS1DWPDH2ie/gvLWykWZdrWcqKwYpnggqQSenFMjuRF4h1a1N04mklR5fKjOw3A/wBWxAHJbGMdOasXmo619tGoy2N/HZMstuIdOQGVkK/LL5f8RBx7kVtXkEz6LbQ3TzxXCOj7ohskdgRgtjlecfjULsaR8zldT1s3tpaTXWmSiys7ovHFpA8t5BkYKqPuvnhu2Aa1dZe71jUdV023t7Nbm1f7QLR2IEcrAHfgfdkK5GCcZOavaLHcTaYuk3dpaJrNkJbi4MRGVBf75A6hskknoak0DVj4jvtTvIdP320M8ltJfSTLEZWhAHzJjJ4PBJ7VPMr6lKKOcvra9TSdNW/sLlpFuXlhW0nAitmx8iyMcnOCSSMjdxjmtCy8CQ6NI1xpGqXkEj25t3m80SqxHPKnPfI4wRXV211YwwX81stxdSGNpPsi43rEV4O/+LkHHSuNFreaba6RPpRTTNIkkLf2ddZVk35LlsZJcnke9NO7KSRW07w3cadFfuGW71CcOwuLyLdZvvGCiqD9CSB1Fakvg2CCw0i3YeUlrN9ouG0+d13zEHlO5TJ5Bqbw/pWoW+rXz3d1M2j4XyLQ7WEBHJYnjg56GtLUlu10nU1s7+YNIjNbXNnHvkh+U7tqj7x46VfLoV7KybJfEtpNEmlaDpP2ex1HWWEtxFbRBguAAGbHQdTnnFcD4p8I67d3s6SWl1eX2igzNc3UoWG6BIRVUD7p6knsO/Nd1ZXN/p76e3/CQW1xqaWYa9nktwtxM7YCRov/ACyiXv3Jqxe6XPeXe+7hubG801VEUhmGJoZR+9LEHnJyPm6dqyTlbUyS6mJ480TzrHR72/uLK/1vw3PYLc77hYkuUcHzUG445DADPPH4VUtrebTbrV10rWpbGO9vlksZ5DvhtEic/wCt9FZSV9+Kw/iBoF14p8Ta7a/ZTJqMUxns7T7VHDbzwIq8NnnKp8wwPxFT6nLcw+DLLT1b7LNcwLqawzsVivQi7PIR+hb+LB7YNTTVtG97EPuzpvGUd3dWFlqOmWdnrOkXKstzbrHmWaL/AKZnI6HnB4PFa8axza1/aAne3+1Qra/ZGGzcCM4HBJbK9M1zM9xHqM1v/wAIPqUumauljHbxWwdZSnmAOp7puBVu/IOK6/xNMmktcSurXvkRC7byBsljdQCflOOM8jpgnitObUqOph6fbw3dnp91Jv0u6uppbqS3gnKrIwO1mwfmYbdpIOCK3vD4mSO5tdTu7a7v7NlHnWjBlmjPzIXU9Djr7Vnw6lpurXqxWHm22uMi3VxaG3AeBXG7Eo7SMOT3I5pmranDpNnFqlnZfaB56CSJG2mRTwGJ74JzjpTXvRLvFK5uaxYrd2T3culwX0/LRwMwVS4I2tk8BTxg1hX9hbXemJqb2Fvb3flNujFwFjj5+YylSFKrzyKXT9D1VbbUU1LXnvJbrEiiHMaQp18uMdQT9e3FN1zTbe8U3UtnDPPBE8FqG/dh94wykcgAnGcg+tEUxpN6os6fNEY0v9Oa3tBOUuZJbONXjmj24KgHgbl/i61nW/ioz+Jo9Mu5tMtrAK01tcRzFrxMDgOhGCoBxtODgZqx4fuLh7WCPU45LeaFVjkMgG2Nh2UgYZewOBV99H0e+s4tWsreC51m+hzNMMKZPmOA2euOme+M05KKtfqFtFrqYLS3dz4eS38NpPfPY3TSj7SS+EcAvIc4YIGORjOOOKb4c1gahd2d68y3tjdSzRXKQWhijjkj5aQMcEHoAAOuSKzpb6506aGx0+a386BZHtNPa4KSahHICCjuR8hVtxwCTgDtWppjtIt1YLFPpSoPJVjIJjCu0YdcdQDzjqcc04a3SJjD3tRkF5ZXA8Na1odzLaaRJuvC4VlkluFLRvHOu3ayds9cjnrmt7UdKGvvNFrT2H2Kdv8ARRGnkmMbeA3JBcZJDjtxWW8f9kx3c2maimo2stx5zRjIZINoWYqo6MSN2B2qr4W163+1mDX9QNsbzdNp1q1uywsEAyscg4Knjg89alKy5nuJctrM6ETX2leG9OtrmyW7kWSOL9xIxItwT++YtwcAHOOTx0qpqGq2OtWF9BputwpELxY7gwoTl1O7yA38eRwQuQK5Xx3c63p2nPrkkdulrZ7LNwJN9wLedtoRFzgMhyeAd2aqeOtFgsPDWn3IEtvbRNuEz4WWGOTAxHCOfNcHbux8mT3oTir3eoKXS2hoa3qnjFNXsbjT9BX7JdkRT27NvltVRtpO4HaAVy2e2eay/AtlfXV1DHYtNY2g1CS6mtZ1CSLb7P3bt6jPRevNbukNDJqSJBo13pt5dWvlv5k3mfuohtUMQcYwcevqTVyDwkuk21wfD3iK0ttUlG7yNUjbZuOCEMhJOwDO3uODVX5dWxat6liOPUrddQt4bCwkuI2H9nleWuG2/wDLbbyOeAB261rsNr2t7qUYTVIrXyZ3jyp3k5AAPGAxwPWsOa8Oj6xqM2oavYwwwwwSw29kxkuIiflkY7QSyknjin69JoeqxS2MOuhdRmmMFsASXMqqGZQMdQDkg/ShuN73LfKtiAa0NQ1bVNDFuY7axVYmklIXz2fttU9vWrul6Qtzo4sddFnBaoC08dopVFVGygUDknp9TT7PRrjRQswaKeJ4UT7dLHiWW5GQ21OuzHP86vm+020vrOK6WaK6uNyCOGElnZF3EgH7qj1PrTuraDgtLyK13fSxW9vLJHI585IkWMhWDyNhWOfQAk5rB8PPp0+r2GpX0Kt4mWeWxihguluYreFS2ZUxkIzY5PU9Kv8AiG6eKwl1eRLS80a1tjfQ2hg82WSZflVt/wDDjcTx1rn/AAItna3IttMvxo1xJbCVZrfTQ7QQxDcS8h4+YluCe5qZ63fRE1Ja6bHQ6XrEeqa9PaaZBPBpywrOJLuI4kcsUO1sdNw/WtF5YtPvo5ru4lgF2qRt58rPG0zZCx5/hY4PPTpWdrXjF7vW9M/s6ddQgFy9trFpCnyxgqPKdsnKA5yGGQa39Lsmu7WGG/8AKl1CRpI5pkXaHEbZj2r0+6eD6ip5nbUKdmUIY7mdTYz2AuLNziKV8Nlic7GT0GM7veorzU7We9tPLvopbeWWRJ1iIeNio+cjHHynGR3FaOu6fqVrNZjTpraSFvMF7bFtssilSFjjz1z36Vly2NloOjW9tp2jSx28IW0MNnHv+zllJaWQd+QAdvc01NN6bGjktbbGjqet2MOoWel3ctrFeSHzE+zEsgh+98hPGCOmP6VxWpXd3e6jq2l2OrQWMtzbrNYuEVZ4FjJMgBbh8jg9/Sr+gQW1p4O05dRgtIrGaFUhnE5nJuZmYuiE8qQcDHbmsHxNawRi3vNUsYtatbO6FvNbiTetsqkGRxs+bzdpGFHBPUGlG3IYt+6jtrzT49TeBY4rE2racY1ui7JIxYDIdO4yeDXNaZo3iaa7h07ULO1F3aIvlqkqvcLtQhzG5xjPy8HNdXI2neFDp9ri4ktpnMEchcygDglZCec/MB7U2+a2fU1SS1jktyGJ1CJistq8eWVh3z2qozdrxBxTV7nnx+3W1hplvq080V1PNKuqWcwVZ513bkSRvUtjkHnjFP8ADX2rW/EpguZb+KztoJVtJUUKYo2DGKR2b/WNkMh5yAa14bXUVeeHWLJNUgceauqSuBI2FykcidS2SPmHXPbFX7PQJ4L62trJIIdIhRptkshMhdiMj0Cj0/KqS01Fbsctcl75vs8Un2CaKM2V3ZSsVZ2K7opUxwUPIHfNR+F4Le31K00K3h/s+C7Cw+fqW0s7AZyMdDknp0wK7S706S4u2umUpb2i8SOQxXBwQP8AZP6Vl3kDXOoTWohH9sN5r2F4qApp6BPkcbuHcnIz2BFO7Wq3HON9zktRns9M1PW9Dtr5ZLG1XyxcsPmEvRX3DkEDPSqM1kWbTCy3AitbqWAZLIY2VRtYuf8AWK+7d9DWlPBZ2dxZajetFEtxqDw6tbX1xHHKshULuTqWQMdwPocCrt1pM91BZTXEgF5ayvbB/tJEEzqCBnPC5U5B4B45pxmpbsy5WuhlailppOgR+Hoorme7uLsahMu0BIWKFQEYD7jNjd1OKfo3n2ulaxLexWNo8wSdbSwJmfZ9xm2Dk/N2x710XhW+1N3csF0qC0tooXuI41nd5TnAQkHCoeT1B71pT6Pc3Woyrmwd2ZWhMbeTdONp81mIOck4YYGKE+V3RShdGN4T0m10bSDZ67HGtvp94shbzipJcbIwSOmTjIrl9Nt7+TxFqVhrGoSQTJOl3HJJIQJYmJVBGOmRkj6c12mvWVzB4avLDxPYaXfRTyKFkmWSGdFXlJHKfeZecnjORmsyPw3IlpFe2KBYI3WdJJ1OSx4ChT0GO59aSk27roUqbtqMv9OS91+e3tIEh0uFBCkrkkM2SPNcHIznjIrIs/EMcNl4eEFtJNctPJHHMQdsmUMboc9VJGVNaSRuRqsen2eoI88olvIZwzglD8wiUD7mT+pqa00G5tL+eK11G5vZ/JjEKIg8jTFBLbXZupTsFyST1pud7Ij2ZQ8P2dvb2F9BJcyWa25NzLIieYHgRdwRR1PPWr2i32be9urnSnltNSijkdNPi3YSRsKg7kr94/WtbTtMuLPUxc6b9oQW0oVDLDlhIerKxP3cHuDnpVy5K+F7g317fWtvc3TtFBufbbzTPnYMAfL3yenNTKXc0jC2xiXEN5ZXV9psV06LHL9oWCW3YNOwG0MSOmV6e45oq/4XXT4LKWxjuL8XFszf6LeMWeDJ5XcfvKCTg9xRUKy3NYxUkcVJE8P2WOEvcSK6xxw/cRhszgt3I5/AVS8U2+oeJfifb3GjW15avaqoSeZNyhYlA3rjgKTwBXpGm+ErOz0+OWRlvL1ZNxlX5AfQBegwuAam8VXEtnFbxaPeQSarY7Dd6eAUZIGOD847jOazq+8tSIqKPPr2Z7aZrRLK2vSXC3keDDJGrd0bo+CSSB6VUt/smjWUT3UbbnZ0Tcf+Pgo/zF8/dXbjaR6V1eoxH+2rjW5Qs2lwqFtrRCsi+bgDen8XXhjg469Kh1CHQUmsYPENnqMV9dTxssUNnvg83PC+YDgp7fmKPaW1E4J6mfoEdo1lEii8+wT3YhT91gwlycyM/oOwzzmu6XTNS054YPDy20DyNs1HU1UIqoB12nOCRgYHuazisWi+IrOC7gE39qylIlgUssSqeJCDhYxnI29TV3XA9xpxtoNSbTDasdQZ7mXyiElYxIJRzvXA4UdCacqjYKKirEOvWVjrkNlE97eiKznElw9pIYvOHTaHHI+oqbXEu5fEen3+mWdxeA/uEsROFW8O3BZ3PJCLkn1I9awrGC90fQbm5W6s7gQSGK2cS7lLKu5xIOqk5z71ettPsm13QNQvNUvrXULiJIGW2YiFwfnIA/2v5CiVmrrc0kk0mjQ1Dwzqk2mX81hq0UV/azjy9QWMgmIdIZF/ijPernhsXZ8mS+0ZrNJ2NtJDBKJIwxb5pVz99Sce9bkeyCC4uZpTFDGwjmdP4oyeW2nv0z9arWGqWMkTxWmoWtz9mbcqRy7ns0bG3IPBB6hunFJ6MdlDqY6aPa2cd7JphS0u7yRw04YsQ2PlMhJ4G7jbVK41U2upaVY6vpuoXNzfxiOCe22C2mnVSZHbJ3IF446ehrQEGnSeMI5dUuxp+jaZGNQuFidZFvSchUYjliDyQBjtzWBY+MNK1u/1EafcXX9kwSjZN/Z7KV5JaJsng49B6Uue75Vp/Wocy7mjKsekqtnoEkNtYRn7Rfx3Uxl83f8A635snjnj8BV2PTrKTQLePw1ZJaWBLLJbSIzRSw7vmKHcGjY5+8M9KrWNrJ4mh1O2s5NL1XQxIz3hZFDAZyFIU5Xgf41magbvxFJb6dajVNIivAQL/GSIhwERf4Cw4BrRJdOhHMupsWOpaemswaRqOk3llOIDFbXz3In8yNPuFpcZHzHhDya2obZL2a/0aDVDFd6gDA80jBpYhJuPyJ6ZBI9K4i319E8XjR7fSrtW0hCkJhu963Mm0Rkyr0YqvP1re8OXFrodnr+vtbabFeWF0LOCaM7hPey4U5HXjcOPUn0qJPlg2QpdLnA6fZwa9rmrTalZT3GlWNpPbwvKVMjFNsavK2d43NkccHoa6H+xpdOnSw8Q3ljf2+tOtvFDHMZPstyVK+THE3zIHQY3KQARisfWr27tdU8WaTFera2tmHjjt1RSb5vNy8pPVgjdgfrW18PYdQls7ud9UhhSESrYarNBDKLySMEjaDh/NjbecHsTzS5ra3IkTajf23hvRIPD/gzTr3Tr3V5JYLU3Ya3EN2n3hu6jphccdfWq3hR7u90e/h8Yt/atstq1xHa3V2knmSAkvCACGOMBuTgnFVvDl6tvZzS6RGdQvrWCXUbi3IklmhDyj50Y8K7DJKjpniotO0+G88QWoS4n1GXVLgG3SSLDWhPzGI7Bt2BQQSaqKVrtj5WbHhdtRfTj4is47fxDe37ra311DKtu0UZT9zJJF034Ozg9MHtVjwld6kpms9UtUls4FVoYrbBW0GceWrn75yGIJ9KXSrTU4dTvbK107SrfS31Ce4tksolilxtCxzbATvBz5agDsTxitOyu/wC1tLv7cTCxcJ5W6Nh5pZiVLcdlwwH1qqb0LgruxrabBcadqd9bXkVu+i3ES3NpfLMWnMrDHleWeqkgnAPFSaLq+meJfCg1ewtr2yjS4lgYXkBjPXBKjJ3DIx7H6UupXlvpWmTm9nuZdKsmWTZGvzKwGdh77j2YGszQ/EA8WW095p8Er2ARXtpm+VDNyTEinjcMDJPGTU6812zWFo9dCt4VfUNb8fX1jZ3S2+kaWipqUpCsZXK7tqn/AJZ7RjJPfir+v3g0+zi/s+cSq12iRy+UZgV5XcADzn8OayLTWLexv1At1g1q+KtJpkEm9Y5STnznUASE8HHf6Vb1TSrnXNLaw17X9R0y+3+ab6xtlhEijIKMg4yDjn2qveu5boLSkm0jK0LXZtc1PUJ7/TTFZ6PGkoZ49shlJYPyMhWCjp15xWroc0HiPR0uJNKmsrOZt4V2wJY8kD5eGU9+euas6BeW72N3bRW1xatFd+U73MZQXjbRmUn3GDn8q0J9KnvtXsEn1WfSbS0YXExQrtuAD/q2J/hIzjHNVeyuwprS71sR6TbjS9RtrO08m3t4wIractwj4LAMfQ/dzzWFq06eC768KwRTaeQ95cW1m5uLm3mZgCqx/dCN14Ixzmt7VJkntJ0IwJzhQow2N2Vwex6VwNtPfLaanG+nzajcNcF45oFMDRxq4SRZiPvMmdwxyVFOUbO5daHI011Omtbvw54jWTVLyVr+NY4NTlRLc7owuWjIA6uSNoVfSqeiraXHjWwtr2/a+8R3UUr2zzL5brBJ87RY6AIBjHXrWxMmnaelpZ2t+Y1kZnjt4FAZ41GTID1KrxjHPzVxE8mkjVby/bUJLfT/ABBLHYpbX6sbqzORvKv/AA7iRwvbrUO97/8ADIwcvvN/xLJpOo2F9qmpXlmnh2zkNnHJbTsRLIV2yxvt/i9s0aTpFpd2t5b6XJf2drdRL5AhYSSHYo2TK/c4GDnoBg0mqyW2n60mjQvotpo5SaK+sjbmQl8YWRwPlQghW55IJzWX8L7KC48M63oN3fNcTXBUWi28rRomOSIywyquc8HI6U1JpXJeruy3danPoDaHG3l6lrJyL/UjbrG8cKtlU3oMFs/gK3PDtu7fatW1K9DXF7i4i0plEiWoJwQj8Hcy8kdKzLbTZ7R4IPEunoNQe2W3nsbe+R4rVQxKO4zne44PY10muziO90pIba2W3vYnee/EoBhYABIinqTnBHQikmmlbZjSu7mTNda95t1P5VvYGLdBYhpVudxPSUrwV4/h9ar+H9K0zTbK6ilN+13cLLE13ezFriEOv7wR56L1Nbd9Z3M0ETW+pXEnksHDPEGBP8aOvU+xFZuqyWEtlDfvp17qEkSedBbyYSZ5B1RBnkEfwt1FXo1dmiXNd9ih4VvWt49X8Lx2kVvYw2sUWnlpDKLmMg/vC/QAdCAeKpPNq2oaTjRta0MwfZo4rtVnPMMZKgo4GDsAOVxuaneMV0i68IRWUTJpNlqIljtI0h+zKbh1DBSP7xIxjoOaZZ6rH4b0zQ4tdtbpZ7qJY7q8kgBSOfHEbBeSwHdQeOtQuxL1e5oSWllqd/LZQaxaahcQ2cWn3cSW5ja6hIDqBJgEsFOD/dyOhrZ8Haog0aW7mN3LFDPLBbLcQ+XKQnyoinPTtvPXqap6e6/27aX8WlQqzJJaz3EVz81tFgldueGZ8AkDkZ56VneI9YvtAXUpNS0zQ2sDbpJaRzSPGY0HEmZO7HKkDFD21/yFbl0OkQW188F1rDJZara4lVM+aIm24Ks4OC4BGexzxWd4mvxo9pc68l3JN9o8u1lubt3itLeBDksgUE7znjHUitMzWsmlRSz29rGFjEkkKZHJA5BI+cjg5Paqv9pafC8dpJKiSlHaK33cuRjcQpGAOmabi2rmkYuSuZHhm4OhfZIb27N7b6tePPp4RPlw6F/MZ++7kg8E9Knillhu7myuHs7u9t3NxbNZII7tYtow8inAkYYGHXkY5rkdcF7pPiTUIfD2j3djqF1LFcv50hWC9jRgT9nQj5XAILKOSM4rp9RFxc3qamsQNvFDIzLBERdJKRt+T+6R1HPXg0l7+vYiMeaOnQ5HXkWDWLa5W2s3+2XCx6hdQl1FzOzZVguSqSsOrY5YDNdzBf29vJr0qQm5Iu1lnlDHG0qNxxjqqj58dwa5W7sWu1t20zUb7RdbitFP2wxl/MT+JmUj5X4+YYOD0qDwdqFjDHqAO+TSbmVrszxzGIo8R+Z1jPz7WOcg8EGntolb+tSbNO51GnatpCWS39pJcmwj/wBGhPlsMhiNjJ13oxPDe1R6XpCSXdjrtvrF3dMwNuxScNFLLGxH7xQOuTyfb2rS12K1l00M2px29mJY3yknlIFb/lmDxtBz+tWtUvrXQ/DsZuVS10+KRVSK3iLEsWyFwgz75Pbmm3tc1Wj1JNRuJrV7q4jafUtO+zujWtnEGcPj58nIyRk4+lY2n2+qeVoy2g+2WQDvcyXX7uWG3bBTA6OQeOeak0+7FtpN5Pcaa9q9xds0Vsz7lmP/AD1BB4X2NOh8R6fa6lPo2vXJFxdKYrZJSVSUMvOTj5T1wPSk9NRNcqu+o290Z59TXWoZpJoPKaOW3IjeKVV6E8EEDriuZ0VNB1S/068s9B1woJJQsj258jJPPmqW4XuODiu58P6foMPh+2/4RlIG0IEm1itpWZDKchm3E/NznNZkGo21zfy6xFb6lPqNpGLG4s4FJxHk4KhsKRn5twP+FSpXVybX1I7Yw+GLN4tHhtxC7A3CyXAjQb25wW68noPpTdKgEclhPqs9uurIZlXeitNPbq2TMhGSqkHGDz8prVl0eTVLC6t9YtbW80h3R7YRxsG2AD7+f4geciq97Y6ZputvrsNi9ze29o6LBbqSxUgZ2rnBYY6n3ptvoDiSwOniNbTVvD+oyT2CytDymVk7ZO7nH+FJqWo+TbJZXUTGJi4fYcBgozn/AOtUUV5AL+0sNPj1CS1v4jc25gtz5DKRn5jnCnPUHpTdYuzHbtcW2npqkkbAtFBIPN3AgYXPynGScGqTsvQtLTcwbue3t9f01dG8Qa1ZanqKC6SC3JlRoiu3LKQdgx0PTP0rrYI0/so6fDMRdRxFfMlG7APTJ7tnmoLbTtLiuLtNTRy1/AkEjlmjdo1+6uV5UDJ4FY3hv7VDqEtrqGm3MzQ7oIb+xfFqkZOVU7uWIA5OOKl+67PqHI09US3b6rc6JGHa00jVpCABLL54ESnDSKPcc47ZrUvtMefTo5Fjtr+6iXEP2tQqux/iwB6dxUN5NetqC2rW63FptYS3K4YxEDOMdxx1FR3muILVptt68qBfL8qHzTzxwD0GO/tQ9EX7O3UZbtqV3q0EE1tYSiSPM9zbAhbZl5C8/eGKKsNEJLKJbcRorNh3BwzkdBknoaKiTEouOlzPhuWN54h1S01Ff7P0q0CQwMCXMirliynjIbgY4JrxSK7u4JLfX4lu7RJpD5+p3gDNeAtl4gAfmb+ELjmu2+ICNJ8PdUvrC3vYzHNFJcxHCRqob5WbH+1/D0rDhh0rWJ5L7w1DizBjuYsKRNb3e35/MXOF5yQRwc1lJ3ly3MGrM3/skV1otnrKzXCamXMFlefZtktqzPtI2r8q7QcE9B3rt5b6WPXZNGnDvBYoLk3tyAiqxT5QMcOrEZOOlee+G5dS8IaTeSajAL7Q7eYMb1Z/lma4xlVPTcDy2O1XtW8R39nq+oW2ow2pFhaC4tLIMzZfdtI80gAodwb2zxTUl6Fxa6m3b6Pe38Fnc6jODqS8yWsEhNvJJIf9YxPI2qBj0p8cmli80zxDbM2prFOTcwyAnBQkEJuH+rJG7B6HmsnWdO8X6to2nWP+gadLcxGe8jiYllTf8qIwPI2g5HUCta/k/s+0vdTuL1L66UNDZFtkcJLKFVBnop55OTRdddi7XWiHakml6rL4iv49Iuxa6gv2h7eMmV5XGBujVTgYUHPOCOad4VjtmMt2kj3N7au0Vvb37YMEYA/eRjuvzdRnpg1NjS5tOi8MebHZ3Vzao81tHOfLECjn5hyFLZCjgmqx8VeHNJujZ3a2pazBy8mTPDGQBlcZwP7wPUUKyRMrK1i3qN/qFvq1tbRrp95pAhaOcROv2i3nOQXbk5VwQCD6VZ0/QdLtvtiQ6ZuGoASXUJTAOAFAJ6hABwo45rnbuxu7aKebw/4MttRvtWhU32oyz+TDHFuDKpOR94DJPXGK6OTX5PtXleH5Lae43JDqUi5ZEO3mOJiOx/Pikmm2mi4yu2rXMqaNdHh1Bjc+Q08H2HT7aNxF5QHKrAAMtKSD8xPbFZ1v4U1KeTw5/a969jJaEzFo7dWBaU/MLnnJlxjLnvWnofmWviKHTDaahrFnZ3Uou7u4RUKShdwSEKCzYyBu+tYOtrp1r4mgto5Z21PUJJFvrazv3WO2bZ8skyrnDA84yDRdGckn7yH3/iPS7CDxLaxw+VcW6+ZeG2h8m4khB2lg44Iwe9aF3ax2Him1u7Py5b828NzpUkE7vNNbBQu+UP8AKGAJGO+OBms7S7drDZd293qlrdalGhmW409p4JFhUgh26puJ4PPTkUaB/bGl6VJaa9pANtbRzCLULaXe7yD5xlDguuWAXbg5HSrvd6/kS3f4gsbCxmv9Ai0uW/gt3v5NRuJZrd0IGTuVnB+VywyEPXODWvqGo3uj6L4c8MeH4bXTtb1W/ubi4kEnmeUzSFkZnKnDEYDHHyjIHOKx4b59L8m9sLJ2is9HnmeayYukcrtkvtPBlySQGGRiqVlod5cWOoardaN4kure30hRGGmNtJcCbsXP+sYY3MB0okluzJ9ixY6LqN5pg0u3t9Ht9W0zUZoruSZQI8OCQIpG5G5gQB/FuFS+Ho31MT6RcRPbXGiQS+IY5pYsJc3W8q7A8gLjjae4yO9Y9t9vOk/bbKGC9tJnjl0+MHzXuGRfl8tG+ZpF557YzXcy6BrWtalHaa21tbaFawQJb2aENPM+OJJZB9wB2Y465oeqViuU5nw1bNeaRLdprmpwapJKkkV/FDF5pwpOwEAYBzklumBU2s31/JYabey6tNFqELfY7a8QoJr5mYEQKVAjOTyc+p5rQ1+4sNL0jULeSzk1Bbm9j8qCR2f7a+QAkcagEgEfd6nqeK1Filt9RMem3F3rGoRSSwRWN8QthbnhncKBxs4QBeckjPWqdum4ONtGiz4O0rVNN8Tapql1fQzmWErC1w4EltbkkH0+5yABxzmq+kQaJpniPWNO0rT5HvUSO4uLieQKLqJgdmD3VepUdTVS9tdT1Ge88RfZ/Pu3drax0+WRUiQ9JZCevl8Z2nptAFauoGODWtNfTNI+1XMsSR3GpTPsEW3sq9ZOeV7U7Xa0NacW9kVNLvrabxhrdtHcWs+oPEjTaUsZk+WMAqZNxxwDzj+9iuk3f2etiuj6d9j0yBSIbd7fCRBhkGPB4IYk5bOenFY+nt4fi1iSwtobOfVSGdraN1ikkBOSpboTnkruroyl5fMkcstxaq0Tts3gxhR0X29B71Vk3qaRhFbGZetZT3en2eoaVd3t1csZLzUTOUe1bHyBdvVyOf8AZHWsmy0u7s01Ndb1G41aGec+XNenE0cOPlBZTwfpVrWX8N6pp2oeH9Evp/7cYJJq2oWzOslkqncWJ6buNuB2zmmahrz2miWF1awxvfwD7VcpfKCXQYA2KP4yuGAPGTWcJRbcrN2NFJJ87RX8yOxt/t+iadcXQ2m0SKa6YqF3biwEnRc/xYJ7Vq3WowoE80rBHtEjeawZVwOzdzmjTVvNZxq9rd3luuCbeO+AVoiSC29cEO2Bj+6AeKd4l8SGxs9Nn0LT7S7l1K68l1NtvlMWDlFOR94ggN2Faqo4/CiY1Y073RDc6xpgeCaTULQz3AENtbxSb3lY9lUdOB1PQ1nat4gk0ObV7uTTLuSzija+upGcRI8oAU8Dlm+6Caox6La2+kxSjwtY6NLhbS3SSbzp4iH3MQQfugd62fFEF7a6DqthLc2KxXUAmaSQEqgXDKshHIUkE4UZ9aTk5K/UhylJczMDXrufQ0n8QCXfqqRWsURKg/ZLa4bDRqD0BOcueeapWmm3ut+L9KDX0t5YWmrELM6L5kC7DIFTjLYxgMeldHeaL/wlfh9zPCIZdZtLeGS6j+9bmJ9yMAeDGSc4PrXP6bFJpvijStTsbq3aw0QrZ6hI0hBeZC0eVHfnqBmlq7mL0epz9zqNreajd68ts8n2iJ737K0YWe7ZnKKCcnOApBYjuKu+HrrWbfxtZX1vCsUjIjSsB80cr4Jh2+y9se9Xvh6g0/VNK2a/HNffZZri3Ith9nZlLPgk4ZQxbnPoO9Fp4p1qbx6g0SxWe6jnVdUuJUCxs0/yt5Z6jb1BUE/Lg8VXNaOv9MlfETaZaW2i6l4hu31WO51DU2Em24VflTeX2rIeWGR07dq7q4gXXNJ0+TZbXFhehbqBoRvjmZF3Jk9QQwz25rjtZ8Ivp8kctjaancaTbPNDNJdQFpmeMk71A6qWO4NwCM1Dpl1e2+gXur6d9i0qyuQzNfO+6GW6GCuecR5xt5AGTRzRcbxHF20Ohtbn/hGvDGmXHl398EZTPE/zTOJGPmFvfLHp2FaNxayHxCbi01WG50CGI232eKMB4Z1IO4v3I4BFXbB5tT06ynvtOW0v5YxKLfzB3wQAwJDfUHnin6aIFe9i2SxTqzzvsUDc2MuXXHJwM570aKz6HXaNlK9iG+tZbyGNbe1tPtakMLq9QuIgDztHZjk4PbNE6SNpcsMNnHeajbss1kt0/lxEjhi55xjrkdaLe7t9Ytbe703UIwyuVaHLKsueBG4xwe49KjntbW3+0nVEuIEvVaCS6kYNG8eMGEbTnr3wCCaJNaoibTTUUZviO/GmahG8eipP4hW0VH+zLmCPdyWTPAz0JxnAAo0ODU9QllXXpLfdcxhzHKSyyYHICkFd3A/GnaJdahda5qFnc6VBa6VAqPZTyTF5Z93BQnucAcY4roZ7d4rSRmtJ1SNQSRnAJGMYoja2o6dOEo3e5y3iPxZDpOuxaZaaRNe6rJbLdWkbz5SfJIYHHCkYPFalpPDqmlx3k9lFp9y8ZEaTnfMGzgh2HH4d+K1dT0O8ivVu7mN2SG3MSrHOsYuC2DuOBkNjjOayreynsb66uY9M0yK4njSG4jYkrIq/dJy33sfxDn1qIyb2/r/gigpSej/Ewteur6OGW0me+ka4jCQXoYPJalvl3RA/6s46k9u9bdtqFvLBE9pNPKLZPsF086BXMqgLvb+9u/vjvV8xrLp4lsIo0uZEKpLAAWgY/wAPP38ccHg5qKzltLi4uow0apJCY49+VBbGD8p9wePar0vdFU376ZSttHeTRLNLu+muZbO4EyzxsVlbaTtJx3wdrdmFVzaxXF08thdq62siy3MEfltIF7oe4QnHPWtCwg1C01C4kmkWa2nMRgeNNqQJjafMPXJIzu98UzVNEtdN8Ux6rBDDZ6iA0E8qpk3MRHCk9ux3c8ClfpEJcrvylKbZqOpDfJZC1dzHeafe25eX7vylGU4Y56k8CtCS/t3v57G0AgvrdY/t0cgcLGCvylD0YEDnB4NV2t3+33NvNYrHFZxpJHeh9xklb+FR1B6HHfrTdLv2uUnWGBXjguXiEgJCSEDBLlgDn1x6cVKd3uKN3LcdcTKLs3d1HE1jBCscMf3XeRjhgPY569qoWlt9quZ2tbxZ7TTLkiV5tOUyqSOEV25OAcbh2rO8RatqugWGYpJtWlubsFkWKOQQqcDyyp/1aY9ee9S+IdevNIkt49a1Mx6fqsSLb21ta7VtX3BWHngbRnHAPOPrScrMyqNcx0STS2ojs4RFp68mNI4wUfPPIHHPXNc9Y6pp9hcT2Wn6xqLahdyvK0N3KBhupWIHhRx0HSrXifULbSp/sTQtqF99ma5tra3j8x5IlOHkMjkKDwTt68UyPUfDN7Z2t3/ZDomFMd3KyO7Z6EoOQvXBBzTum9BtxlaxNPqEzWkc181153DCJF27iVyqjoCT0PbNUXu77XbeyhuYJ9Lu4lNxcRWso3x7cERt2DH+6TzWxqr2VrHpbW0UrNqE6WkLJukjViCyk+ikAjPY1CsEd9bxQiMWksd0ZpZsqyXQxtG8YySvaquPlcmkVvCFzJbadrTzWV9Y3MlyJEsru5DY3AfOjAYCsOSBwDW3NZ2dqqGzigtgzl3SI43tjLFvU9veqd3YC4gnt5XIBiZQVGGBPAI9BnFAvTFYQS6+sWmrbxL9td5Bsixxy3cE4+tGkdzZ04wlbyuQafLbpqZlmS83tHvRn3LHHk9CxyFOeg/KrpvokuFtHnUS3A81owCyEA8jK8Ejrisbwbrt/wCNNR1mKS3aLSbaQeVeKqk7P7pJPUDnp3robqxa0ZAGnkhzuUh0Tjt05zSU77GcJ9EZZtXk1t9QjWYWxUJBJAW2v2P7sH7wPrVPUNDul1KW8XWHtrmcL5sX2fczKvO3aOBn17VsXFtAtwjAxR3VzuW3inYlpSoycEenUk1j6brq30t7YG2uIZ7Y7J5BE0cMjD+455K1PMtmXGEer2Lj2lvd6p9qs7Dy7kxCEySOSAg9ew5PWiszU9MinezvrmK7ukhcMttaTBFGP4yDw2O2aKzVRW1KlPlfLF/hc5671O/tNMg1y61S1tsnzt7WjSRTwk4CPEf4jnBz9aw9e0S/0uC9l1GeGCyIFy8VrAIgwxnbKFJ3LzgL+la2kWFtFZ3tlpUl3fpb37iTz5gwllx78bcdO2awdS0eSWL7Rp2tf2HZ7nF3blvOeR24JUL8rE8gZ6VDVtf6/wAjllqkdzpeuQeJNO0i9L2P2Szg8o6fCpSGJh1cIPXj6Yqhd28vi3WtYsb5Li1sxE0Ebx7CbpWA3SliCUAUDCiuYS0c6XLZ2sNzpekBPLjtxNtkkJA3TO4GS5xnH3R05ro/C91pmqfZ9JuL+EHTCGiMk4i8yUjJy/QuFGcdhURmvhNeRqK5yW4jg/sEWUF1qVwkC/Z47i0cC5LdPM5xtwOp6H61HoXhWz1DTWivz5dut0r/AGUTecgKjHmrnjc3JKngHOK1X1LSpI5p9FMN7FC213ghO+XB5XIHzgdeKkh023ubdr3QbY2UrkMDJuiU85Py9d3tWi1epTjFq5HpvgHw5cTSSSma8uhvIbKobWI8KAFI2gDkE+9LP4Zt9M8Q6RqOnaXZI/lvHc+Y5YyRngNkfe3AcZqHWLfSdKe/vtTa4hFxLtadAfNmJj2bEUck7SRtAOOvFa2kQ3Fnpel/Y7eeGxto0gjivIyHMbA7BzySPf1xStZ2RMUm0mSanf8A2e50nS4HZLG9lMt0dv7m1RQdobHJctgAdMDNVLe5sPCXhe2utVllMSSEbreItLczkkqiL3JJ6ngUlzrBkutT0jS7cjVbWFZ2lniBRF7bTnDN6DpS3lotpZWmtaiyXF1p1uIWkv7jy0dm+YjA4JA4GB1NGquW5KN+X7zn9U1RUt9MvvEm631v57ezhsbiYCFWO4qSnJkIILH8Kh8M6RofhxtEuUvryS8v2ms4Z7myktVeUkn51/i/3m61XfX7zT9c0i407Ube30e0hkTzLdczQ3dw/wA6vuHzPyABk8Lmm2/2iLw/rdxf6ubuwt4m05PMuy9w9zI26PYzfIj5zlgTxxxUp2adjkb1vE077VbybxDeT3in+zdHnQTMjSBreTZlkh2nEjk84IIxxWrpNmsurPdyW1y9lclLtre5kWd/OwfLcr1h45ycZ/CvM9J+2re3Gny6lDcXF7GwRpbcutu0Skl1YEbdqllB7lua2J/GElpolxdQnWYvEt68du07Qf6RMifdVxnaRs/iHTtWt+rQldGjr1pqGgTXUesNHaaTfeI7a5it4Ztkk0aoQxZQCfLyMnoec1BpUWoeN/HNxq9/dS21vZMrCG53FLUf8sti52g4BGRnOfepLYibV/8AhKLwk6RaBZ4TMrKIpAPmxEx3/N0LNxnpW3fvrV9a2eux2d3fWeoTRrpcFkvlhVYHeJkHGYypw1UopPUS1ZJqs0+s3FtqzabE+kW1sYIJgvlTQlj8zQqhyAeMjt19axfD3iHSJvFWrQ6yLtNWtJojDOu9/tECAAYXIHy5LH+8Oa7q1s7TTnfT7B4bd4x5pgUBWy3Jfb1AJ79657xhqkljc2s9rbW8+qXd0qtp/lI0lxb42uEY8xpyckfSm9PkdM6TjFNdTS0hNK1aUJZa6mt3to7/AOlw3AWSHc2cKwwF4447VvLC1pJPNFdPCsrb3hsRvVT03l2+Xcfbise2udD0mWLS4rS2tnIykEKiMqCeFxj6gHvWpbWNrA11PLJdTz37iSOCGMMsSjhY0BPTgnOOTmr0VrlqKTta76mTZanDYM8ej6Y01jbyF5pGf5ZZGb5/mP3znkgDHGK5+Dx5qVtbTT6xod/CpuJVnedApt43x5aRY5dmzwO2a6DW/FugaVe3Vt9tuJZbSUQTQQQeY6jGcgcD6jPFXdK1208TD7Vp983lFQqWtxbGOZQDzIScgDjAxzSUruyYSSnaMH8jP8Jw2TzvNZ6Ha2vh9fMZJbwuty0w4YFG+4M+/wBKn0nVheeMJNOiOoWipbSxvazWbRI0yMCJFc8bADgep5qfTtZstUu72PTZJYrvTpjDMZFzEeB82TkZzwM8k9KNY1F9JePULq21DULuQrGDGu9iCeDtB+6OpJxnFNbaMF7r5ebqa8Vtptu2oG4uoLe0mdYmjeVY21CY/wABY87V/ujrWdq/nXEV15FqZp8DNw2AEfjC5Pc4AArC1jRLbUv7O1+S1l1lfNRbSyWQLcRPv+eQITx6454Ga6/T9Qs7uQ3GmX9rcW8MrR+aBujR1OCM49eppQsm0jZ2lfuc1q2nS3LQ3Gt+IdRSe2USyW9vOY4sjkqcDLD+fpV3w/qN3eXU3iHS9JvL5FiaKW7v4jbrJkfJFax5yqg9WOM1bm1FLW5sNRuJobTQ7V5WvVnQmWZ2GEAGOAWOc9QMetXY9U/t7w5KmhXUN9Lab7cqk7JCJSSVEjA8gZyccipqWbVjnk4LRI5rVNM1TULWOWxZbe/dS5/d7ixAOY8k8JuI+b2NQ32saxZ6d9tubbTWvoIQ1/beaHEknChUB/hxyxH0FT6JrskaS+HFiZbyxtkM9wswa3dzyfnY78ZPXoK0YtN+1W6W2o2ltNeOEe+VV3x5yMBWOMoBjgda0TuhuzTcdzC0BNSW10/yluNG0jTDLiyaTz/tkbcqxK88MT8n0zWZr1qAukJb/aHjeQndFBlkkkdjuZF9Dg/rXZ+K9PM9pp1rp0UsaR3SXbmCX95EEJO0YIyOxB455rmR4qSwjs9WvH+1yxXUjzWmlx7AsqyFfs6k43ABhlumc0X5Uc91eyOd0jT9a1aO1iMVovls4vpkAREweCo67GbGSPQ16lpllImiJYaXJa28kZUG5I3zblPVD2G4n5hzXGaDpd3d+C7/AF/RLiJreW4ks75FAZWiDn5lPcjcFI9q6nUtHiv/AA3b6VbX8sMAETm4gTdIm0qxUdDztxx60OXNHTUcFuVdE8Pano9xcGx1i/XUWfesj3e5JWHXIb7/AB1CirU3h64vvOS31GC01SVDJN5Vsotb5RncJoDxg9M8HvVjWYPNv31gWAvPs8SiC2jXEyz55fc33Mr27mr1hqFvNZz3CajZhJX2XE0silosH5kY9sHg8dalq++htyL7Whz+nm90y1l06bwwtj5QP2VbdibeUddg67D6HNZkGr6LreqQWE+qXuj34jWWbTryAoODkfvAeuR07107axC9jJPp02pNuYmBYoy8UkYOCVJ6k9qyNTisbzw4sOtQQXemFi2/UgfMjOS3LcOhHJAyRTfN0JuvsP7yDTtcs7S41K8vdRvJWurncUurMqVO4KNoQZMfoecZrqpJYondJYEgnQ7ittJw/wDdbB7+pFcNcabbXnh9rqOMRadFErQXzXBmg8kDO44G5eveuk8PaUkmj6ZLc3yAshzOs5ZDk8bS3OMY60Ky0voKM7+ha+06vc+KWmMWn22ntEfITdvkml45J6IuKutCNDjdtQkla3d/MaaQvILYg/dTB6E+tZeo6xq9hdwWnha30i+vpi0YhvmcK4Xq4cdh39604PGP9rXd5ZpoEtvfQt5DPKv7u5bH34CTyM5xnnpWbb5uWxLepQsU1Wz1e6WGyebSrtvtP26TUS80zN16jaEHQKMYrQkW0ETefmPg4juk3Iw/3sfzqppYtvLEKXd5BPAStxHIQHZx1zGRgZzziueQ62qazplnqQt9csX86C3sZ133ELAmMmGTcEf1UcMKafJojSFRQWxu6FpN1b6hLdw6p5/2s+ZDbXDqVtOMbFzjcuefYECpvK1RbnUZpb+L7E7wiK2e3WJLQ8q5VjyS3p2rz6P4f6xqE63nizVDqtpcRf6U6ZimickFNoGPKbPykYwcVvPrGg+HbMabrPiG/M6qssb6sfNeTdwBGR1xjoehpX6tBGV7c2x0d5YE32nzQSXSfYWlSOAtthn3jBWT++ByQDxmo70zX9zJYPZhtIitpJ1uvOPmxSIOFK4+42cDB61FoniCTWPDqajYWtxHZeaYXGpAeZGvTKRjrntzT/Dmk6nqk+u295dukk/lCFImHl28GT85P3vOP8S9BxUzatctNJ3Zw0Hj5rjVX0qK5LNaqkgAPCsflC4Izu+ma65Ibe7unt9ft7ibT7l081JGdRGf4cYwQCeScmpvEfwp8IaH4ejl1L7dfXYuVdJvMxO7kjABHYcn86Wwe9gjuLW4uZbnSn4W1uXMjRY7o/3gPY5qKU3UjrqWpc6aUdDl/EltZeH9Ju7fR7GG/tri7Y3fz/J5vd2Xq5U7fkJHGK3NT02K5t/Et7olwq6hcW9vLdX9xN5NvNAIwJBEOUhfACliOP1qybLSraNjbz2nlTP5ksMzjDt/ePcN74zS3SLf2jwG2tpbeQbJY5HKrKhH3cDrx61Uo3Whk6Dex5R4S8MaqNegEEunanf2kM09qNPvVuEgDLhRcydABnIXvkmtXw3osU/hAXOj+G76OdpjBfY1L7PFuU4Z4Vwfkx07V1F54a0RI/KNiLSK4kDGS0ZoHZl+7uK/eA9KuXqlrfbDqM8NwBhZYog23t0I2nijlto2SqD6mfaW09t4UFvJBcaTGHVYUS4aV4SG+RmlPUtjOcAc4rr4zbxW12wmRlZQ6oi/xH75Udh6+9Zt4p+zsWTz5JEHIwQOMDIH8qoXtzHaIiBSkpQJNESHIOOMjsPbrWjbirnTTgk0rnS6hHZixtreeVvtN4iSI8cZULGM7ct2zzmuVRdTHhlrC3itbieCVy0+ruGiUBsqOOXx0Wqnhxb3N5Z3t3cSWwBuooJCX2EjG1AeVVv7o6VY1GBGgaNvDb3ViYv3o88BN3cYyG44xzURfPC76mcocju9y3JcrZRR2+r3FpC8jhmih+VC/fGOo/yaZqPiKx0ya8W7k+zPCFCtOm2O4ZuiQseSfwqhp9t4ZuYbOObTr2Gex2+SojMbhRyRuyQevU81oW2k3l7rsGpXdyr2UO5rWxuBGzh+nmFyM5A6AdKp1HL4RpzaslY1reP7SkFxdW0kcLKG/eoVdQeoH+eaoxQeRqFx9ru0nsSR9njgh8uSMf7TEnd9MVena8nYpdEyAnO8yFuOw461ia1baoFnh0ua2t7wY2vLGZI2GfmHHOcfzrKdR7o1cXa0mTa1NqVnd6c+gWtnc6W7FLieUhTCRyNsfdiT15HFFVJm3CJo9OktmB+YrMXyB1KowwMdaKyU7bv8iFFJaox7iVNItTay6T5WnpA9zNfLtxK57P3LYzgU3SdKtlgF9BpMVpeXAG2M4+RMZCqvQE5yao2D63r88d7q3lWE6L9oOlKpEXlbsAt1yx64JrpLG2Zr6KK/upLwbvMafb823du8pQOwA59q0clYxprXmtsZNrpjS6vavJe3E9tI6zSG4ZVjQ5wqoO/TPPOa17PQbIWzq9pb/aJJ5ZGWGAd2IZ8dckY5rI8eazZ6H4pnfVtO8vRk2z6Zc2rCQqzf8s/K65zk596reJdUtNQubG6tptQsb+FdkcMkZH2jIBEmQeAnIIPGcVmpJXK9pdqRr2SXugWi2tvPBe6fCXObhDG8EZ5VA4GM5zjd24rB8SaylpqFpqJhvZLWE+ZJJ5oMUCjqWHc+gFL4A8Zah4YGrwajpVtrUOqSBYHDsCzE4UOhBGzOfm/Kn6h4b12S5t53urO0ut5aW2WPfAwPRQOwA70nVsthw5padDZv79ZV0rUrK1gurjUpY47SW6i3vCrnLuMcI2Oh4zWZPpcGi6dqF54jnmuYmuhe+cZ5H2Ih/dgg9OT0HBra0nUbTSfsy3zmC5vRIgt5EIjkRerB+R/ujg5rL1KSx1u20W9S51RrFZTOtisJIlC9PNRscA85NDfP6jvGOo3U/NtmEum3MDt5ZlQXBbfPcsCREe21Vzx1zWNb6fBc3XhU6wLzUtRv7pL63S7uRHEib/lhZTycYLbccDA71s6bqczvcXGoacE1T7PLfWtpFiYaXbxg4upcn5jngKOp46Vz91rVhqsEGonS4ry6VI7e51K+la2uLjcMiW3RR8rE54A/hqudSOapvoVbK+vLr+347gQw2iXLx263ECkLOJS4fH8O1SBg8/NVu21bUJvCOpaZY6ZNq+h/aHeeW5tiRZIoH/HvgALlycHsKwNHht5NF+wXhkLiWSOWXdgEE5BGBycAAk85NdNrXiPXLN4mt7iTStAsrFI4dIt2OwxbsebKn3iWPQsPmxV3uk2Z26GG+mzQ3SaW4g1PU7m4aVBFcZgWAKGYmQdVUHn3U1q6OdIufC0d5q+mpq8OlTy2+nt9rkt91muf3jouS+0nAxywqlp88b2k9wtpDHcTs9sbbOyZSw+4EHI3A9OnOKcnhnWxpWnPNpt4LeO3mj/s6aNXe4OekUakMxUYyBjA61btuOzsdHp97qF/fanr2gaF9rv9QKWEKzsklpJbphGjiOQyvg7sNnGKpajYarqfiSfT/D3icRjSzGbQ2k5FpBCnBQ4+9JkncfwqfVLTT7W20LR9J0+8j1OJ1v7q60iJolspXTawjZyVUkDLLzgL61d8EWaaNc3ui2WnmWGK1SaW/K48+R2wFC9z1OO3WhO++w6cLu72O3sZ1uHEUNus19sVZJUh/eSDrw3XGc4HTmqX2K0n1UXskcL6kjG13L87xLnmNSO56k9OajutP13W5ZBbXMtloKRr9omshtnuGAwUY5AWMDsOSa09Hg0nRLe3ttHjuTb26ERRsoz6k7iecn1qubWzOxXT91HIeHbMW/iTVdSvTLqepzSyxR6mVAtrZYzjy41zk4zt3dMg10y6/Hc6ydNiv4rvV4soUji2mMbfvBxgYxxkdzXP+Oda1G3t7Gy0SOymup3TzvNbYlqjk7JHAwSGO7AHpzWhDGLaSaK1t9GS6uCr/Ir/ACn+LBPYnOPShSSX9fgZxWvLDfq7FkCxsr6xhawM8moySqJ1gEiReWBu3/3RzgdSTT7nRlup0+z3cllFHkrFBGvmT8YG7sig8+tXbaRp/LJMs0CEhfLUIM/xdOccfpWfrv8AaksMEnh+xknkQmRLc/LGUB+9IeCQf1q+a61ZtKThdlXSNF8L2UOrQW13c6fLbxm5ubu63CyeX7qYY8Oc9ccjFQW93c6nanR11uY6g1xDDqGuWcCxK5xnEJIxtVTtDY9TUN9BceJ9CudIngsdQuYIxcHRLKRlM6Fhn5/uqQTnd3HFVNMk8U6XrWoeJT4dlOk6XbFbjQBcoWgVD8gXAw3QuWOT2FZN2bucKkrnU+NNF0uLToLXSpobtI1EMV1d3JBQg7ZD5vUsec45PauWn1jWbW8tdJtrK40K1llNrb3Vsodnm5+eMYIC4H3m6Vc0bWL/AFiRNautNs4LdWF7Z2wYhYPMHDSMRhjngBRk03Up9fso4vsXm61ePKRO7ny0QFuqIDjavU8knFWlaKW5quZq/Q3odMjudPurO9gmnikjZZ5NzF5N3Vj9en1pYNMttAaysbmzj07wvBG3mTfaBEsE5IEaY53FieT7Gs7QvDl8viLWLyG+nk/tJQhtiP8AVqMfMT+eFHTNO8f3/hDWTpujXsmrapFcxE6eNPQqiSRFl3Oy/NgMSCSDg9aJz7Iqo3TjbZmVr+jfbzJo9s1lp+h6icXmoRsEluJAN3lwn/lohUc45PPArXW+svC+lxSQXF9eWt7Fcajb3zjzbS0KgIRv5MYxnAx1FZnhrVZPDnh7XLrUNOii/saa2tbFVYXlvaLtbE0QxzKdx3bTknisq8js4rnVv+EhS4h0yeeM3NpFOFg1I/eSVFz8uBy0Q+Y4x1qVJs5XJt6kGkeJNMm+GN5ostpqWqanawy3n2yzkHmsI5R8rHO4ABgxGMEZFUdVlhihOjXlx/bU+mRrcXdxH+7E+8FtiHoF5256jvXR6Zr+lw67r0Or6jfTaHNp6arHqFvbCCba0mCsoUA7QCq7T261hWbtbeEtRtpdMWwu4HivJwiKkAhdyscSKCdx2sGYjgcCnCWok7bj4tbksLaCSznvYtI1BIjLDdRmKSONlI3FRjLJjhgMNtBrudIv7M+Bra4TWHto7jdbWWtyBWYNnarsDwWLAnBxXnl5fT6lZ3d/4ksrmTU0R7We5tNvl28aKDAGiJHD9CwwB+NaXg+9ttB8GaW/iJ43tNXIk02xtoA6gH5mYn+J89s8AetUm37rNItLU7TRotchvILFJHvrm33PfaozeVNJu+46pnaVB+8vYcitKWTRrrzorDT4NQ+yOFubnYCgmYcocEblJyc561R1wzWmlW96lq1157KsKSS+SGHUgsc4cDop603XG1vTdMurjTLSCdmdVgeKPEZQjgyp3dTnj8c1TSvozaXKndO5qI80OHSUwNF8j2TrvgYdBt7oR7davDUXXcFit4wq85UvgHrnd+lY1ncazb273GoWE0WkRWglfULt44gZf4gqgnCfX8K0rXVorqzjaG0haKUZgnX5g/HfP3lz6dqLxlsXDk6RuVbnXtNn1q10mfVLdL6VDIsCxgYRRy7BRgAAHr+FZnie90zRhOLIXF/fTIot7NJEV5dxwM5HyjvzWy6zm6Ey28M14U2tM8arlQegIHC+gpptpZZ0uxpk0dzHGRuI3BQT8z7vTHftSvbqVOE9loivoOmRaRps9vc3c+o6rLGC8eAEtB12bvUfrXI+NvJ8SwWQ0bVWiWO23yl/9U0u7AVXHPy4PTOa7GV7eG1ieS7s18xswQzyCN7k54EaE5bp1PFeRfEIzaJ471SK7tPOtXjF9ps/nNGLdm6Kyjjjng8Z71EpRvuYTilpHU7DRbzUDJHdeM9e05ltbWabyZ7Z1nEcJAEoccOvI7ndxVddbTxXo2o6ncMJIrRZLkS2Fqsd/Pa9AqsDlPTLHPB4rB0fUdP1W2g1a/jvtTSyiRBbWT7lnuPMBxszgMFY/KflbmtGWfSfC3izU7yL7T/wkcp861tk3WdiIyBtiuGPEknJOMcHAolKxk4tm14M1ua+1n+zDDqluJrEXFk2oSLM4MYzIolHOSpB2tnnoa2tQ0mw1TXNEv8AVdI/tCK2E0KSuV2RKy5Durfw7v4uxzXOaTFrltdtrf8AYSabeYcy2FvL50t8SeEQn5UjYHJ6Y/St2/1O0vrJ4PEmmTDT2QW9xawyKGGR8ysR94Z4FPpynRCnJx0RU+waxqFlEkd3bRXsBIgaCQeQsZ+7tCj526ncah06y1bQtPGn6feXVgFna6e5gkLSTyN95pHIbcCe2BWtb3ujQW9nF4Z0XU/skCFFguh5MYVemGGSw+n51y3in4l6xb3MNlpEOmQahM3yKbNnGQf4cnkHpj8RWVSrGKTkjVU01flv+B2sk+pat5D33iW9txGgDpbwxsJ3z1zjgdsDFTT6hATP85W6c4MnlbCyjsAPvf41yUuteMtQsxc6hpOnfaIVxmKIpk+u0nkCqPg/VNT1zXVs7vVdPncH5bea2+ySkn/ln3XryD1NCqR0drDVOMd1Y62XSrHULqCWbTIpp4fnjW6Ox9w5YjaeuKntoFntcXlvAZVYn7RFuB25yFwOAQO9Q3X2i1e9nublY9Pjuhbxyw8guByxJ5LZ9O1SyX3nT232LUbuN0UkwW8gKsf7xAH57ulU5rcqKb1X5/mO0zT7XTLm4bT4njnuH86QNl2d8Y3HPQY+matyyvcgLJe+YoRsxKCR+IAqtFcPcfupbk5c5kcgvvHrx1+hqO6+z3sluY/Og8hw0e2XGD744yfSlzxWxXJ5DHgdIXNlL5Q6gvJtA45IFc43+jXsL3kENxaSSeWzKpUqxGS271A/CuuleWRf9ItAwHBd1BI/Km2lpHrTtpkrafv8gyWlusgV229SgPJ96znLXQpySV2dMNEs7jwxDNpczNNaEvG8qguFPWNsdR3HpXLa3DbtqUVpNdIlzMm9LWW4Ch1A52KOW9ag8LLrHhO6b7U0tzYSqSEK5BXoU9iKua3c6MZw9ram3mYh8yYEi8DCBj933ANTGblv+Jz8rhLTW5TkgvLe3/0NoY5iGKJgli2P4u4X1HU9qqX2qLa6NeXd68NwLdALkWuWkiG3IUD+HcTwDzS38+pS2E11oFlb3155i77OSTbIUB+cjB6gcg/Wn6fbAavc6np7tmUqG2g5YL0Dg8n0zVOVtzWU3KXKiu9pDrdvo19bXl5aW9rEk62sXyeazjnzD1yvYVNrdvfXEF1c2t9Lb37qAHXpnpvK9Dj25p2sw/bZluYr25skWQybYhjccYCt6j6Vnww3MUEl9N5zy28I8zKklv72QPT0rNyUdULlvo9+5li11qIW4t9RjNlHAX1DULhjufH8Izzk0Vvarp9vq2lk27hUljX5Ei3F8noQf4fXvRUSnVv7lrGfIr6nNLeTawk2nWQW1tYNwOwHdJcEYTcT/Ci9B75qbwpPCt1NpNyPK1cxK2BLgPjhypzz0GcVdub2wtpPLSK302yj5nkLcD1Yn+lcdpc9veaofFFvLM9rMHt7a1uIAHYqcb4yeEDe9NzTWhHK4tJHXa3o9unl38VowbTne4kThvtb7cYBOSAO2O/NZ1xJbeGtH+3aiJRDc3KztJLliiSYJXj+AHv65qa6+zT7YRPFp966hoxMdygj7wBU+lXY7eWaz/sy4e2mCJ5cbynqr/wnPas3KzszSPeIXGom7vbexsbNkjv4yYbuNg8Q29Ix6HGSN1U9PuLnTIJbU2eo3iLcskk1x95S3O4bv4egAHTFWorMvM9jfXNvET91LPEEpIGAvOVxVO91KHTdTtIftMtjeMjL59xKphVl5EUg5HI5yRirbvqCdjpo7i1urOEyQSyRhMIpIBQ/xK2OBnrxzWLY6oNQD7fIOnG9FlbXKxlpJOmV9AMnAz9aqafrEviKTZpmqaTJJGwNxDYxDKoePu8Hn1GcVr2VrCIJ7KOK5tYYmIUyqQT3Egx7091dAlrocP4q1yXS7jVtH0vSpbaHU5mW91IvvMkqqBsUD7sa9cdzWJbaFeXUmjSNOZ7+A7kKYU8nAX3Ddx154rtdc0DXJLq81LSrnTbiK9ZWY3Me7acAFYnB43AZOR1qC3ihS1hO2XRNfjLLc6ssisEiJ4jVTwGIIXeOR1FNO17mPL1tqc2l/LFHqulaaqWG+RbO3vraN2mkuuMpHG2CEB3KXPt61DPMmo6499GL24ukkiwkFtvn1ML8kryuxAUDBG0cDGRzXY2vgiw0bVYNQtmuGht0PlCZjLskZwzOGbBZuB7CuptZ5ry51aC6tEjtZm2Le+bmS7jI+c9PkHOB+dPns/eFGlKW55zpnhrXNRt7dpYYksprt2+zasiuUQ42yvJGQzFei5NdLa+EdP8AD9hqms2iodSsbaR4Z0dsM/JAiBON7EDJzyOK6jR49M0nSk0yyaBbKI4htstNgZ4DuQM9yc1zV1rl3eanbQ3tpPFPcJN9ggkTA8uPgEgcRq7cDPOBml7VWuaKgupFolqNW0bTpIvEEs+o61At/etOVZWAGGjhXgLzwxxxXXS3ttE0p2zSzYCH7DHsiteOAG/ibGea4zTJ7PQbK4/tO4trXWr0RyXkLAD7NuPypAgBcKxAyAPmOTXSx2+oXGlWbHVLzT/KkeWWC3txvVVO7lB/E/oeQDWqbatciMlA0/EOqT2enJYDSott5Ii2NrPciJG+XgliR5jE84HUnFYHhW4vfEdk8+q6SNMtJEZYYpHdLlypw0rDjaM/dHfFZHh3S5/s9v4mjl+xXl1cyPHb61i5a2jDEnYTnyh3wMGrWiXviJ9VmvdXkGvafeKptX0+RI2we5J+8APT+dEW49BJ63bOgs00uNhZsS9yA0iwllaQqvVyCOQPXoKz9QuLa9ubRNOie7W481Gk35SN0wSHYd8HIFTatcyy51bR7Ce/1TTEFjDabVt5ERj8wBbJYAcmqemeJbW81CWystNvJbeVfPSZsNj+EhgoADf0FDd1aRvCrd8qVjUE8Vv9nVrhLaeb/j2KSbZC47D0BHasLxRqtxZajLaWcL38ms3CpJBHNlh8vRySNqgjjtWhqGi6Re69breRLcXa6cnluwO0xs53FG6EgjBPUVW8UeG/t8CfYrv+zYQpiuJ4lHmuuAUQOeQMg57nNOM737jnTlUV0c5qNxfz2f2Kx1AaNq8KiC5g0za7ypglohLgDlcYxkZ6mrfwe1HWtF1i4jubx7G0vI5hY6FfzF/NkA43y4LbiATge9WNX+xeFdHl1KE3MtxYoZZJAu52bjhmbjqQKoaJq1r401TSo9Ctp7XUIFMzXkzCNRdyJ/rI+5RSNpPHXionOOz1Zl7Czsd0lzG6R3VxbeTbx25nSzhztUpxhS3OSxAyelR6zqt1o/hibULu2E81nEHNlZLjarOAQpPU5PJPJ5q1p1vq9zDNfeJWdp4YQjtKuwhycBFU84zk56Go7jUNM1SG40/+0LdWtLhBc203DqwGQ2P4gAcjrz2rSE+ZX6m79xe6S6DDYW2uy6gzTzanJ5EkmnRz5khOP3a7c4QHOT615jq97okWoXVt/Ztxq/8AZVyxtLmycw7nkJ86FDnLLvLcnqQcV6fb2l5fQatqmk6bHFcGEk/aYCDdMFKqH6Er3rwrxN4d1nQPCFjN40max1G9uUt7XSY2zLMq9ZCwOE5KgZzx71Mp2ld/11OavrbU7XwPYa1q/hey0yHS7XRPDlpeQ6jPezXEluUSOU7kkB+8WXuOpGTVK4luW1XVZ49Vju7W0ubmV5FEUjec74SZYSNqOqbTnI9T1qL4peKbuXTdH0CezisLYW8V5NbyOWiaaJ9vloRzIo67epY1YhsXg1XVNJ1SZNU125017lgyiEiYoG8hgvQDgEfezxVwtzanNaxFoOqQXOt6fqHiOKa2lW0fTtSvJJFZL5rgbVAjXodwGQMcc1R1WLWNa1SS2vNOl1ZpUkizor5itjGgQRLIQAApAJLd+M1Ponh0+IdAg0uGM2Mr3Fu0P2iYolrHvJkUN1MhIwAeea1fE0VvLY6np1u7aHZpeW8cVvql09vHJARgFTGvdlwUYHJyc1T0C1noYkMUOqS6hfaldy6rNp1rFazXEESG2uGBVnjlT/loyqOShxkZzW7qemWFtrrafa6zq+maDfSxyWMVrEJLC3Zx0MrcKhbnAxjJFQ/8I/qVpfz+FNOuIDcyGX7db2AEElspyyNCoyCTnDN0xVbUfGOh6Y+jaTbx39z/AGcxguraMA2seF27GIB3AdcDuKp2STvqFrvUtwSy2fiyy8PWmpoLyeJla3IjmsbiVPvSfKxZAV+ZWb0xXoKX+qG5vobiK1tNFTabaW3nLSbMfN5qnoeBjHrWH4f8OeGbe/u9X8JRRi2fK+YYkCRkqC6ocZGR2/LFadvJPsANpHaYkLM7nzty9m6Dn/Z6VUb7yZ0U6T6GB4rV4pLO/vLmeKzhRmureIBorpG+6rK3HQ4z71seBfE6alY/Y7LR74aZHEVEXk7VG08hMfdK8Yx1pyw3t68Ud6NM/sgAveghpZZ3BykeOijuQBzWbp3jJ7t767ttP1CW0gVgksatC80qj5IolHGOxb2pN3HP4rGsnifRLye4s9Lb7dcQFRKJLkHyvUlDhiQeCKr6hcz+ZHLb3ETNC++NkkCbD0xtzyvPfiqWhyXVqlre6roVnb+Ir5nnuYZmXzMdchs5JAxnNdRqetaZqOizaXqen2+mfaEMX22SETggjnaE5VsetRJ2VzWM2o2S5jEudL0+9u4fEAgtp/EFtatBDcBTKpyMJvAP8Ptg0zxDrGm22jWLeJNLnlhZfIlnjtGkEbYzllGW2nt+VWdH0uw0xooNFumOmW0SpHM6kOSB1PdsmptNvNS1PUdVtLOzuoZ7NhF5t6ViS5JGSUB649e9JzVtNDRU4xXNsym2k6RcWEUNvb2sds0BhSSKJoAI5B82SMMGI7nkVltpUkN1cyyXM0lvvjMUV24kS22rtHlk9Mjqa6e2g1C2t2jvYYp3f/WAyKQzH0weRSTG0t54UCQzXRG1UDiRIz3B7E9/ar54qwKEL3SuzntV1q20W0Uzf2jfXtwN0MFhmQk5xtLdE/GuZtZNTvvENxd6jDb20ECiS00UzLIYww2tJMOpP16ZrsDP513/AKLYyyBH/fGJ8MkfeTcOOOwNaGkeCLS71GbV7VLPTrmdNrz3T+ZMvoCT1bGCe2aylU5veT0HLli9WV9HstRvIfISIeUVVWZSSsadcbumK6SKw8J2d82o+I9Ut5SHWOzhMnyxEDAZccljXO6rpmmWWIte8a3N+sY4itcvI4Pqq/KPTpWdb2dtf6tJq81osSRgJElywHlRIMKqr0z3z1yetYurz+6hS5p2toj0m4Hh8LO+ntHLcSJiKK6dkiBz97JFZ9vY6ZpemxTnTNKl8QSB5BNBtdU5xvz6e1c9JNDdt5NvPHIFO75m3FT7+v0qvI+t2dqY7W0tjDuLRRFUVWJ6k+n0pNpa6sXsn3MXUfAnifXtVS9k1QCzhfzHnObRbeIfeSIj5RuzyxGe5Ndxc26R28du1/Ax8tAVs4wzcdPMlHDdvrXIazYxanEbG8miutjBp7O2uMxI+AQGjzz/ACqadDa2hS3t54GhG3BQKv0GPyoTcU2EaavdHSqRKWSaylhnALRNbwGMTqOoCt1I6nHasZ7mNby7TTrrFxZTLFe2VzhmgZhlD04BH61zEms3bQLJc306sZVljcXkiTQuvACjPQ9xjmtDQL62F5qEL6gupyzZnZrhwZ0PdWxySO3pQpKpsw/eRduh09tckqWlE3mqf9dEcgg+oPX61TeG3udRttRdkGoWDlo7iSLY8Z6dewIq3p01hI4w8mG+WFZZRuz3GO9YV/BNe30+nXkb3FoYyVYHbLH9DnDc/kKI62b1NW9Njcl1nW7mKWfUZbQMrERS22cMp43EDvXI6Dp2pvaXia5El3KkrSJPbyZdh/eZMY9PetW2tb21t4x/aEySKoG1QAu0eqgc5q097eW1l9ogtkF1nCndsSQ+jD2pe0S06EciWqRwWtQahayRy6adQin3nybywU4Q45ytanhfXLi/gaPV5Y5tRh4M9uGjeTHqn8LfTg1lax4f8U3OuR6s2p21tJcFd9nbzM+0DlWTOMHj8a375ZIrBLyd91zGBGWWH5yWPHA65PFJ7WM4O7uaVpqbaqh8qC83RoS0d4PKMhHde5B7etU/EPiG80lS2n2TXCNCr7Fk+bzM4J2t6Crtsz61YCaSJ7OVDsMk8WwgD+Hvx2q5d2E9xHapGtvNdLGyLh9zuOoGe59qym5apF3UviKbaxY6ZHBJdN5aaiVSCKJi7Suwz5Y9DkdDRUWn3cttH5c9k/2jaGjSeLiN/wC9gj8iKKnni9bEyhO+kin4rsv7Z068sQqPO6FlDDCRjt+PFYuszxWHhbTZrpbW+aLZFJaqo2xkdHyeSc9B9av3WqNea9c2FnbvdG0TzbiQfLGzdo93TNWH+y2Vmt9qlsLKJlEsyzhGCMB1P0HpVRqavyFKN9mZuneF7PVT/bt/cX01xGBHJYbgn2dSc5THY+1dhbWhkRIdLTMOwBZhtZ/16n6dK527tbfUdNjnvPIkhnj3CSKfBUA5V3K/dBGDSRjR7/Toby1DX32eMPBLaS+W/XkgtwR60n7wRSjsV/FOlyCC3aSOEtbuzkSkox49e31rmfDltNqLpHren2FvFJKXW6jn3KXx8hxk8e54Nd5b6nFcIi6k0d9EQR5MylD9Dnj2zTzDpzSpEi6fbRogbyVlR/LUdMbetaU7paBOKb1Z5/c+DL2Wx8uW4uIdVt7zfbXFuEHmIevzjBX6Dityw8FXl5o17a+I9a1a8urwRFUS4YLblSf4j98kdRxT5dY8QabqhsLTw42q6fz5M24Rg9wFPVce9dH4XvdV1Cwe51S1uNNl81kS3Zlfcg/iZjzknt6Co28x8kWx9hYrY6Fb6U86pplkm1PMGNoXnLN6+5rMu7HT/Et7aXWmTWOo2Vo5FwYt+FkH3VJ6Fgec9MV008lysDJM6S2knyyRMu5XB7H1FV7bSbGaOWGwe2so36QxRbYjjqcDkN796pOI2nsthtrFKbuRhNDftboZnthLu2gcbmXJOBkDtmraR38mrLHqFo4Row0c8koiDn+5gdvenaNokeiTzSaVbw2rSffazOPN9m9fxq7PdSWcYRbVWxnD3REnlZ67Y+gJ96XMoop8z6ixaRLLB5kNlf3eWz5KOoib/gS88fWpYYbayv1TXrKwiu3DTWelq3mTzGNc7jySEXqc1n6xoy6zCI9TmvosrjyhMYQoPTAXGKx9J8GWOk3k01gii+uI3xfyM7zBe6hs8HAx704ptkyUraDbubQfC9iAbSaSeWR3YWkLXNzNI/LBWPI64yTgCse9stQuPG9pry6pZaFGEEDWlzcmSZ0IBKrF0LsOpycGuiudMtfENnp5/tHUYbWCMJ9njfbJIO+5wASM+nXvV690HRJjaJfWy3QhKvFLdkDyiO645+ma10a+4lwb6WOE8WWt/a2ury6Tfzrc3M29owolmMXGLcA8BcZyepzzW1oGg6LrTnxBY28kdvcRRxWNpIuz+z1QbWjC9A27kkV3oe+tmDxXtv5YG1FkiQq4PQFsUhLXiySGeExsN3kyR+XsxxtwvXv8wqpBCmoSTaMC70C51MXNjY3V1b3c0YH2hWBmUjP3Seh61FZaQLDRoLKzTzJLfASZmwzyqeSccEnnit2TTLTULYwh4oYyDiaKRxIpxjIYngjrWdrdtrS6pYto93YQW6EG4eaLznuMcbzzhDgdu5zQ2+XXqabSukS6TJHLcJboqpFcPmEseIrjoef7jngj1qV9txLcR3EAVAGikGNg+mPXOazNTFzHJA1rPFFZRq4lg2ktu6h0brnPanab4kk1i6lSwljvNRxtLhAhTA5LluBgdT7VC5rW6F6J3ZH4m0S0k8OrpVzCJVuUCItxIdsabsh3PVuBwK534WeELnXbi6utDuRaWljMPmkXIuD2QD+FcDn6itq1tP8AhIocq95JJPK0ZnnjMYlXO0lAeSvU7j1xXoln4Nk0G2c6ZqjpMmPKB+UbAMFSB19c1nODlJc2nYUqqhHR6s4rxnYfEaDS9Xnjg02W6ubpZYbhAz+REFxsK9xwCD0HNcB4K8H3cOqNqWr3dveyXz/aZrmGTY+VHO1OuA3G7AGK9L8VP4nvpYtniS+0mVWBjSGJSsgBHBx1B9etO0Pw5Frd99u1GG0ubtF+zNqJbymCdfL4IJHtiumEXDWXQ50rb2Q6xv8AUNNRpNLubu1t0YKVulJRvUgN3/KsTxCLbxDqVra6pbT3F3Zwma31JUA+z88BWP8AF0IyOgrp/wCx7PSp/tekalfo0seyaM4khkPptbPI9a5ae3gvrm/0/VNFns7FmO2XT7rInixlvNQ/Mp4yAtOF+a7RVZrl5kiS3tobqLT5b+0ttR1Oxd0t9SkXy2jP984+VmA5JPpXC6F4MnjvLi6t9be6jN3LIHheKd7lWPLpsORknH1FdzoZt9Q0KC401P7RtJ1MSNFHtWYAlfnU8qccNkc45rl7Xw/dWeo308Hh60gW0YW6nTx5ImRzlish5wMcgDnsau6urEOldKSRftfDVrPePrOkarImgM4+0WjzLLbSzRsCvyn7jBgCR1JrPt7nwuPGPlyG51XxJeXPmK+pM0oMi5IC5AA2jIGBVrSNF8TWesFpZtNs9IWNktVhIDy7v4pO3HPOBzW54RuNXt40h1HTrb+1PtEn+nhldwnRXUnPVfxqtN7a+n9f1qQoNtWW5i6Xa3+o6RBqGh6fNaaos7wx3N7D5bpAz5kbOSzZ5wDW/Z6NY6TMscNhZPExZiQo259h2981vOIYcPf31vvBwN05lc/QDv8AWpILudlWHTo3O4FiVChge5Y9qcdVdPU7FQjoZ/n2mmiCKWJVlLNJFHEuAzEYLH+8QO/auOl8XandTyXfhTR7vVrW0neC5URbUk6dJT93BzyB9a6vUdOuJL61vlur+G4t3Ehkhm3B0xyjcZCnuB1qposGnwRrpXhi1s7G2ZpLiZ1leQB2H3iM84/u9KJtqVr2uKcZNWSsvU1NDu9TvLPbcadHYXbx+ZN5M3nvCh44OAC3+12qtrF/psM2g2g0uaRhdCe2jS5eEuV+XLAdRznmlsdKvraxuJrzUWuVh2+XcTEW4hdevl7eST3FZokuNTu5LmwZ7i8WM/vmO7b0ycHqcU7L7RjNSkn0sSW2gaNB4i1DU7GyT+0S0iYnZn8hGfcR838THPPYYArcgtRLKUghtgXUySzTOcJ7KOnXt371laTo8ul/bLkvqTyXkgknluJA/wA+MAIpwASOwFT2OpWtxeSwqbtDbIBN58fJUcjJbgEetKyS00FB8iSNb+z7aNQzmdGUbnmJQbfXArnfEMN1NNayaaFu5fNVFM6kbU/iYjuOmB3rTuNZgi11tH82ZLoR+eHW1JV07EOeD+FPUl9S3TTzC6tgJFdgArccDjg/SsZQlJmzqw7lCz0vU9NtZw1zBrN1M+ZJSih41HVY1UAYpgttMnVpLy0Z4EUkpc/uVD/7IXmtvWfD17NZWbi8WzkuUzJLNDsWM5yAFzkkVy03hnVrKSEapeR65bs4WNo4jCzk99ueVHehxUvMUaqW2iEg8RQ6ne22i6LBGtqHxPcJG0UC+ykjLkevStTTfDunWuntADcTWkc7OhklaRpXJyWZjy38hWnbW0UaD7ZZmEqQyuyNz2A44FQX09ukEsrW0zQRr92QNG6p3wvQjPpSlDoF4r3mUbm2srNGS3sbaF2zztzn/H6U5bWbAj+x78x5G9Nxx3OOwqt4V1awv3mmkuLWSGNiI0jZmwScDIPI47VuTyNHZXb6Y0ySZEscpLYiI6sd3b/ZPFS4uKvf7hxqqXwop2mk6VdlBdSu/kn5I48Rjd6Hbjj2Jp84WygfFupK73SL+KQgcDB4z2GaZFerdtJHqa2FzfxxpJJPZYhmjVgSGaPoQfXilmu7eJWhlYi3LAEtCzAgck4Jzmoin2G5dzM06L+07GLVTprWd2JVE9pdwIJVjPAIZeoz37VeS0gureVLi8a3swGwZFMmwZxyB3+tLpj3MKX8usyRLM7Otv5JKqYWwQWX++Pbiq9le3TQXEl/ZGxV3MQcOG89B0cHoAfz61XK/tAmYWreBZtZs5V8G20n9qrFuS8vpQp2k9RGeB7dSKXRvCmpeHVW48S6CdS1U/NNfmDeF4xxs7e9dAZvMlWd550mYgK0cnliNew9fwxXN3PjvV4ZryC8tdev9Nt5FSRrG6UyTtz8uD91ehJFS48j00Mara1dmVop7W41QT2+kRx3MTv9nmuIyXUdxk9DzgV0k1hdWNydSlddhiVIYJCqFT1YqDyST3PaoofGuuXc9jElvotlDdMVRXB8/T2xhA7N98nPLdK5CxebTNJ1R7Fv+Eh1u2Rp9StZbtvMLK2A8aN8xU+3FKN4tti9rtdWOx0eW8itrlNatfsk/Ijit2835TyGkJ6fhVK08S3WkajdPry2LaeqBbULZussbZxz13ZGc8cVkX+sC5ktLfTdd0/R7ieNZxcXcgUoOuwk8K2exzxWZ4lWLSJbHXtcvbO9W6mNpLPHfb4BtGQQq5G7GemKqWmt9hOrfRM2PFHirRUmgvJdTS6RHa38i25aZ2XhSMcbRUx8rVNLuILS8ulJ8m4hjaPypIJlOQjA/eU42/jWDLp+g6XZs1usb2FvJ9tYu6yIkrD5Zd2eMggAGuzTOoKG0q0v7W5CopVmWVJfdSvTPpSd9hRs3dsSO6S90lNQszKr4BlhZsiGQH5kPuDn6il1GVN7SWRQzrsmQgkIj8E5Pr1rlPtVvaeLrjQ9Qu7i1u51+0M0kqlS39xs/cHpmn65d6bBpsE11rrS6VJLJYubJmx5mOAzAfeBHHaud/FdGvOrWbNzxFqMmyaSBr4tct5u1Vyqp3APse3vRXNQeMYLK3kilvhcTrgLNGdqjsPMTqp9TRU1KauXGsoqxraPa2MmlwR21tIIom2xrcAjO08kL/ESema27nT7ExM+rRLeXEnLC4iDEgdAF6VbV2hR7SJttuoGExnHHUZqSztYo/JlUN5jOEDFidgx1HvTlJt2RnZJaox4pYLeRbdorS2jAAMMm1AY+rLs9AOgI61TvDCkIj0O0g2blREkkKb0B9hgHB7d+tE2j2FnNctDbr5zyfNMxLOcn1NW5o47PRxcQovnOHO5hnaQMAj0xUQbbsi3FctzHbT7dY5ZNGDeXKxBWSYsXOfmwT047VINFs1iT7bpkdrbRSCbzWlAUsBkEsOQB6dKvaHplvommWkdrvk8pNwac7yS2Sc+tO8UW0U3gjUZ2UqwtpJCqnCtgDgj056DFbxk5PlIfuxuWUlg/wBHubSaCW3uD8s4bKL6Y9R71Nr3iKGy0hrz7CXit/ll2RF/MYHkqM5rivhldHyJtH8qI6fbMJooiM7S6gkfSu/sd1x5sTOV8qJirIAD06ehoUFe39XG5c0eYpy6nqWoaaj2UKSzXQC28ayZjQk8q5AypA7Dp0rQ1SzfT0gtbSykl1FY8GMS4LE9gfrWNrOrX954IFhDctYLJNEpmsgIpdpcZAbHGe9dPHMbOEvEqmWElRI+SzfKOSe5qnBJihOUrmH4cHiGUxvrtrFZWrIXW3guWlmYcj5n+6uPxNM1XwzDqc0ct9q16bRZEDJaTsiHB3AMo5I7E5reszIuotbQyyQwpH9oUIf4vxzxzTbe4e4knZwqghiyIuFcqDgkeorNdUim9NSzITcXBzLJKsh/dlW3Kuehx2HanCeexkV0YK6Eh1I3Kx9CO1VLay/tKynR7m5gwrBWgcIVwARjirXhi4nvrJRcTOzJuBfjc+PU4rWOvzKv0Me6+ypM00VkbcEk7EbMYJ6lc9PWs6HxDDHKjxJt3L5JlNwMP7EEYP1rqNQXZbNKnyzFgnmADIB64/xrzX4g6xceHreZrGOBk81B5cse5BzzxS5WtU9h865bs6rRdVudS1HUba2sprG0gKFJLkhorjI/hb+Fh6EUmsajaadDLc32pOlvuA82BgIoz/dYNjj6Vt6ZHb3V02nvbRLbxlQu3cG5TJ5z61Bd2cf2QwuTLC4G5JQHBBGcHIqn7qvLXcF72zORvdcub23a20t5rK7l2mG9u7YiPaf4wD8pOOmTinN4yXVte0/QvD0sF7qQkRbu5RlSJIAMOxI4LZ7LW+sn9jrcS2yrIkkyxSQTDfFJGSFKFemMdhijxfBa+H7u+h0yys4ooZkSFRCo8pWIyFIAIFVz2drmdRSvruMVZJDdLaXqTXUDhCGf5VbnC/Ujn271Rto5ZZQ+p3NvbzyEgR+UE3fUj73HejxnqVwZvDukwiK3t76KZpZIYwsm8qT5gb+/8o5rjfAevajqHiD+xZp1W3tgB5yRoJpcD+N8fyxTk+bRaChX6NHsbeJ9F0a80a61m7jtklmFtE23cGyPlHHQDqSeK6HxjqKafq0X2uTy4JYwYnzxkda8j+KlhFqNjoOnXBbydSvZPtLLgMyxgsqjjAGeeBWXZ/EPxD4Z8NeGrGG6jv47i4SEyX8YldEaTbtU8cAcDOamd3K5m5pTvbY9hmglv9PBjgaVWdZYIy4VzFg5cA84JxxXM/2E/hQ29/otqstykbPcWuqXBUSsx5POcbeg4robGCPUbC6ubwGSWEuQSxG7ByM/TtjFY3iXWbiO90hHjglfUrlIJZJI9zIuM/J2B4x0Narrc0eu/wDVzYs9SZkuJRbi2urlRvkgmDpbE91Rhz9R+FUpYVlvv9NhaWJVUSBT8zOD97PcH0rD+I9lJpfiFr3TL+8tJpM2sgjcbXjVQyggg9CTg1seFIw+lwz3Be4mkBnkaVyS7dOeentWkElqgjOO1jJkt7+W0n0ueJrGzjuBLZz2UuyQeu/1znkHii20m51Rlt/7SFndWqmOKSeFVXcx5Iyec8f0roo7mW5tEknKuWJwCowo6YHHSsu+uXnnFo6xeVGNyny1LZPHUiiT5VqU6TktHZnI6DbeIrjV9Ul1q3sZrODdaJHaLt+0lWyswU52r25611+kzyylIv7DntZH3GOKfJGBjJB707SLWNLuKP5irOyPk/fGO9TeH9Hh0ea5tIp7u5QLJOHu5jK4Y4OAx6AdAPSqUtCKVNwnZvoT/YoYbcyXkMEAMoj+VRI248gYHHPWsLR/E+m6prqaXaR65ceekoEjWIgt8xkggsTnORjpW9JcSIYjCRFIX4kUAlSR1GcgH8KjeZo5HkTCuzLKSBj5+Oce9WoSlrc3lzt2T0J/sSzW9rEg/dMhkb94fkCkbdp7j61kawW1jUbjT7a+uLa3jImlNm6xMAeFAKjOCQST+Va/iZjaW2tx2zGONYXKKD9zOOnp1NcTaXLWXxc1G1t1RYrjRkuJOOS8WFU/kcH1pN3VzCbi5xT2f6naw6PD/ZES3xVo3AMaq5ZiinncWP3s0xooIbYxW++y8xgZrhIjudF5GMdM9K3dJSO4kSGaJGUQ/aFOOVfB5FZMYxpsU7MzSNIRlj0AHArKTu+V7mkbK8UeW6xeeJ9R8TabNqnhSxksbWaU2Nw87o67vuSSKDywGBnFbXiCx1ebyopJ7+4s0jeO50lWBil3cN1GSOehrvL6JIr+NDmXyrcTqZDklyM5P07DpWbBfz2lydjb5SVmMr5LlmUk5Pp7VnGV9O5Pso2uilpMdp/o11aWs9pLDGIRDctvMUagBcHoMDqKx/EOkW/iI3Wkx6ykUVpMlzdx2MphmKt/y0PdgOOnFdSt1NNOZp3EhkDbkZQV/LFYvie0tzcPfrAiXulskdrMowyIeqZ7r7GtW3sT7PmVl0OmtLdv7OsxdTz3QtUCrJM29yp4Jz+VOUKkjy3TeZcBNqSDuewA7ccVy9vbC1MEkEsyLKA5jDfICeuBXQQxeWGRXf5F3A55zTlGyNUradhmq6hDHZXUX2xbVjAwWYOFw5BAIJ43A9jWF4L1x9d0VTdW8wubU/ZphcFFeQgcy7skYPXj3roRbQTbUnhjkRxgqygjnuPQ+9cf43gGm2KJpjfY3lmUNJEibsFwCBkEc/TNZa35ugpK2p1Eat5SbIYIFQEbbIAx+YT80h7sxHGe1Vbia4jVms7eWe62NIkLEMkhA4UD0+tZV+JND12drK4mMc4SJoZW3xqB3VT0JzyRWf4V1m78Sx6ydQKotrfG2RIMxgoBkZwc5otd8vUVlFOyLUmh3V5q1tr8iyrqktssN9ZJtKOo5+cDrsJ4qdbIzzYnLPyXAIOTt6qp60tpM1jq2taNaDy7aDymEmSZGyCSGYk8e1aUsrRrFGhwq42+oyM8UnFPboVR1V31OcnnuIZYodL1O3m0m4kIkdAjAOP+We5s4bqNo54qDxVq1zPBb3V5NgWW1p7OS4SPyYicKxT0/iGPet3UreC203U54IIUaPy3AVABuPJOPU+tcT4l0m11Gw168uUzfRKqx3IA8xAwAIBI6cnrmtLXRzVbxVyzqPiG7MFte2GrWGpWVk0q3IsYcLNKq5jgGRk7zxms/wAWGLUJpH0e1j0vXE0dJLsBiJLbzPmKktwVzxzzitDQrKO/1q+8Hyl00Gx0iGGKCI7CSTuMjMOS+f4qyNbia41uDdNMqXKrZSorfK8akAZ9T71DWl2YQ1dzkNQub6Lw3ZmK7la8nCxsIm8xZnVsnLdeenpW7cyT6hb2U0Atl1dIGgKMvmvBkHcqsvIG3tnjtWv4l0bT7fWLxre1SI6ascFvtJ4DEZJB4JOetTeBtCtb+18bXE0lwtzo86z2k0chV1Lx5ZSR1U46U3Zaf1oNOyuzlH8i9sdOvorK3v44ZFSRooQslw7cROhcfNgjDAZ4zmrl7faU17qPhKz8PQtq9szi3Gc288o5cYAxnJwCemMZpl5dPe6HqGsTgNNay2lzBByYYpJCFYqhPHcj0NWvBWpT6J8NPFt5abXuJ9Tltg82XMShCcp6Ek8nvWcnbcm93cx9fupNG8P3TveWkOtROLO9W0tRNbTHG5YyGHzOi8lhxTb3On6Veq8dpJfpYAF7TUJFYDAdmKdAx7Ecdql8lrM+EEW4mkWZZnkDkfMSvU4AzwcfSnazZp4QvrR9Ad7b7StvGQwWTYrtlgpYE4JPQkipa3b/AK0Hcs6fZ6a2g6bHd29jeWEgN59pl+QXG7jksc7x90j1GaoR30untPb6VHbLp8CGSbSolLMEzzKCc5YdcU3XLC3isdS04p5lu119tj3AZgkPDbMcAN3BBHHGKo+MZJLGyt9ZsZZLfUQUtfNiO0lCpz+PHWiTtfTYtO8dDTj8V6Ze6dAVsINU1aAbLczxmC6dScZ3Ljf/ADorg21S8n0txczedvuQcuq7lO3OVbGRnjODRXPKavqNTl0P/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Epidermal spongiosis and spongiotic vesicles are present in this biopsy taken from a patient with poison ivy. Infiltrating lymphocytes are apparent in the epidermis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rubin E, Farber JL. Pathology, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 1999. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Varicella",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 339px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photomicrograph of the skin from a patient with varicella shows an intraepidermal vesicle. Multinucleated giant cells and nuclear inclusions are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rubin E, Farber JL. Pathology, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 1999. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_36_36426=[""].join("\n");
var outline_f35_36_36426=null;
var title_f35_36_36427="Catheter size for pediatric hemodialysis";
var content_f35_36_36427=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Catheter size for hemodialysis according to the weight of the child",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Weight of child (kg)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Catheter gauge (Fr)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Catheter length (cm)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Double lumen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3-12",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        12 or 18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10-25",
"       </td>",
"       <td>",
"        10 or 12.5",
"       </td>",
"       <td>",
"        12 or 19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        15-30",
"       </td>",
"       <td>",
"        10 or 12.5",
"       </td>",
"       <td>",
"        19 or 28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;25",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;30",
"       </td>",
"       <td>",
"        12 or 13.5",
"       </td>",
"       <td>",
"        23 or 26",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;40",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Single lumen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &lt;5",
"       </td>",
"       <td>",
"        6.5",
"       </td>",
"       <td>",
"        29 or 32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;10",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        36 or 40",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_36_36427=[""].join("\n");
var outline_f35_36_36427=null;
var title_f35_36_36428="Single gene causes of obesity in animals";
var content_f35_36_36428=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F76948&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F76948&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Single gene causes of obesity in animals",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Animal model",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rodent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chromosome Human homologue",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gene defect",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gene product",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\" rowspan=\"1\">",
"        Dominant inheritance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Yellow mouse (A)",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"1\" rowspan=\"2\">",
"        2",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"1\" rowspan=\"2\">",
"        20q11.2",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"1\" rowspan=\"2\">",
"        Agouti-signalling protein overexpressed in many tissues",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"1\" rowspan=\"2\">",
"        Asp",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Gene= Agouti",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\" rowspan=\"1\">",
"        Recessive inheritance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Obese mouse (ob/ob)",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        4",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"1\" rowspan=\"2\">",
"        7q31.3",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"1\" rowspan=\"2\">",
"        Stop codon produces truncated leptin",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"1\" rowspan=\"2\">",
"        Leptin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Gene= Lep",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diabetes mouse (db/db)",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        1p32",
"       </td>",
"       <td>",
"        Splicing defects or extracellular deletions",
"       </td>",
"       <td>",
"        Leptin receptor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Fatty rat (fa/fa)",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"1\" rowspan=\"2\">",
"        5",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Gene= Lepr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Tub mouse",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"1\" rowspan=\"2\">",
"        7",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"1\" rowspan=\"2\">",
"        4q32",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"1\" rowspan=\"2\">",
"        Insert",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"1\" rowspan=\"2\">",
"        Phosphatase (?)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Gene= tub",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Fat mouse",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"1\" rowspan=\"2\">",
"        8",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"1\" rowspan=\"2\">",
"        11p15",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"1\" rowspan=\"2\">",
"        Insert",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"1\" rowspan=\"2\">",
"        Carboxypeptidase E",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Gene= cpe",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_36_36428=[""].join("\n");
var outline_f35_36_36428=null;
var title_f35_36_36429="Testosterone critical illness";
var content_f35_36_36429=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F51402&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F51402&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Correlation of serum testosterone with severity of critical illness",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 233px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The serum testosterone concentration on admission (left panel) and the nadir level in the hospital (right panel) in men with critical illness according to disease severity as measured by the APACHE score. Men with increasingly severe illnesses have lower serum testosterone concentrations. To convert serum testosterone values to ng/dL, divide by 0.0347.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Spratt, DI, Cox, P, Orav, J, et al, J Clin Endocrinol Metab 1993: 76:1548.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_36_36429=[""].join("\n");
var outline_f35_36_36429=null;
var title_f35_36_36430="PEFR in men";
var content_f35_36_36430=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57257%7EPULM%2F62839%7EPULM%2F64420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57257%7EPULM%2F62839%7EPULM%2F64420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Predicted average peak expiratory flow for normal males (L/min)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"6\">",
"        Height",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        60 inches/152 cm",
"       </td>",
"       <td class=\"subtitle2\">",
"        65 inches/165 cm",
"       </td>",
"       <td class=\"subtitle2\">",
"        70 inches/178 cm",
"       </td>",
"       <td class=\"subtitle2\">",
"        75 inches/191 cm",
"       </td>",
"       <td class=\"subtitle2\">",
"        80 inches/203 cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        554",
"       </td>",
"       <td>",
"        602",
"       </td>",
"       <td>",
"        649",
"       </td>",
"       <td>",
"        693",
"       </td>",
"       <td>",
"        740",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        543",
"       </td>",
"       <td>",
"        590",
"       </td>",
"       <td>",
"        636",
"       </td>",
"       <td>",
"        679",
"       </td>",
"       <td>",
"        725",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        532",
"       </td>",
"       <td>",
"        577",
"       </td>",
"       <td>",
"        622",
"       </td>",
"       <td>",
"        664",
"       </td>",
"       <td>",
"        710",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        521",
"       </td>",
"       <td>",
"        565",
"       </td>",
"       <td>",
"        609",
"       </td>",
"       <td>",
"        651",
"       </td>",
"       <td>",
"        695",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        509",
"       </td>",
"       <td>",
"        552",
"       </td>",
"       <td>",
"        596",
"       </td>",
"       <td>",
"        636",
"       </td>",
"       <td>",
"        680",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        498",
"       </td>",
"       <td>",
"        540",
"       </td>",
"       <td>",
"        583",
"       </td>",
"       <td>",
"        622",
"       </td>",
"       <td>",
"        665",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        486",
"       </td>",
"       <td>",
"        527",
"       </td>",
"       <td>",
"        569",
"       </td>",
"       <td>",
"        607",
"       </td>",
"       <td>",
"        649",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        475",
"       </td>",
"       <td>",
"        515",
"       </td>",
"       <td>",
"        556",
"       </td>",
"       <td>",
"        593",
"       </td>",
"       <td>",
"        634",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        463",
"       </td>",
"       <td>",
"        502",
"       </td>",
"       <td>",
"        542",
"       </td>",
"       <td>",
"        578",
"       </td>",
"       <td>",
"        618",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        452",
"       </td>",
"       <td>",
"        490",
"       </td>",
"       <td>",
"        529",
"       </td>",
"       <td>",
"        564",
"       </td>",
"       <td>",
"        603",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        440",
"       </td>",
"       <td>",
"        477",
"       </td>",
"       <td>",
"        515",
"       </td>",
"       <td>",
"        550",
"       </td>",
"       <td>",
"        587",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    These values represent average normal values within 100 L/min. Predicted values for African American and Hispanic minorities are approximately 10 percent lower.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Leiner GC, et al, Am Rev Respir Dis 1963; 88:644.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Predicted average peak expiratory flow for normal females (L/min)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"6\">",
"        Height",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        55 inches/140 cm",
"       </td>",
"       <td class=\"subtitle2\">",
"        60 inches/152 cm",
"       </td>",
"       <td class=\"subtitle2\">",
"        65 inches/165 cm",
"       </td>",
"       <td class=\"subtitle2\">",
"        70 inches/178 cm",
"       </td>",
"       <td class=\"subtitle2\">",
"        75 inches/190 cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        390",
"       </td>",
"       <td>",
"        423",
"       </td>",
"       <td>",
"        460",
"       </td>",
"       <td>",
"        496",
"       </td>",
"       <td>",
"        529",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        385",
"       </td>",
"       <td>",
"        418",
"       </td>",
"       <td>",
"        454",
"       </td>",
"       <td>",
"        490",
"       </td>",
"       <td>",
"        523",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        380",
"       </td>",
"       <td>",
"        413",
"       </td>",
"       <td>",
"        448",
"       </td>",
"       <td>",
"        483",
"       </td>",
"       <td>",
"        516",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        375",
"       </td>",
"       <td>",
"        408",
"       </td>",
"       <td>",
"        442",
"       </td>",
"       <td>",
"        476",
"       </td>",
"       <td>",
"        509",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        370",
"       </td>",
"       <td>",
"        402",
"       </td>",
"       <td>",
"        436",
"       </td>",
"       <td>",
"        470",
"       </td>",
"       <td>",
"        502",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        365",
"       </td>",
"       <td>",
"        397",
"       </td>",
"       <td>",
"        430",
"       </td>",
"       <td>",
"        464",
"       </td>",
"       <td>",
"        495",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        360",
"       </td>",
"       <td>",
"        391",
"       </td>",
"       <td>",
"        424",
"       </td>",
"       <td>",
"        457",
"       </td>",
"       <td>",
"        488",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        355",
"       </td>",
"       <td>",
"        386",
"       </td>",
"       <td>",
"        418",
"       </td>",
"       <td>",
"        451",
"       </td>",
"       <td>",
"        482",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        350",
"       </td>",
"       <td>",
"        380",
"       </td>",
"       <td>",
"        412",
"       </td>",
"       <td>",
"        445",
"       </td>",
"       <td>",
"        475",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        345",
"       </td>",
"       <td>",
"        375",
"       </td>",
"       <td>",
"        406",
"       </td>",
"       <td>",
"        439",
"       </td>",
"       <td>",
"        468",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        340",
"       </td>",
"       <td>",
"        369",
"       </td>",
"       <td>",
"        400",
"       </td>",
"       <td>",
"        432",
"       </td>",
"       <td>",
"        461",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    These values represent average normal values within 80 L/min. Predicted values for African American and Hispanic minorities are approximately 10 percent lower.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Leiner GC, et al, Am Rev Respir Dis 1963; 88:644.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Predicted average peak expiratory flow rates for normal children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Height",
"       </td>",
"       <td class=\"subtitle1\">",
"        PEFR",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Height",
"       </td>",
"       <td class=\"subtitle1\">",
"        PEFR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        (inches)",
"       </td>",
"       <td>",
"        (cm)",
"       </td>",
"       <td>",
"        (L/min)",
"       </td>",
"       <td>",
"        (inches)",
"       </td>",
"       <td>",
"        (cm)",
"       </td>",
"       <td>",
"        (L/min)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        147",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        142",
"       </td>",
"       <td>",
"        320",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        44",
"       </td>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        160",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        145",
"       </td>",
"       <td>",
"        334",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        173",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        147",
"       </td>",
"       <td>",
"        347",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        46",
"       </td>",
"       <td>",
"        117",
"       </td>",
"       <td>",
"        187",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        360",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        200",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        152",
"       </td>",
"       <td>",
"        373",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        214",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        155",
"       </td>",
"       <td>",
"        387",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        49",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        227",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        157",
"       </td>",
"       <td>",
"        400",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        240",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        160",
"       </td>",
"       <td>",
"        413",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        254",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        163",
"       </td>",
"       <td>",
"        427",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        132",
"       </td>",
"       <td>",
"        267",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        165",
"       </td>",
"       <td>",
"        440",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        135",
"       </td>",
"       <td>",
"        280",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        168",
"       </td>",
"       <td>",
"        454",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        137",
"       </td>",
"       <td>",
"        293",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        170",
"       </td>",
"       <td>",
"        467",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        140",
"       </td>",
"       <td>",
"        307",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Polger, G, Promedhat, V. Pulmonary function testing in children: techniques and standards. WB Saunders, Philadelphia 1971. Copyright &copy; 1971 Elsevier Science (USA).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_36_36430=[""].join("\n");
var outline_f35_36_36430=null;
var title_f35_36_36431="Mediastinal goiter MRI I";
var content_f35_36_36431=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63277&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63277&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mediastinal goiter displacing the trachea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial T1-weighted section shows a soft tissue mass due to mediastinal goiter (white arrow) displacing the trachea (black arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_36_36431=[""].join("\n");
var outline_f35_36_36431=null;
        